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Summary 
Chemokines are members of a family of small structurally related proteins, which can be 
classified according to the positioning of four conserved cysteine residues, into four 
families – CC, CXC, CX3C and XC. They have a wide range of functions, from being involved 
in embryonic development, disease processes and cell migration. Broadly speaking, 
chemokines can be divided into homeostatic, those that are involved in development, 
and inflammatory chemokines, which are produced at high levels during infection.  
In order to exert their function, chemokines bind to seven transmembrane G protein 
coupled receptors; this causes the activation of numerous different signalling pathways 
which can lead to cell activation, migration, survival or apoptosis. The chemokine system 
is further complicated by the existence of a family of atypical receptors. Four of these 
receptors have been identified to date; CXCR7, CCX-CKR, DARC and D6, and they all share 
the apparent inability to signal after ligand binding.  
D6 has been identified as a member of this atypical receptor family with the ability to 
bind and internalise 12 inflammatory CC chemokines. D6 expression has been 
demonstrated in barrier tissues, such as the skin, gut and lung, as well as being expressed 
by numerous leukocyte subsets. Studies looking at the function of D6 have demonstrated 
its involvement in the resolution phase of inflammation, and D6 may be involved in cell 
migration and inflammation driven tumourigenesis. Here the analysis of the role of D6 in 
neutrophil migration has been carried out, in the well-characterised TPA model of skin 
inflammation. This work also shows that D6 plays a crucial role in melanoma metastasis.  
In the TPA model of skin inflammation, 129/Bl6 D6KO mice display an exaggerated 
inflammatory response, which causes the development of a psoriasis-like pathology. This 
pathology is dependent on T cells and mast cells, and is associated with an alteration in 
neutrophil positioning. In the inflamed skin of D6KO mice, neutrophils are found at the 
dermal/epidermal junction, whilst in WT mice, neutrophils are restricted to the dermis. In 
this model, D6 is required to prevent neutrophils migrating to the dermal/epidermal 
junction. D6 expression has been demonstrated both in the skin and on neutrophils, so 
there are two hypotheses to describe how D6 is influencing neutrophil movement in this 
model. First, D6 on neutrophils is required to limit their migration within the skin, keeping 
20 
them away from the dermal/epidermal junction, alternatively D6 in the skin may be 
responsible for chemokine clearance during inflammation, and the localisation of 
neutrophils is influenced by these chemokines. This work aimed to investigate the role 
that D6 played on neutrophil localisation in inflamed skin, carried out using a model of 
neutrophil adoptive transfer. These results demonstrate that expression of D6 by 
neutrophils does not alter their positioning in inflamed skin, suggesting that the role for 
D6 in this model is in regulating chemokines within the skin, a hypothesis which requires 
further investigation.  
The second part of this work aimed to investigate the role of D6 in melanoma growth and 
metastasis. D6 has been shown to be involved in murine models of inflammation driven 
skin tumourigenesis and colon cancer. These data presented here show that D6 does not 
influence the primary melanoma growth, but has a profound effect on the development 
of metastases in the lungs, in the murine B16 model. D6 is required for the development 
of lung metastases, but the precise mechanism is yet unknown. These data suggest that 
D6 can alter macrophage numbers within the lungs, which permits the development of 
metastases, as well as pointing towards a role for D6 in lymphangiogenesis within the 
lungs, which affects metastasis development, perhaps by altering the development of the 
pre-metastatic niche. Overall, these studies contribute to the investigation of the role of 
D6 in skin inflammation, and show, for the first time, that D6 is involved in the pulmonary 
metastasis of melanoma, suggesting D6 may be a potential therapeutic target in 
pulmonary metastasis.  
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1 Introduction 
1.1 Chemokines 
Chemokines are members of a family of small proteins (8-12 kDa) that are best known for 
their role in cell movement. The name chemokine is in fact derived from their main 
purpose; CHEMOtactic cytoKINE. Chemokines have essential roles in a wide range of 
processes, such as cell movement, development, proliferation, cell transformation, 
metastasis and the development of immune responses (1, 2). PF-4 (Platelet factor 4) was 
originally discovered in 1961 (3). At this time, the biological role of chemokines was 
unknown, but they were known to be associated with inflammatory conditions (4). Since 
then 46 chemokines and around 20 receptors have been identified. The chemokine family 
of genes is thought to have derived from a primordial chemokine gene, which after 
duplication and divergence became the chemokine system we know today (1).  
Most chemokines are secreted, with the exception of fractalkine and CXCL16, which can 
be produced as membrane bound forms (1). Almost all cell types have the ability to 
produce chemokines. They can be rapidly synthesised and produced in response to 
various stimuli, and they can be stored in a wide variety of cell types, e.g. endothelial cells 
store chemokines in Weibel Palade bodies. Neutrophils, eosinophils and mast cells can 
store chemokines and release these when required and platelets can store CXCL1, 4, 5, 7, 
8, CCL1, 5 and 7 (2).  
1.1.1 Chemokine Structure 
The members of the chemokine family share a common structure. Chemokines have a 
flexible N-terminus (amino terminus) that is joined to the rest of the structure by 
disulphide bonds. This leads into an extended loop with three anti-parallel β pleated 
sheets. These create a flat base from which the C-terminus (carboxy terminus) extends 
(5). The N-terminus of chemokines is important for their activity as shown by deletion and 
substitution analysis (5-7).  
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1.1.1.1 Classification of Families 
The development of EST (expressed sequence tag) databases allowed rapid identification 
of sequences similar to chemokines, using molecular cloning techniques. As a result, this 
led to many chemokines being identified simultaneously by different groups. One 
drawback from the rapid rate of chemokine discovery was that many chemokines were 
reported under different names, e.g. MIP3β, ELC and exodus-3 were names reported for 
what is now known as CCL19. In 1999 it was decided to adopt a systematic nomenclature 
for chemokines and their receptors (1). The nomenclature is described in table 1.1 along 
with their previous names (1, 5) 
The nomenclature system was developed according to the positioning of highly conserved 
cysteine residues found in the N-terminus of chemokines. The four families of 
chemokines identified to date are the CXC, CC, XC and CX3C families. These can also be 
referred to as α, β, γ and δ chemokine families. The two biggest groups are the CXC and 
CC, with 16 and 28 members respectively. The XC and CX3C families are much smaller, 
with only two members of the XC family (XCL1 and XCL2) and the sole member of CX3C 
family is fractalkine (CX3CL1)(1). Within the CXC family further subdivision can occur, 
based on the presence of three amino acids – ELR (glutamic acid, leucine and arginine). 
CXC chemokines can either be ELR+ or ELR-; ELR positive chemokines can recruit 
neutrophils to the site of inflammation. The addition of an ELR motif to PF4 (which lacks 
one) causes it to become a potent neutrophil chemoattractant (5).  
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Systemic 
Nomenclature Human Ligand Mouse Ligand Receptor
CXCL1 GROα/MGSAα KC CXCR2
CXCL2 GROβ/MGSAβ/MIP-2 MIP-2 CXCR2 
CXCL3
GROγ/MGSA γ/MIP-
2β DCIP1 CXCR2
CXCL4 PF4 PF4 CXCR3
CXCL5 ENA-78 LIX? CXCR2
CXCL6 GCP-2 LIX? CXCR1, CXCR2
CXCL7 NAP-2 unknown CXCR1, CXCR2
CXCL8 IL-8 unknown CXCR1, CXCR2
CXCL9 Mig Mig CXCR3
CXCL10 IP-10 IP-10 CXCR3
CXCL11 I-TAC I-TAC CXCR3
CXCL12 SDF-1α/β SDF-1 CXCR4
CXCL13 BLC/BCA-1 BLC/BCA-1 CXCR5
CXCL14 BRAK/bolekine BRAK unknown
CXCL15 unknown Lungkine unknown
CXCL16 CXCL16 CXCL16 CXCR6
CCL1 I-309 TCA-3, P500 CCR8
CCL2 MCP-1/MCAF JE CCR2
CCL3 MIP-1αS MIP-1α CCR1, CCR5
CCL3L1 MIP-1αP MIP-1α CCR5
CCL4 MIP-1β MIP-1β CCR5
CCL4L1 MIP-1β MIP-1β CCR5
CCL5 RANTES RANTES
CCR1, CCR3, 
CCR5
CCL6 unknown C10, MRP-1 unknown
CCL7 MCP-3 MARC/MCP-3
CCR1, CCR2, 
CCR3
CCL8 MCP-2 MCP-2? CCR2, CCR5
CCL9 unknown MRP-2, CCF18, MIP-1γ CCR1
CCL10 unknown MRP-2, CCF18, MIP-1γ CCR1
CCL11 eotaxin eotaxin CCR3
CCL12 unknown MCP-5 CCR2
CCL13 MCP-4 unknown CCR1, CCR5
CCL14 HCC-1 unknown CCR1
CCL15 HCC-2/Lkn-1/MIP-1δ unknown CCR1, CCR3
CCL16 HCC-4/LEC LCC-1 CCR1, CCR3
CCL17 TARC TARC CCR4
CCL18
DC-CK1/PARC AMAC-
1 unknown unknown
CCL19 MIP-3β/ELC/exodus-3 MIP-3β/ELC/exodus-3 CCR7
CCL20
MIP-3α/LARC/exodus-
1 MIP-3α/LARC/exodus-1 CCR6
CCL21 6Ckine/SLC/exodus-2 6Ckine/SLC/exodus-2/TCA-4 CCR7
CCL22 MDC/STCP-1 MDC CCR4
CCL23 MPIF-1 unknown CCR1
CCL24 MPIF-2/eotaxin-2 eotaxin-2/MPIF-2 CCR3
CCL25 TECK TECK CCR9
CCL26 Eotaxin-3 unknown CCR3
CCL27 CTACK/ILC/PESKY ALP/CTACK/ILC Eskine/PESKY CCR10
CCL28 CCL28/MEC CCL28/MEC CCR10
CX3CL1 Fractalkine Neurotactin CX3CR1
XCL1
lymphotactin/SCM-
1α/ATAC lymphotactin XCR1
XCL2 SCM-1γ unknown XCR1   
Table 1-1: Chemokine and receptor nomenclature (adapted from (1, 8)).  
The nomenclature assigns a number according to when the genes were cloned, and is 
based on the human chemokine system. The human and murine chemokine systems are 
Claire L. Burt, 2011   24 
very similar, but there are some human chemokines with no mouse homologue and vice 
versa, e.g. there is no mouse CXCL8 and no human CXCL15 (1, 5). The number of 
chemokines described above can be expanded by the existence of splice variants and 
various different chemokine isoforms. Chemokines can also be processed by different 
enzymes, which can create products which have very different effects (further details 
found in section 1.1.2.3) (2).  
As well as classification on a structural basis, chemokines within families can be 
subdivided according to their function, into inflammatory (inducible) or homeostatic 
(constitutive) chemokines. The inflammatory chemokines were amongst the first to be 
identified, e.g. CCL2 and CCL5, as cells in vitro can be induced to produce a large amount 
of inflammatory chemokines. Inflammatory chemokines have been identified in a wide 
variety of inflammatory processes, with both pathogenic and protective roles. 
Homeostatic chemokines were discovered later, as they are expressed normally at low 
levels. These chemokines play vital roles during development, as exhibited by studies 
using gene null mice, e.g. CCL19 and CCL21.  
Animal models have been extensively used to elucidate the role of chemokines and their 
receptors in vivo. These studies initially used blocking antibodies and were rapidly 
followed by gene targeting to create null mice. Mice with a single chemokine gene 
removal often have no overt phenotype, this includes null mice that lack CCL2 or CCL3 or 
CCL11, as well as CCR1 or CCR2, or CCR3 or CCR4 or CCR5, or CXCR3. This is a 
characteristic of many null mice involving the chemokine system, due to the redundancy 
involved. Inflammatory chemokine receptors are much more promiscuous than 
homeostatic chemokine receptors. For example CCR5 can bind to CCL3, CCL4, CCL5 and 
CCL8. This can make it difficult to clearly interpret the results from gene null animal 
studies (9).  
1.1.2 Chemokine regulation 
In vivo, the majority of chemokines are secreted; they bind to receptors and induce 
downstream effects. After secretion, the function of chemokines can be altered by the 
formation of multimers, they can be post-translationally modified and degraded by 
proteases. Chemokines can be regulated at the level of gene transcription and protein 
translation. During inflammation, chemokines are not expressed until tissue damage or 
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infection occurs, which leads to mRNA stabilisation. Post-translationally, chemokines can 
be secreted from granular stores, activated or inactivated by proteases, or proteases can 
generate receptor antagonists (10). 
1.1.2.1 Aggregation 
Chemokines are able to form multimers – usually dimers but oligomers are possible, e.g. 
CXCL4 can form tetramers and CCL3, 4, and 5 can form higher order oligomers (5, 6). 
Dimer formation allowed the crystal structure of chemokines to be resolved and was 
responsible for identifying chemokine dimers. The shape of dimers differs between CC 
and CXC chemokines, with CXC chemokines such as CXCL8 forming globular dimers, whilst 
CC chemokines, such as CCL4, form a dimer which is more elongated and has a cylindrical 
shape (11). Variants of chemokines can be created which are unable to form dimers. For 
example PM2 is a mutant of CCL3, which has two acidic amino acids in the C-terminus 
neutralised. This makes it non-aggregating but it still retains its function in vitro (12). 
Chemokine binding to GAGs (glycosaminoglycans) is thought to involve dimer formation, 
which may be involved in chemotaxis in vivo (13). Heterodimerisation can take place, as 
chemokines share 20-70% structural homology (14, 15). Although dimers can form, it is 
commonly thought that chemokines interact with their receptors in a monomeric form. 
Data argue against direct interactions between heterodimers and chemokine receptors – 
they may be involved in negatively regulating chemokine receptor activation or regulating 
chemokine function in vivo (7). 
1.1.2.2 Glycosaminoglycans  
When chemokines are secreted, they are thought to move away from the site of 
production and form chemokine gradients, although there is limited evidence for 
gradients in vivo. Chemokines have been shown to bind to GAGs in vivo and in vitro. GAGs 
are carbohydrate structures found on almost all cells, e.g. heparan sulphate, chondroitin 
sulphate, dermatan sulphate and keratan sulphate. They are linked to the plasma 
membrane via a transmembrane helix or a lipid anchor. Heparin and hyaluronan can be 
secreted; heparin may protect chemokines against proteolytic cleavage (16). GAGs are 
extremely heterogeneous with different chemokines having varying affinities for different 
GAGs . In the extracellular matrix and the vasculature, chemokine binding to GAGs is 
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thought to prevent chemokines from flowing away, which allows chemokines to be 
presented to the appropriate cells (17). 
CCL2, 3 and 5 mutants with no GAG binding domain can induce chemotaxis in vitro but 
not in vivo (18). GAGs may be important under shear flow, preventing chemokines from 
flowing away in the blood (potentially allowing the formation of ‘gradients’), so they act 
as a mechanism for chemokine localisation and can be involved in chemokine receptor 
signalling (19). CCL2 and CCL8 dimers bind to GAGs better (hetero>homo) than each 
chemokine alone (7). GAGs can provide a substrate for chemokine presentation to 
chemokine receptors, as well as being able to protect chemokines from proteolytic 
cleavage (20-22).  
1.1.2.3 N-terminal Cleavage 
As briefly mentioned earlier, the N terminal of chemokines can be processed by 
proteases, for example CD26 (dipeptidyl peptidase) and MMPs (matrix metalloproteases). 
Processing of chemokines can alter the affinity for the receptor, as well as affecting 
receptor specificity and downstream signalling (23, 24). Proteolysis can lead to chemokine 
inactivation or create receptor antagonists (25, 26). CD26 cleaves chemokines at the last 
two N terminal amino acids, if they have a proline, hydroxyproline or alanine at the 
second position, meaning it cannot cleave all chemokines (23). 
During inflammation, stromal cells and leukocytes produce MMPs. These are involved in 
ECM (extracellular matrix) remodelling; they can mediate inflammation, angiogenesis and 
metastasis. As with CD26, not all chemokines are cleavable by MMPs. CCL2, 7, 8, 11 and 
13 can be cleaved by MMPs in vitro but they still retain their chemokine receptor binding 
ability (27). Cleavage of chemokines by MMPs can create antagonists of inflammation (7). 
MMPs can also cleave GAGs, and in doing so can release bound chemokines (27). 
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1.2 Chemokine receptors 
Chemokines mediate their effects through binding to seven transmembrane G protein 
coupled receptors (GPCRs) that bear similarities to the rhodopsin family of receptors (28). 
As with chemokines, chemokine receptors are classed according to the positioning of 
conserved cysteine residues of their cognate ligands and fall into the same structural 
families (CXC, CC, XC and CX3C). Chemokine receptors can also be classified as 
inflammatory or homeostatic, according to the chemokines that they bind. Chemokine 
receptors and the ligands they bind are described in table 1.1.   
Many chemokine receptors have the ability to bind to numerous different chemokines, 
but these tend to be within the same family (with the exception of DARC – see section 
1.8.2). Inflammatory chemokines and receptors tend to be more ‘promiscuous’ than 
homeostatic chemokines and receptors. Homeostatic chemokines tend to form 
monogamous relationships with their receptors, for example the B cell associated 
chemokine CXCL13 only binds to CXCR5 (2, 29). 
1.2.1 Chemokine Receptor Structure 
Chemokine receptors share a common structure; all are ~350 amino acids in length 
(~40kDa). A diagram is shown in figure 1.1. The extracellular domain of chemokine 
receptors has an acidic N-terminus with three extracellular loops which are involved in 
chemokine binding (3, 6). This N-terminus is critical for chemokine binding; N-terminal 
truncation of chemokine receptors abrogates ligand binding and fragments containing the 
N-terminal of chemokine receptors can bind chemokines (9, 30, 31).  
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Figure 1-1: Basic chemokine receptor structure.  
Chemokine receptors have a seven-transmembrane spanning structure. The extracellular acidic amino-
terminus interacts with the three extracellular loops to bind to chemokines. The carboxy-terminus and 
the intracellular loops are involved in downstream signalling, in particular the DRY motif is essential for 
interactions with G proteins, required to induce signalling events.  
The C-terminus and three intracellular loops are found within the cell. A common feature 
of chemokine receptors is the DRYLAIV motif, found in the second intracellular loop, 
which is essential for signalling. Chemokine receptors can be glycosylated and/or 
sulphated on tyrosine residues present at the N-terminal. Tyrosinase sulphation can 
increase the affinity of the receptor for the ligand (7).  
1.2.2 Chemokine Receptor Dimerisation 
Chemokine receptors have been shown to interact with one another and form dimers, 
this has been shown by BRET (bioluminescence resonance energy transfer) and FRET 
(fluorescence resonance energy transfer) analysis; homodimerisation has been shown for 
CCR5, CXCR2 and CXCR4 (32-35). Dimerisation can occur shortly after synthesis and is 
ligand independent, although ligand dependent dimerisation has been described (for 
CCR2 (3)). Dimerisation of chemokine receptors has been shown to alter signalling, e.g. in 
CCR2 co-expression with CCR5, binding of chemokine to CCR5 can block CCR2 signalling 
and vice versa (7, 36). This could mean that dimerisation may represent a mechanism for 
alternative chemokine receptor signalling in certain contexts.  
1.2.3 Viral Chemokine Receptors 
Viruses have evolved the ability to exploit the chemokine system to assist in their 
propagation throughout the body. They can do this by producing soluble chemokine 
binding proteins, e.g. HHV8 (herpes virus 8) encoded M3 protein binds chemokines from 
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all four families. CMV (cytomegalovirus) produces US28, which is a chemokine receptor 
thought to use constitutive trafficking to clear chemokines from the site of production, 
MT-7 (expressed by myxoma) is a chemokine binding protein which does not resemble 
chemokine receptors, but binds chemokines with high affinity (10, 37). Virally encoded 
chemokine binding proteins can help viruses subvert and evade the immune response, 
allowing their survival within the body and demonstrate the essential roles chemokines 
play in viral infections.  
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1.3 Chemokine Receptor Signalling 
1.3.1 Ligand Binding 
Chemokine binding modifies the tertiary structure of the chemokine receptor, which 
causes changes within the cell. The intracellular C-terminus of chemokine receptors is 
coupled to G proteins, which are essential for chemokine receptor signalling. This has 
been shown by treatment of cells with pertussis toxin (PTx), which blocks interactions 
between G proteins and GPCRs. PTx treatment does not fully block chemokine induced 
signalling, it only blocks association with Gi, which means that chemokine receptors can 
couple to other G proteins, e.g. Gq (3). The G protein complex that associates with 
chemokine receptors is the Gαβγ complex (common signalling pathways are shown in 
figure 1.2).  
Upon chemokine binding, G proteins exchange GDP for GTP which causes Gαi and Gβγ to 
dissociate. Gαi binds to the receptor and causes conformational changes that lead to JAK 
(Janus kinase) association and receptor phosphorylation. Gαi and the phosphorylated 
receptor promotes recruitment of GRK family proteins which cause recruitment of β-
arrestins and further receptor phosphorylation, which prevents further G-protein 
coupling (3). Gβγ induces PLC (phosholipase C) activation, which results in the release of 
1,4,5-Inositol triphosphate (IP3), which causes intracellular calcium mobilization and 
activation of Ras and Rho pathways (4).  PLC activation also causes DAG (1,2-
Diacylglycerol) release that acts with free calcium to activate PKC (Protein kinase C) 
isoforms. PKC activates signal transduction which results in chemotaxis, adhesion, and 
downstream gene expression (3, 7, 38). 
Claire L. Burt, 2011   31 
 
Figure 1-2: Signalling pathways activated after chemokine receptor activation. 
Upon chemokine receptor binding, the G protein complex associated with the receptor exchanges GDP 
for GTP, which causes dissociation of Gβγ from Gαi. Gαi associates with the receptor resulting in 
phosphorylation and subsequent JAK/STAT association. Gαi activity also causes activation of protein 
tyrosine kinases and GRK which cause further receptor phosphorylation and recruitment of β-arrestins, 
which causes receptor desensitisation. MAPK pathways become activated, which can result in activation 
of transcription factors. Gβγ induce downstream signaling by activating PLC, which causes mobilization of 
intracellular calcium stores, and together with DAG, activates various PKC isoforms, which cause 
activation of transcription factors and signal transduction. 
Downstream signalling can have different effects, e.g. CXCL12 induced signalling can be 
pro or anti-apoptotic depending on the signalling pathway induced. The downstream 
signalling pathways induced depend in the cell type, for example CXCL12 signalling in 
human CD4+ T cells induces both pro and anti-apoptotic pathways, but this has an overall 
anti-apoptotic effect. But in neurons, CXCL12 signalling results in apoptosis, so the 
downstream effects are cell dependent (39, 40). Multiple chemokine signals may result in 
synergy or dominance of one over the other (41, 42).  
1.3.2 Receptor desensitisation 
After ligand binding, the chemokine receptor can be down regulated, in a ligand 
dependent manner. For example, CXCL8 binding can cause down-regulation of more than 
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90% of chemokine receptor (CXCR1 or CXCR2) expression from the surface within 10 
minutes of binding (43). The down-regulation of chemokine receptors involves 
interactions between GRK (G-protein coupled receptor kinase), arrestins, clathrin and 
dynamin. 
Desensitisation of chemokine receptors can occur via steric hindrance, caused by receptor 
phosphorylation by GRK family proteins (3), which act on serine and threonine residues in 
the C-terminal tail of the receptor. Phosphorylation of the C-terminus increases the 
affinity for arrestins which bind and prevent G protein recruitment, this causes 
endocytosis, via clathrin coated pits and/or lipid rafts/caveolae. This method of 
desensitisation was first described for CCR2 (44). The two methods of internalisation, 
caveolae and clathrin coated pits, are regulated independently(2). 
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1.4 Chemotaxis 
The movement of cells can be described in a variety of different ways, for example cell 
motility would be used to describe a cell that is able to move independently, sperm cells 
or bacterial cells for example. With respect to leukocytes, numerous different terms are 
used – cell migration, trafficking, chemotaxis. Cell migration tends to describe the 
orchestrated movement of cells to defined locations, but cells can do this in a number of 
different ways. Directed cell migration towards a chemical stimulus is known as 
chemotaxis, whilst cell movement along adhesion molecules is known as haptotaxis, both 
are types of cell migration (45, 46).  
Not all leukocytes have the capacity to move, they require expression of the relevant 
chemokine receptors, for example, and they need to be in the appropriate stage of the 
cell cycle. If a leukocyte has this intrinsic locomotor capability, then it has the potential to 
undergo random or directed locomotion (45, 46). Random locomotion can be used to 
describe ‘random walking’, which has been used to describe the movement of T cells in 
the lymph node, observed using two photon microscopy (47). Directional locomotion 
describes a cell moving with either a preference or avoidance of a direction. Chemotaxis 
describes the directed movement towards a chemical stimulus, but this stimulus may not 
cause directed movement, instead it may increase the speed of a cells movement, a 
process known as chemokinesis (45, 46). 
In relation to chemokines, the best definition of cell movement is chemotaxis, which will 
be described here, as it is the most common effect of a chemokine binding to its relevant 
receptor. Chemotaxis involves detection of a chemokine (or chemical stimulus), which 
causes establishment of polarity, and results in directed cell movement. Establishment of 
cell polarity involves changes in cell shape, integrin affinity changes and recycling at the 
leading edge (3). During chemotaxis, cells can interact with selectins, integrins, GAGs and 
chemokine receptors (7). Leukocyte migration, i.e. chemotaxis, is essential for the 
development of immune responses. Defective leukocyte migration (leukocyte adhesion 
deficiency) causes recurrent bacterial and fungal infections (48).  
Chemokine binding to chemokine receptors induces a cascade of signalling events which 
leads to reorganisation of the cytoskeleton, to create a ‘leading edge’ or pseudopod, and 
a uropod at the other end of the cell (3). The pseudopod has a high concentration of 
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integrins and chemokine receptors which makes it specialised for chemokine detection 
(49). The uropod is similar to the pseudopod but at the opposite end of the cell and is 
important for motility and adhesion. Adhesion molecules such as, ICAM-1 (Inter-cellular 
adhesion molecule-1), L-selectin, Mac-1 and CD43 are concentrated here (2). This 
promotes binding of other cells which enhances recruitment and allows transendothelial 
migration (3). The induction of polarised morphology is not a response to a chemotactic 
‘gradient’ as it can be seen in cells during random walking. Chemotaxis is characterised by 
an enhanced rate of locomotion and a unidirectional response (2).  
1.4.1 Signalling - Chemotaxis 
After chemokines bind to chemokine receptors the resulting signalling cascade is involved 
in chemotaxis. As mentioned above, chemokine receptor signalling causes the production 
of PI3K and PIP3 (phosphatidylinositol (3,4,5) triphosphate), which translocate to the 
pseudopod and co localise with Rac. PIP3 then activates Rac via guanine nucleotide 
exchange factors (GEFs). PIP3 can become a docking site for PKB (protein kinase B), which 
also translocates to the pseudopod and causes actin polymerisation. PI3K causes 
activation of PKC, Akt and Ras pathways that are involved in altering integrin 
adhesiveness, cell migration and polarisation (2).  
Rho and Rac are confined to the uropod and pseudopod respectively, as they are 
mutually inhibitory (50). Rho activation causes focal adhesion of myosin II, which forms 
and contracts actin:myosin complexes. This is involved in uropod contraction. Rho 
prevents lamelliopodia formation, which is essential for the formation of the pseudopod. 
Rho family proteins have a role in regulating the actin cytoskeleton. (2).  
1.4.2 Leukocyte Adhesion Cascade 
In order to leave the blood, leukocytes must be able to detect chemokines. This process 
involves a cascade of events often referred to as the leukocyte adhesion cascade. This 
occurs sequentially, each step being conditional for the next. 
The first step is known as rolling, which involves leukocytes in the bloodstream, binding to 
the vasculature via selectins. These interactions are not very strong and can easily be 
broken due to the shear force in the blood. This causes cells to roll along the vessel wall. 
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In order to stop rolling, cells require integrin activation (e.g. VLA-4, α4β7, LFA-1). Specific 
combinations of chemokine binding to chemokine receptors causes integrin activation, 
which leads to stable interactions and the cell comes to a stop (48). Once the cell has 
come to a stop, the cell must migrate between or through endothelial cells lining the 
vasculature and migrate through the basement membrane (51).  
1.4.2.1 Selectins 
The family of selectins consists of three members of the highly conserved C-type lectin 
family. L-selectin is found on most circulating leukocytes. It initiates the binding of cells to 
the vessel walls at sites of inflammation or injury and in HEVs. P-selectin can be expressed 
rapidly by endothelial cells (it is found in preformed granules) which is quickly followed by 
E-selectin expression, in response to inflammatory stimuli (52). These selectins are 
important for T cell, B cell, neutrophil, monocyte, NK cell and eosinophil recruitment (48). 
Rolling is mediated by L-selectin expressed by leukocytes, which can bind to P-selectin 
and E-selectin, on the inflamed epithelium. Selectins bind to sialyl Lewis-x like 
carbohydrate ligands presented by sialomucin like surface molecules, e.g. PSGL-1 (P-
selectin glycoprotein ligand-1). PSGL-1 binding to L-selectin causes interactions between 
leukocytes and the endothelium to facilitate tethering. This selectin binding allows 
leukocytes to adhere to inflamed endothelium. The shear stress caused by the blood flow 
is required for L- and P-selectin to support their adhesion. This type of bonding is known 
as a catch bond, which strengthens when shear stress is applied. Selectin mediated rolling 
of leukocytes allows activating signals to be transmitted via the binding of chemokines to 
their receptors (51, 53).  
1.4.2.2 Integrins 
The next stage of the leukocyte adhesion cascade involves integrins, which stabilise cell 
rolling interactions on the inflamed endothelium. Different families of integrins exist, e.g. 
β1 and β2 integrins. The β2 integrin family is the main class expressed on leukocytes, e.g. 
LFA-1, Mac-1.  LFA-1 can change its conformation to increase the ligand binding affinity 
under shear stress (48, 51). Chemokine induced signalling causes conformational change 
of integrins from intermediate to high affinity causing cell arrest, e.g. PLC (phospholipase 
C) activation causes activation of small GTPases which leads to integrin conformational 
changes (51). 
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1.4.2.3 Chemokine receptors 
Selectin mediated rolling is stabilised by integrin interactions, but chemokine receptor 
signalling is required for cell arrest. Chemokine receptor signalling causes tight binding of 
integrins, expressed on leukocytes, to Ig (Immunoglobulin) superfamily members on 
endothelial cells, e.g. ICAM-1 and VCAM-1. During inflammation endothelial cells can 
become activated which causes expression of adhesion molecules, production of 
chemokines and lipid chemoattractants. These can be presented on the luminal surface of 
the blood vessel (51).Platelets can also deposit CCL5, CXCL4 and 5 on inflamed 
endothelium which can trigger the arrest of rolling monocytes.  Chemokines can also be 
presented on GAGs which may be required for efficient leukocyte recruitment (51).  
1.4.2.4 Diapedesis 
Once the cell has come to a stop in the blood vessel, it must exit the vessel in the final 
stage of the leukocyte adhesion cascade. Diapedesis is the movement of leukocytes from 
the blood stream through post-capillary venules. Rap1 and RhoA are required to 
coordinate the process of allowing leukocytes to cross the inflamed endothelium. During 
inflammation, the ECM undergoes constant remodelling, and leukocytes can induce local 
proteolysis to aid their migration. This proteolysis may modulate chemokine binding 
specificity and release chemokines stored in the matrix (48). Diapedesis through 
endothelial vessels can occur via transendothelial, paracellular and transcellular routes. 
These methods require the presence of apical and junctional endothelium ICAM-1 and 
VCAM-1 (51). 
After passing through the endothelial cell barrier, leukocytes need to get through the 
basement membrane and pericytes (mesenchymal cells associated with blood vessels). 
Within the basement membrane there are areas with low expression of matrix proteins, 
which makes these areas permissive for migrating neutrophils and T cells (54, 55) . These 
areas are found to co-localise with gaps between pericytes. In extravascular tissue, these 
areas may be more permissive to chemoattractants, and so create areas with high 
chemoattractant expression (51).  
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1.4.3 Therapies Targeting Chemotaxis 
Altering cell migration is an attractive target for combating inflammatory conditions. 
There are numerous points where intervention may be possible to inhibit leukocyte 
extravasation, e.g. selectins, integrins or chemoattractant receptors. Targeting 
chemotaxis can be thought of as a ‘double-edged sword’. It is difficult to develop drugs to 
target integrins or selectins, as the small number of targets means that drugs may be too 
effective, and have serious side effects. Targeting chemokine receptors is also difficult, 
due to the vast number of targets and the high level of redundancy in the system (53).  
Despite these problems, treatments exist which target various steps in the leukocyte 
adhesion cascade. Natalizumab is a monoclonal antibody (mAb) against the integrin α4 
chain. This blocks binding of α4β1 (VLA-4) to VCAM-1 and α4β7 binding to MadCAM-1. 
This has been used in MS (multiple sclerosis) and Crohns disease but it has side effects, 
e.g. the activation of latent viral infections which can cause encephalitis (56, 57). 
Efalizumab is a mAb against LFA-1 which is used in chronic moderate to severe psoriasis 
(51). Inhibitors of selectins can help in ischaemia-reperfusion injury and atherosclerosis 
(53).  Although therapies do exist which target cell movement, they carry serious side 
effects and may not be the ideal target for these diseases, as they could have effects on 
normal cell trafficking.  
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1.5 Chemokines and Development 
1.5.1 Development  
Homeostatic chemokines are involved in tissue specific migration and lymphoid tissue 
development. CXCL12 and CXCR4 are essential for normal development, they are known 
as the primordial chemokine and receptor. Gene null mouse studies have been very 
useful in defining the roles that CXCL12 and CXCR4 play throughout development. CXCL12 
null mice die perinatally and have B cell lymphopoiesis defects, as well as problems with 
the bone marrow microenvironment. These effects can also be seen in CXCR4 null mice. 
These studies revealed the essential role that CXCR4 has in embryogenesis, myelopoeisis, 
B cell lymphopoiesis and organ development. CXCL12 and CXCR4 are also involved in the 
localisation and retention of progenitors in the bone marrow (58-62).  
1.5.1.1 Thymus 
Throughout T cell development in the thymus, thymocytes change their chemokine 
receptor expression in order to move into different areas of the thymus. Thymic dendritic 
cells produce CCL25 and the expression of CCL25 is important for the early stages of 
thymocyte development, where they express CCR9. This CCR9 expression is lost as 
thymocytes undergo maturation and CCR7 expression is upregulated. This switching of 
chemokine receptors allows mature thymocytes to leave the thymus, and is essential for 
T cell development. As a result of this chemokine receptor expression, the important 
chemokines in thymic development are CCL19, CCL21 and CCL25 (63, 64). 
The use of CCR7 KO mice has clarified the essential role that CCR7 plays in the 
development of T cells and how T cells rely on the thymic microenvironment. CCR7 is 
important for thymic compartmentalisation, if mice lack CCR7 (CCR7 KO mice or plt/plt 
mice – see section 1.5.1.2 for more details) then the architecture of the thymus is altered, 
which results in impaired T cell development and a reduction in the numbers of 
thymocytes (65-68). CCR7KO mice also have problems with the process of negative 
selection, which is responsible for eliminating autoreactive T cells – this process does not 
occur in CCR7 KO mice. This impaired negative selection may be due to a reduced 
responsiveness of these cells to TCR stimulation (69), or due to impaired migration from 
the cortex to the medulla (70). This may contribute to the spontaneous autoimmunity 
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exhibited in these mice; alternatively it could be caused by incomplete peripheral 
tolerance or defects in Tregs (71).  As well as having problems with the development of T 
cells within the thymus, CCR7KO mice have a reduction in foetal haematopoietic 
progenitors in the thymus. These cells are the precursors for T cells and require CCR7 to 
get into the thymus. 
1.5.1.2 Lymphoid Tissue 
As with embryonic and thymic development, the development of lymphoid tissue (e.g. 
lymph nodes and Peyers patches) is dependent on chemokines. Chemokines are 
important during development and during the initiation of immune responses in 
lymphoid tissue; chemokines are involved in naïve T cell homing, B cell localisation in 
follicles, and cell recruitment via HEVs (37). The most important chemokine receptors 
with respect to lymphoid tissue development and function are CCR7 and CXCR5.  
The development or organogenesis of lymphoid tissue has been shown to rely on the 
chemokines CXCL13, CCL19 and CCL21. The initial development of lymphoid tissue starts 
with clustering of two groups of cells – lymphoid tissue inducer cells (LTICs), which are 
IL17R+CD3-CD4+CD45+ and stromal cells (VCAM1+ and ICAM1+). After this initial 
clustering, LTICs express LTα1β2 which can bind to LTβR on the stromal cells, and cell 
adhesion occurs via interactions with VCAM1. LTβR signalling causes the production of 
CXCL13, CXCL4, CCL19 and CCL21, which recruit more haematopoietic and stromal cells, 
creating a positive feedback loop. Once a large enough cell cluster has developed, blood 
vessels differentiate to become HEVs, and a lymphoid organ is formed (72-74). 
CCR7 is essential for cell entry into the lymph node; it is used to guide T cells, B cells and 
DCs into the T cell areas of lymph nodes, facilitating antigen presentation and the 
initiation of an adaptive immune response. CCR7 is able to guide cells here due to the 
production of its ligands, CCL19 and CCL21, which are constitutively produced by stromal 
cells, CCL21 can also be produced by the endothelial layer of HEVs (75, 76). Mice lacking 
CCR7 have impaired cell migration into Peyers patches and peripheral LNs, they have 
increased numbers of T cells in the peripheral blood, which correlates with reduced T cell 
numbers in the LN (77). These mice have migration problems with their T cells, which fail 
to home to the LN, and DCs which are unable to leave dermal tissue to get to the draining 
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LN. Further problems with these mice, include the development of spontaneous 
autoimmunity and disorganised lymphoid architecture (71).  
The plt/plt (paucity of lymph node T cells) is a naturally occurring strain of mutant mouse, 
which has lost the genes encoding CCL19 and CCL21-ser isoform, but the genes for CCL21-
leu still remain. This means that these mice lack expression of CCL21 in lymphoid organs, 
but still express CCL21 in lymphatic vessels of non-lymphoid organs. These mice suffer 
from various defects, including defective thymic architecture, which means T cell 
development is impaired. Plt/plt mice have impaired migration of CCR7 positive T cells 
and DCs into lymphoid organs, resulting in reduced numbers. The mobilisation of DCs can 
still occur in the periphery, due to the expression of CCL21-leu (67, 68, 78, 79). Studies 
using these mice have shown the essential role that CCR7 and its ligands, CCL19 and 
CCL21, play in the recruitment of cells into the lymph node and the development of 
immune responses.  
Whilst CCR7 and its ligands are mainly responsible for T cell and DC migration and 
placement in lymphoid organs, CXCR5 and its ligand CXCL13 are responsible for the 
segregation of lymphoid organs into distinct T and B cell areas and the movement of B 
cells within lymphoid tissue. Stromal cells in the B cell follicles of secondary lymphoid 
organs constitutively express CXCL13 and CXCR5 is expressed on mature circulating B 
cells. In mice lacking CXCR5, there is a defect in the segregation of T and B cells in the 
spleen and PP, which is similar to that seen in CXCL13 KO mice. Study of these mice led to 
a startling discovery that CXCL13 and CXCR5 are involved in lymphoid organ development, 
these mice lack (or are present at low frequency), peripheral LNs and PP (76, 80, 81).  
 As well as being involved in homeostasis and development, homeostatic chemokines can 
be upregulated during chronic inflammation. Here they can contribute to the formation 
of ectopic lymphoid follicles, e.g. in rheumatoid arthritis (82, 83).   
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1.6 Chemokines and the Immune Response 
1.6.1 Innate Cells 
Pathogens first encounter the immune system via the innate immune system. This 
developed to respond rapidly to invading pathogens, and to allow an adaptive immune 
response to be generated. Pathogens cause activation of TLRs (Toll-like receptors) via 
conserved PAMPs (pathogen associated molecular patterns). These trigger production of 
a wide range of inflammatory cytokines and chemokines, which creates a pro-
inflammatory environment. Chemokines can also be produced under the influence of 
fibrinogen, elastins, defensins, and cytokines such as, IL1, TNFα, IFNγ, IL4, IL5, IL6, IL13 
and IL17, all of which can be produced during infection (84-86). Chemokines then cause 
cellular recruitment to the site of inflammation, which include neutrophils, macrophages, 
NK cells and DCs (dendritic cells). Dendritic cells, both resident and those recruited via 
inflammatory chemokines, are specialised to phagocytose foreign antigens. They act as 
the ‘bridge’ between the innate and the adaptive immune system by presenting antigens 
to T cells in the lymph nodes (87).  
The main job of neutrophils and monocytes is to arrive at the site of infection to 
phagocytose pathogens, as well as to produce nitric oxide and reactive oxygen species. 
Neutrophils are the first cells to arrive at the site of infection and can both protect and 
cause tissue injury. IL1 and TNFα cause the production of chemokines which attract and 
activate neutrophils at the site of infection and inflammation, as well as chemokines that 
bind to CXCR1 and CXCR2, the main chemokine receptors expressed by human 
neutrophils. Blocking both of these receptors can inhibit neutrophil migration in vivo (38). 
Monocytes are the next cells to arrive at the site of inflammation, their recruitment 
involves CCL2, 7, 8 and 13 (CCR2 and CCL2 have a non-redundant role in monocyte 
recruitment (88)).  
1.6.2 Dendritic Cells 
In order to communicate between the innate and adaptive immune systems dendritic 
cells (DCs) are essential. Immature DCs arise in the bone marrow and they are able to 
migrate to the periphery and secondary lymphoid organs. DCs can also arise from 
circulating monocytes. Within a lymph node there can be up to 6 different DC subsets 
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(89). The main job of DCs is to process antigen and present it to T cells in the context of 
MHC, thus helping to mount an adaptive immune response. In order to do this, DCs must 
mature and migrate to the lymph node from the site of inflammation, where they can 
interact with antigen specific T cells. This involves down-regulation of chemokine 
receptors (which are required to get to the site of inflammation) and upregulation of 
CCR7. This can occur under the influence of bacterial products such as BLP (bacterial 
lipoprotein) (90). CCR7 allows DCs to migrate into the lymph node and reach the T cell 
area (2). Immature DCs express CCR6 (which binds CCL20), as well as inflammatory CC 
chemokine receptors, such as CCR1-3. As DCs become mature they express CCR7 (binds 
CCL19 and 21). LPS causes a reduction of CCR1-3 expression, and causes an increase in 
CCR7 on DCs (91). This receptor switching is essential for DCs to leave the site of 
inflammation and reach the lymph node (38).  
1.6.3 T Cells 
T cells are responsible for mounting an adaptive immune response to antigens. Once 
dendritic cells become activated at the site of infection, they migrate to the lymph nodes, 
where they present antigen (in the context of MHC) to antigen specific T cells. These T 
cells become activated and can provide help to B cells to produce antibody, or have 
directly cytotoxic effects on infected host cells, depending on the type of T cell activated 
(CD4+ and CD8+ respectively).  
Naïve T cells circulate and express L-selectin, LFA-1, α4β7 integrin, CXCR4 and CCR7. CCR7 
is the chemokine receptor responsible for T cell entry into the lymph node. CCR7 ligands 
can be produced by HEVs (CCL21), or produced in the lymph node and transcytosed to 
the luminal surface of the HEVs (CCL19) (2). Within the lymph node, T cells move into the 
T cell area due to production of CCL19 and CCL21, which are produced by mature DCs and 
stromal cells (79, 92). For T cells to move into the B cell follicles and provide help for 
antibody production, CXCR5 must be up regulated. Cell exit from the lymph node involves 
the alteration of chemokine receptor expression, but more importantly, it depends on the 
expression of a different type of seven transmembrane receptor, S1P. S1P is a receptor 
that is involved in T and B cell exit from lymphoid tissues. The discovery of the role this 
receptor plays in lymphocyte egress occurred through studies using FTY720. FTY720 is a 
compound that was found to induce a rapid loss of lymphocytes from the blood, in actual 
fact, it inhibits lymphocyte egress from LNs, by binding to 4 out of the 5 S1P receptors. In 
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the LN, when T and B cells have recognised antigen on DCs, S1P1 is down regulated. This 
allows them to remain in the LN (through signals from chemokines) to activate and 
proliferate. After activation and proliferation, S1P1 is upregulated, which allows cells to 
leave the LN. Studies in vitro have shown that high concentrations of S1P (an S1P1 ligand) 
causes cells to have reduced responsiveness to chemokines, which may explain the 
mechanism by which S1P allows egress from the LN (76).  
CCR7 expression is essential to allow T cell exit from the site of inflammation and entry to 
the lymph (93). The location of chemokines within the lymph node, allows co-localisation 
of T cells with DCs, which allows the initiation of immune responses (94, 95). Evidence 
suggests that chemokines signalling through chemokine receptors are able to modulate T 
cell responses via the TCR, which may allow T cell movement to the lymph nodes or keep 
T cells at the site of inflammation, depending on the chemokine stimulus (96). Mice with 
defects in CCR7 expression, or its ligands, have numerous problems relating to T cell 
localisation and lymphoid tissue organisation, which have been discussed in detail above.  
T cells can fall into various different subsets, depending on the production of cytokines 
and expression of chemokine receptors. Th1 cells develop under the influence of IFNγ. 
They produce IFNγ and IL-2, which can be involved in acute and chronic inflammatory 
diseases. CCR5 and CXCR3 are expressed by Th1 cells and their ligands are expressed in 
Th1 associated diseases, e.g. rheumatoid arthritis, atherosclerosis and MS (95).Th2 cells 
develop under the influence of IL4, they are CCR3 positive and its ligands are expressed in 
allergic inflammation. Th2 cells can also transiently express CCR4 and CCR8 (37, 95). 
Th17 cells are a recently discovered T cell subset that has distinct functions from Th1 and 
Th2 cells. Th17 cells are involved in the clearance of pathogens that are not cleared by 
Th1 or Th2 cells.  Naïve T cells develop into Th17 cells under the influence of TGFβ plus IL6 
and IL21, and they produce IL17, IL22 and IL23. Th17 cells have close ties to another T cell 
subset, regulatory T cells (Tregs). In the presence of TGFβ, a naïve T cell will become a 
FOXP3+ Treg, but if TGFβ is present with IL6 plus/or IL21 then that cell will become a Th17 
cell. IL6 is crucial in determining the balance between Tregs and Th17 cell, CCR6KO mice 
have increased numbers of Treg and defective Th17 cell generation. Th17 cells are found 
mainly at barrier sites, mucosal surfaces in particular, and are thought to protect the host 
against microorganisms which invade at these sites (97-99). Th17 cells have been 
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implicated in autoimmune diseases and inflammation, for example EAE, CIA and some 
colitis models (100).  
T cells are not only activators of the immune system; populations exist which have 
suppressive capabilities. FOXP3+ Tregs are required for immune homeostasis – they are 
able to suppress immune responses and inflammation. The initial discovery of Tregs was 
after the observation that mice that underwent a neonatal thymectomy had chronic 
inflammation in numerous tissues (101). Tregs are CD4+ CD25+ FOXP3+, but in contrast to 
CD4+CD25- T cells, they do not proliferate after TCR engagement. Instead Tregs suppress 
the proliferation of other effector T cells, and this occurs in a contact dependent manner. 
FOXP3 expression is essential for Treg differentiation, high expression is a characteristic 
feature of Tregs. They are produced in the thymus, but can also develop in the periphery, 
particularly in the gut where retinoic acid and TGFβ act together to induce high numbers 
of Tregs, at the cost of effector T cells (102-104).  
Tregs are able to suppress the activation, proliferation and effector functions of a wide 
range of cells, meaning they are able to prevent autoimmunity, allergy, and can suppress 
responses against tumours. CD4+CD25+ FOXP3+ are known as natural Tregs, but other 
subsets of regulatory T cells exist, subsets that are inducible T regs. These include Tr1 
cells, which can be induced if naïve T cells are primed with antigen in the presence of 
IL10. Tr1 cells produce large amounts of IL10, IL5 and TGFβ, but low levels of IFNγ and IL2 
(105). CD4+CD25- T cells can be induced to express CD25 and FOXP3 in the periphery, 
under the influence of TGFβ, a cell population referred to as inducible periphery Tregs 
(106).  Whilst TGFβ can induce the development of inducible Tregs in the periphery, by 
upregulating the expression of FOXP3, if IL4 (a classical Th2 associated cytokine) is 
present at the point of priming, the expression of FOXP3 is suppressed (107). These cells 
can produce IL9 and IL10, but don’t appear to have any regulatory function; after 
adoptive transfer they promote tissue inflammation (108). This recently discovered 
subset has been named ‘Th9’ cells. Th9 cells have also been shown to develop from Th2 
cells, TGFβ can reprogram Th2 cells to lose expression of IL4, IL5 and IL13 and upregulate 
IL9 (109). The role for Th9 cells is not yet clear, but it has been suggested that they are 
involved in both tissue inflammation and responses against helminths (107-109).  
Another subset of T cells are known as follicular helper cells (Tfh), they have the unique 
ability to home to B cell follicles. Tfh are CXCR5+, can secrete IL10 and have a role in B cell 
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differentiation. Tfh precursors migrate to the border of the T and B cell area, and they can 
continue into the follicle where they can continue their differentiation, under the 
influence of B cell interactions and cytokines. There is evidence that Tfh can produce IFNγ 
and IL17, and they may have a role in autoimmunity (110-112).  
Following activation, naïve T cells can become memory T cells. These cells are specialised 
to mount rapid responses if re-challenge occurs with the same antigen, which is a unique 
feature of the adaptive immune response. There are two main types of memory T cells, 
central memory and effector memory. Central memory T cells can migrate into lymph 
nodes and enter sites of inflammation. Central memory T cells have a high proliferative 
capability as well as being able to stimulate DCs and provide B cell help (113). Effector 
memory T cells do not express CCR7, so they cannot traffic to the lymph node and are 
subsequently found in the tissues. This means they are suitably positioned to mediate 
direct cytotoxic effects upon re-challenge and can rapidly create an inflammatory 
environment through the production of cytokines (2, 113). 
1.6.4 B Cells 
The main purpose of B cells is to produce specific antibodies, essential for the mounting 
of an adaptive immune response. As with other cells of the immune system, B cell 
responses can be controlled by chemokine receptors. All mature circulating B cells 
express CXCR5, which is involved in their developmental positioning. CXCR5 binds to 
CXCL13, which is produced in the B cell areas of lymphoid tissue and is found on HEVs in 
the follicles. It is essential for follicle formation in the spleen and lymph node. CXCR5 can 
be found on a small subset of T cells (114, 115). CXCL13 can increase integrin affinity and 
allow B cells to traverse the T cell areas of the lymph node to enter the follicles (116). IgG 
producing plasma B cells are found in the bone marrow due to interactions between 
CXCR4 and CXCL12. IgA secreting B cells are CCR9 or CCR10 positive, and are found in the 
gut or the skin respectively (2).  
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1.7 Tissue Specificity 
1.7.1 Skin Homing 
Chemokines and chemokine receptors can be used as a type of ‘address’ system, to 
confer tissue specificity to cells. This tissue specificity is imprinted in the draining lymph 
node and is dependent on APCs (antigen presenting cells). Populations of DCs exist which 
are skin specific. These are known as Langerhans cells. In the skin, antigens are 
phagocytosed and presented by Langerhans cells in the draining lymph node. The 
combination of a skin-specific DC (which may be a Langerhans cell or another type of skin 
specific DC), presentation in the skin draining lymph node and the presence of vitamin D, 
confers skin-specificity to T cells (117-119). To generate T cells that are capable of 
migrating into the skin, specific chemokine receptors must be upregulated; CCR4 and 
CCR10 are required for cell homing to the skin. Skin homing T cells express CCR4, which 
binds CCL17 and CCL22 in blood vessels in the skin, and CCR10, which binds CCL27 and 
CCL28. As well as the expression of skin specific chemokine receptors T cells have to 
express CLA (cutaneous lymphocyte-associated antigen). CLA positive cells can enter the 
skin via E-selectin expression in the blood vessels in the skin (95, 120, 121).  
1.7.2 Small Intestine Homing 
Similar to the skin, the gut has its own chemokine ‘address’ system, which is imprinted 
onto T cells at the point of antigen presentation. In the gut and its associated lymphoid 
tissue (Peyers patches and mesenteric lymph nodes), DCs present antigen to T cells in the 
presence of the vitamin A metabolite, retinoic acid. The presence of retinoic acid 
‘imprints’ T cells in the gut, causing upregulation of α4β7 integrin and CCR9 (122).  CCR9 is 
needed for homing to the small intestine, where it binds CCL25. Gut homing T cells 
express CCR9 which binds CCL25, and α4β7 which binds MadCAM1 on intestinal blood 
vessels (123). Myeloid DC localisation in the subepithelial dome of the Peyers patch is 
CCR6 dependent. When DCs in the gut become mature, the levels of CCR6 expression is 
reduced, which allows the cells to leave the dome and enter the T cell area in the Peyers 
patches. The crucial role of CCR6 in intestinal immunity is shown using CCR6 null mice, 
which have defects in humoral immunity in the intestinal mucosa. (124). Closely regulated 
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expression of these chemokine receptors ensures that gut-specific cells are able to home 
to the gut.  
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1.8 Atypical Receptors 
The chemokine system is further complicated by the existence of a family of ‘atypical’ 
receptors. All members of this chemokine ‘receptor’ family share the apparent inability to 
signal in response to ligand binding, which is a result of an alteration in amino acid 
sequences within the second intracellular loop, known as the DRY motif. This motif is 
responsible for coupling the receptor to G proteins and resulting downstream signalling 
(125, 126). This appears to be the only unifying characteristic of these receptors. The 
apparent lack of signalling means that these receptors should be referred to as 
chemokine binding proteins, as they do not fit into the classical definition of a receptor 
(127). Members of this family include D6, DARC, CCX-CKR and CXCR7 (128). The ligands 
they bind are described in Table 1-2.  
Receptor Ligands
D6 CCL2, CCL3, hCCL3L1, CCL4, hCCL4L1, CCL5, 
CCL7, CCL8, CCL11, CCL13, CCL17, CCL22
DARC CCL2, CCL5, CCL7, CCL11, CCL13, CCL14, CCL17, 
CXCL5, CXCL6, CXCL8, CXCL11
CCX-CKR CCL19, CCL21, CCL25
CXCR7 CXCL11, CXCL12  
Table 1-2: Ligands of atypical chemokine receptors in both humans and mice  (adapted from (129, 130) ). 
1.8.1 D6  
1.8.1.1 Discovery of D6 
D6 was first discovered in 1997 during a search for novel CCL3 receptors (130, 131). D6 
was identified as a novel human β chemokine receptor that had high structural and 
functional homology to murine D6 (also discovered around the same time). In order to be 
given a name according to the systematic nomenclature, evidence of signalling had to be 
demonstrated, but since there was no evidence of signalling, the receptor was designated 
D6 (otherwise it would have been CCR9) (130). Murine D6 was originally cloned from 
brain cDNA (131) and its sequence contained the predicted seven transmembrane 
spanning regions and four conserved cysteines characteristic of a chemokine receptor 
(131).  
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1.8.1.2 D6 Ligands 
D6 has the ability to bind to 12 different CC chemokines, as shown in table 1.2. All of the 
ligands that D6 can bind to are inflammatory CC chemokines and there appears to be a 
certain degree of specificity in ligand binding, requiring a proline residue in position 2 of 
the mature chemokine. As a result, the binding of chemokines to D6 can be regulated by 
CD26 processing, since CD26 can cleave chemokines which have a proline or serine at 
position 2 (132). For example, human CCL3L1 has a proline at position 2 and binds D6 
with high affinity, whilst CCL3 with a serine at position 2 has reduced binding capability 
for D6 (133) and another D6 ligand, CCL22 loses the ability to bind to D6 with high affinity 
after processing by CD26 (128).  
1.8.1.3 Structural Characteristics 
The amino acid arrangement of D6 was inferred from its amino acid sequence, and was 
predicted to have seven transmembrane spanning domains, similar to all other 
chemokine receptors. Features common to chemokine receptors that were identified 
include the presence of four conserved cysteines, as well as a putative N-linked 
glycosylation site at the amino terminus. The carboxy terminus of D6 was found to 
contain potential phosphorylation sites, as it was rich in serine and threonine residues. 
Subsequent studies showed that D6 undergoes glycosylation and sulphation in a ligand 
independent manner, as well as being constitutively phosphorylated (134). Human and 
murine D6 were found to be similar (with 71% identity and 86% similarity), and compared 
to other CC chemokine receptors, D6 has on average, 40% identity and 50% similarity. The 
signalling motif which is found in the second intracellular loop of other chemokine 
receptors, DRYLAIVHA, was found to be altered in D6, to DKYLEIVHA (130). This alteration 
in the key signalling motif is thought to be responsible for the absence of calcium fluxes 
and chemotaxis upon ligand binding. D6 is capable of binding chemokines, internalising 
them, and subsequently targets them for degradation (135).  
In vitro more than 95% of D6 is found in early and recycling endosomes meaning only ~5% 
of D6 is found on the surface at any one time (136), this is because D6 is constitutively 
recycling, even in the absence of ligand. In the absence of ligand D6 internalisation is 
dependent on Rab4 and Rab11 (137) whilst after ligand binding, D6 internalisation 
requires Rab5, and may or may not require β arrestins (138, 139). Internalisation of D6 
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occurs via recycling endosomes, which results in the ligand bound to D6 being deposited 
in acidic lysosomes and being degraded. Ligands that are bound and internalised by D6 
are more readily retained within the cell, compared to ligand internalisation by CCR5, as 
the movement through acidic endosomes causes rapid dissociation of ligands from D6 but 
not CCR5 (136). D6 contains a serine cluster in its carboxy terminus, which prevents it 
from entering Rab 7 positive late endosomes, and ensures receptor recycling, rather than 
degradation of D6 (138). The internalisation of D6 is associated with, but apparently not 
dependent on, ligand-independent phosphorylation of the C-terminus. Evidence for this 
has been shown by the removal of the most C-terminal 44 amino acids, or mutating 6 
serine residues in the C-terminus, which blocks phosphorylation but has little effect on 
ligand internalisation (138).   
Evidence exists to suggest that D6 is able to interact with other signalling chemokine 
receptors. Despite its low cell surface expression, D6 has been found to form 
homodimers, and heterodimers with CCR1, and within the cell D6 can form heterodimers 
with CCR5 (140). In transfected L1-2 cells, D6 does not induce calcium fluxes after ligand 
binding, and it appears to be able to blunt chemotactic responses to CCL22, which can 
bind both D6 and CCR4. When co-expressed with CXCR4, D6 has no effect on chemotaxis 
towards CXCL12. These results suggest that D6 may in some way, perhaps through an as 
yet undefined signalling mechanism, interfere with CCR4 signalling and disrupt 
chemotactic responses, but this work uses an artificial system of transfected cells, and 
may not reflect the true function of D6 in vivo (141).  
These characteristics of D6 have been led to the suggestion that it is a chemokine decoy 
receptor and functions by clearing inflammatory chemokines from the site of 
inflammation.  
1.8.1.4 D6 Expression 
D6 has been shown to be expressed in the lung, skin, liver, spleen, heart, brain, thymus, 
ovary and muscle in mouse (142). In humans, expression of D6 has been demonstrated on 
trophoblast cells of the placenta, skin, lymphatic endothelial cells, lung and leukocytes 
(143, 144). 
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1.8.1.4.1 Leukocyte Expression 
Interest in leukocyte expression of D6 was based on analysis of its promoter and the 
discovery that it has many putative transcription factor binding sites associated with 
haematopoietic cells, e.g. GATA1, Ikaros (144).  In human cell lines, D6 is expressed on 
K562, HMC-1, Meg-01, THP-1, Jurkat and Molt-4 cells (listed from highest expressing to 
lowest expressing) (144, 145), but expression levels of D6 may not correlate with its 
function. For example, HMC-1 cells have higher D6 expression than THP-1 cells, but they 
have a lower level of CCL2 uptake (which can be out-competed with CCL3 – this shows D6 
specific uptake). The expression of D6 can be altered by causing cell differentiation, for 
example in Meg01 cells, an increase in D6 expression is seen upon differentiation with 
TPA (12-tetradecanoyl 13-phorbol acetate)(144). D6 expression has also been 
demonstrated on breast cancer cell lines, high expression on lowly invasive cells, low 
expression on highly invasive cells (146).  
As well as expression by human cell lines, expression has been shown on primary human 
cells, with B cells showing the highest expression of D6. In particular, marginal zone B cells 
express more D6 compared to follicular B cells in the spleen (147). Plasmacytoid dendritic 
cells, myeloid dendritic cells and B cells from human peripheral blood, as well as human 
monocytes have been shown express D6, and the expression of D6 on monocytes has 
been shown to increase 100 fold upon maturation to macrophages (144). The analysis of 
D6 expression on human cells was carried out using an antibody against D6, unfortunately 
no antibody is available that is specific for murine D6, so analysis in murine cells has been 
carried out by QPCR (144). Primary murine cells express D6 at the highest levels on B 
cells, mast cells and dendritic cells, whilst murine CD4+ T cells, macrophages and 
neutrophils express D6 at low levels. On B cells, D6 is expressed at a higher level than on T 
cells. (144). 
If D6 does indeed function as a scavenging decoy receptor on leukocytes it may be 
involved in regulating chemokine levels in situ. Its expression may be constitutive or 
inducible, depending on the cell type involved. In vitro work suggests that D6 may affect 
responses of CCR4, so it is possible that in vivo, D6 co-expression with signalling 
chemokine receptors may alter that cells movement, but this work was carried out in 
transfected cells, that may express higher levels of D6 than those found in vivo. More 
work is required to determine the precise role that D6 plays in leukocytes. D6 expression 
on leukocytes may be involved in regulating chemokine levels in situ, for example 
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leukocytes that express D6 may be able to degrade chemokines presented on the luminal 
face of the vasculature. If D6 expressing cells express other inflammatory chemokine 
receptors, they may be involved in reducing the chemokine levels at the site of 
inflammation, through the activity of D6. D6 expression may be constitutive or inducible, 
and previous work suggests that D6 may blunt chemotactic responses to other signalling 
CC chemokine receptors (141). This may represent a mechanism by which D6 can limit 
cell movement, e.g. stopping cells once they get to the site of inflammation. If D6 on 
leukocytes blocks responses to inflammatory CC chemokines, it may allow cells to exit via 
CCR7, e.g. dendritic cells and T cells (148).  
1.8.1.4.2 Regulation of Expression 
As mentioned above, leukocyte expression of D6 can be regulated by maturation of both 
primary cells and cell lines. The expression of D6 in DCs has been shown to be dependent 
on GATA1, as mice with a conditional deletion of GATA1 lack D6 expression on DCs. The 
expression of D6 has also been shown to be affected by both pro and anti inflammatory 
stimuli, in monocytes LPS reduces D6 expression, whilst TGFβ increases D6 expression 
(90).  These results suggest that during ongoing inflammation, D6 levels may be at a low 
level, and when inflammation is being resolved, D6 expression may be upregulated, which 
could aid in the resolution of inflammation. In the breast cancer cell line MDA MB 231, D6 
expression can be up-regulated by IL-1β and TNF (128, 146). These data show that the 
expression of D6 is dynamic and can be regulated by both pro and anti-inflammatory 
cytokines, which may effect the expression of D6 by leukocytes, and this may vary 
depending on the cell type. 
1.8.1.4.3 Lymphatic Endothelial Cells 
In humans, D6 has been shown to be expressed by lymphatic endothelial cells, in the gut, 
the skin and secondary lymphoid tissues. D6 expression is lost after in vitro culture of 
these cells, and not all lymphatic epithelial cells express D6 (143). D6 expression on 
lymphatic endothelial vessels may ensure that inflammatory CC chemokines are not 
present on the surface of the vessels. This environment may allow GAGs to present 
constitutive chemokines, such as CCL21 that can bind to CCR7 on circulating dendritic 
cells and only allow mature DCs to enter the lymph node. If inflammatory chemokines are 
presented on the lymphatic endothelium, this may allow entry of immature dendritic cells 
to the lymph node. The role for D6 in preventing inflammatory chemokine entry to the 
lymph node has been supported by observations that in D6KO mice, more inflammatory 
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chemokines are present in the lymph node, but the source has not been determined 
(149). During inflammation large levels of inflammatory chemokines are produced, and 
these may overwhelm the scavenging capabilities of D6, which may explain the presence 
of these chemokines in the draining lymph nodes (148). However D6 expression has not 
been shown in murine lymphatic endothelial cells, so these observations may be caused 
by a lack of chemokine scavenging by cells that would normally express D6. Further work 
needs to be carried out to conclusively define the role that D6 plays on chemokine entry 
into the lymph nodes.  
1.8.1.4.4 Placenta 
Within the placenta, D6 has been found on invading trophoblast cells, on the apical side 
of syncytiotrophoblasts and decidual macrophages (150). JAR, JEG3 and Bewo cells 
(syncytiotrophoblast cell lines) are all D6 positive and D6 has been shown to function as a 
scavenger in trophoblast cell lines (151). The expression of D6 within the placenta has 
been investigated using in vivo models, which will be discussed in section 1.8.1.5.7 
1.8.1.5 D6 in Pathology 
Using a variety of murine models, the role of D6 has been investigated in numerous 
disease states, from inflammation to cancer. These will be discussed in detail below.  
1.8.1.5.1 TPA Induced Skin Inflammation 
The model of TPA induced skin inflammation involves treating mice with TPA (painted on 
shaved dorsal skin) on three consecutive days. This treatment causes inflammation 
typified by an increase in chemokine levels, and the development of a psoriasis like 
pathology. The pathology is characterised by skin thickening and keratinocyte hyper-
proliferation. Cytokines are rapidly produced after TPA application and TNFα levels are 
increased after 60 minutes. Chemokines such as CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, 
CXCL2 and CXCL10 are produced within 4-8 hours after TPA administration. Comparing 
the inflammatory response in WT mice and those lacking D6, show that both genotypes 
have increased levels of CC chemokines during inflammation, with chemokine levels 
peaking at 8-12 hours in WT mice, clearing by 24 hours. In contrast, D6KO skin takes 
longer to clear inflammatory CC chemokines, resulting in an exaggerated inflammation 
that does not resolve until 6-10 days post treatment, compared to 4 days for the 
resolution of inflammation in WT mice (152).  
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The cells that have been identified as being involved in the exaggerated inflammatory 
pathology exhibited in D6KO mice include dermal macrophages, mast cells, epidermal T 
cells and neutrophils. Neutralising antibodies, used to block CD4+ and CD8+ cell 
recruitment prevents the pathology caused by TPA. Further antibody neutralisation 
studies show that the inflammatory pathology is dependent on TNFα, which is produced 
by cells within the skin, and this increase in TNFα levels causes further cell recruitment via 
chemokine production, e.g. mast cells. Therefore it can be said that the pathology 
induced by TPA in D6KO mice is dependent on TNFα and T cells, as well as being 
characterised by an influx of mast cells (152). 
To summarise these findings, after TPA treatment of the skin WT mice produce 
inflammatory chemokines, which causes a transient leukocyte recruitment to the skin and 
resolution of inflammation 4 days after TPA treatment. In contrast, D6KO mice show an 
exaggerated response to TPA treatment of the skin, with epidermal hyper-proliferation, 
differentiation, angiogenesis, accumulation of epidermal T cells and mast cells, which all 
contribute to an exaggerated pathology, which remains 10 days after TPA treatment. 
These data illustrate the role that D6 plays in the resolution of cutaneous inflammation 
(128).  
Recent work using the TPA model of skin inflammation has focused in on dissecting the 
role that D6 plays on neutrophil migration. In D6KO skin after treatment with a single 
dose of TPA, neutrophils are found at the dermal/epidermal junction, whilst in WT skin, 
neutrophils are found lower down in the dermal compartment. In this model there could 
be two explanations; a lack of D6 prevents clearance of inflammatory chemokines at the 
dermal/epidermal junction, allowing neutrophils to localise here, or a lack of D6 on 
neutrophils means that their migration into the skin is altered. The addition of a CCR1 
antagonist reverses this aberrant neutrophil accumulation seen in D6KO skin, suggesting 
that CCR1 is involved in this phenomenon. Experiments injecting compound 48/80 (a 
mast cell degranulation agent) into the skin shows that D6KO mice have more severe 
tissue damage than WT, with increased numbers of neutrophils at the site. 
Intraperitoneal injection of CCL3 shows an increased neutrophil infiltrate in D6KO mice 
compared to WT. These data point to a role for D6 in influencing neutrophil migration, 
potentially by modulating chemokine levels at the site of inflammation, or influencing 
their responses to inflammatory chemokines (140).  
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1.8.1.5.2 EAE 
EAE is used as a mouse model of MS; it involves immunising mice against a component of 
the myelin sheath, known as the MOG peptide that is administered subcutaneously in 
CFA (Complete Freunds adjuvant). Administration of the MOG peptide causes the 
production of antigen specific T cells that contribute to the destruction of the myelin 
sheath, causing disease symptoms. The contribution of T cells to disease development 
can be shown by adoptively transferring T cells from mice showing EAE symptoms, to 
untreated mice, which will develop disease (153). D6KO mice appear relatively resistant 
to EAE, with a reduced disease severity, reduced cell infiltration and demyelination. The 
reduced disease severity in D6KO mice appears to be caused by an impaired priming of T 
cells. Adoptively transferring T cells from D6KO mice shows that these cells have a 
reduced ability to cause EAE, but this is not due to a defect in proliferation – these cells 
can still proliferate with mitogen, but with antigen they cannot proliferate to the same 
extent as WT cells. T cells isolated from D6KO mice produce less IFNγ, so it has been 
suggested that a lack of D6 results in altered antigen presentation and as a result T cells 
are not activated effectively. Looking at the site of immunisation, D6KO mice show an 
altered and enhanced inflammatory response, revealed by the presence of inflammatory 
foci, leukocyte infiltrate (including aggregates of CD11c+ DCs) and angiogenesis. The 
presence of accumulations of DCs in the skin of D6KO mice may indicate that these cells 
cannot leave the skin, which may cause a reduction in antigen specific T cell activation, 
and may explain the reduced disease severity exhibited (153, 154).  
1.8.1.5.3 Allergic Asthma 
In the classic model of allergic lung inflammation, OVA was used to induce lung 
inflammation in both D6KO and WT mice, using two different challenge protocols – short 
and long term. During short-term challenge protocols, CCL17 levels were increased in 
D6KO mice compared to WT mice, but this was not seen in prolonged challenge models. 
D6KO mice consistently had more eosinophils, CD4+ T cells, B cells and DCs in the lungs, in 
both challenge protocols, which indicates a higher level of inflammation. Despite this 
higher inflammation, D6KO mice showed reduced airway responsiveness. These results 
suggest that D6 may be able to alter the local chemokine concentration of the lungs, 
when low levels are produced (i.e. in the short term challenge protocol), but when higher 
levels are present (long term challenge) D6 has no effect on chemokine levels, as the 
concentration may overwhelm the scavenging ability of D6. In light of these results, it has 
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been proposed that inhibition of D6 may represent a potential treatment for patients 
with allergic asthma (155).  
1.8.1.5.4 Inflammation Induced Skin Tumours 
The development of cancer is a multi-step process, which can be driven by inflammation 
and chronic inflammation is well known to predispose people to cancer (156). A murine 
model of inflammation driven skin carcinogenesis involves painting the skin with a 
mutagen, in this case DMBA (7,12-Dimethylbenz (α) anthracene), followed by the 
induction of cutaneous inflammation by painting the skin with TPA. Tumours begin as 
benign papillomas, which can develop to become invasive squamous cell tumours, which 
is dependent on TNFα and T cells. Different strains of mice have different tumour 
susceptibilities in this model, B6/129 mice are resistant to tumour formation, whilst 
FvB/N mice are susceptible to tumour development. When D6 expression is ‘knocked out’ 
in B6/129 mice this renders them susceptible to tumour development, and D6KO mice on 
a FvB/N background show an increase in tumour development, compared to WT mice. 
D6KO tumours contained more mast cells and CD3+ cells which suggests that the tumour 
micro-environment is producing chemokines which are recruiting these cells which have 
been shown to contribute to tumour growth. Over-expression of D6 in the basal 
keratinocyte layer was able to resolve inflammation in the skin much more rapidly than 
WT mice, and the increased levels of D6 expression in the skin delayed the development 
of tumours.  To summarise the results found here, tumours which develop in D6KO mice 
have higher numbers of mast cells and CD3+ T cells and increased keratinocyte 
proliferation which contribute to an increase in tumour formation. When D6 is 
transgenically expressed in the epidermis, the tumour burden is reduced, but this 
protective effect can be overcome by increasing the inflammatory episodes, suggesting 
that D6 has a limited capability to clear inflammatory chemokines, and high chemokine 
levels can overcome this. These data illustrate that D6 may have therapeutic potential as 
an inflammation specific tumour suppressor, and highlight the importance of 
inflammatory chemokines in this model of tumour development. Further evidence 
supporting a role for D6 in human cancer, comes from the presence of D6+ lymphatic 
endothelial cells in squamous cell carcinomas, endometrial carcinoma and Kaposis 
sarcoma samples.  (142).   
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1.8.1.5.5 Mycobacterium Tuberculosis 
Infection with Mycobacterium tuberculosis (Mtb) leads to an inflammatory response in 
the lungs, which causes to the formation of granulomas and subsequent clearance of the 
bacteria. When D6KO mice are infected with Mtb they have an increased mortality 
despite having no difference in bacterial load, compared to WT mice. Infection in D6KO 
mice causes an exaggerated leukocyte infiltrate, diffuse liver necrosis, lung inflammation, 
renal and liver failure. Intranasal administration of Mtb means that the lungs are the first 
site of infection, D6KO lungs have increased levels of CD4+, CD8+ T cells and 
macrophages, compared to WT mice. This increase in cell number was also found in the 
draining lymph node of D6KO mice. Levels of inflammatory cytokines and chemokines 
were measured in the broncho-alveolar lavage fluid, CCL2, CCL3, CCL4, CCL5, IFNγ, TNFα 
and IL1β levels were all increased in D6KO mice, demonstrating that a lack of D6 causes 
an increased inflammatory response in the lungs after Mtb infection. These results 
suggest that these mice have an increased innate inflammatory response towards Mtb, 
which causes upregulation of chemokines that would normally be controlled by D6. 
Blocking antibodies against CCL2-5 led to a prolonged survival in D6KO mice by controlling 
the inflammation, but this resulted in an increase in infection, shown by increased CFU 
(colony forming units) in the lungs. These data show that an inflammatory response is 
required to clear Mtb infection but this must be limited, which is where D6 may play a 
role in Mtb infection (157).   
1.8.1.5.6 Colitis and Colon Cancer 
As mentioned above, D6 is expressed in the skin, the lungs and the gut. In the gut, D6 
expression has been shown in lymphatic endothelial cells and some leukocytes. In the 
mouse, D6 expression has also been shown in stromal cells in the colon (using bone 
marrow chimeras), and D6 expression levels are up-regulated during colitis induction 
(158, 159). There is conflicting evidence as to the role that D6 may play in colitis. One 
report describes D6KO mice developing more severe colitis, than WT counterparts, which 
makes them more susceptible to colon cancer. This susceptibility is attributed to higher 
levels of inflammatory chemokines and increased leukocyte infiltrate(158). Another 
report, published around the same time, describes D6KO mice as having reduced colitis 
severity, which is attributed to alterations in the positioning of IL17 producing γδ T cells 
(159). The conflicting evidence here may be due to subtle genetic differences in mice 
strain used, or due to conditions in the respective animal facilities, which may alter gut 
flora and affect colitis development, so the role of D6 in colitis has not yet been clarified. 
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Whatever the role that D6 may play in the development of colitis, both reports suggest 
that it is D6 on non-haematopoeitic cells that is affecting the outcome. D6 expression in 
the gut occurs mostly on CD45- cells, and a subset of colonic B cells (159). Bone marrow 
chimera experiments show that restoration of D6 expression to the non-haematopoietic 
compartment protects mice from the development of colitis (who were previously 
susceptible in this model) (158). As the only non-haematopoietic cells that have been 
shown to express D6 are lymphatics, these reports suggest a role for lymphatic 
endothelium expressed D6 in affecting colitis outcome, and subsequently colon cancer.  
A role for D6 in the development of colon cancer has been suggested, D6KO mice have 
increased tumour incidence and tumour size, correlated with an increased leukocyte 
infiltrate. This murine work is supported by identification of D6 in the lymphatic vascular 
bed of IBD samples, with increased expression on those cases that lead onto colon cancer 
(158). Together with the work mentioned in section 1.8.1.5.4, these studies point to a 
role for D6 in inflammation induced tumour development.  
1.8.1.5.7 Inflammation Induced Foetal Loss 
The expression of D6 on the placenta has led to studies into the role that D6 may play in 
pregnancy. The presence of D6 transfected into trophoblast cells causes increased 
degradation of chemokines, compared to un-transfected cells. Murine models of foetal 
loss, induced by LPS or anti-phospholipid antibodies illustrate that D6 is protective against 
inflammation driven foetal loss. D6 expressed on the placenta is thought to reduce 
placental inflammation and subsequently reduce the levels of infiltrating cells, e.g. 
lymphocytes and macrophages, which are increased in pregnant D6KO mice. In humans, 
D6 expression has been shown on the invading human trophoblast cells and the apical 
side of syncytiotrophoblast cells, so D6 may potentially have a similar role in humans, in 
keeping the levels of inflammation in the placenta at a level to permit foetal development 
(151).  
1.8.1.5.8 Inflammation 
D6 has been implicated in other models of inflammation, for example the administration 
of CFA subcutaneously causes a granuloma like lesion, which develops earlier in D6KO 
mice, compared with WT mice. This granuloma development is coupled with an increased 
inflammatory response, increased leukocyte infiltrate and necrosis, confirming the role 
suggested for D6 in limiting inflammatory responses(149). Promoter analysis of D6 has 
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recently identified small nucleotide polymorphisms which may be associated with the 
grade of liver inflammation in humans, and there is evidence that D6 may be involved in 
murine models of liver inflammation (160, 161).  
1.8.1.6 Summary 
In vivo studies have been valuable in defining the role of D6, clarifying its involvement in 
the resolution of inflammation, as well as highlighting the potential for D6 to be used as a 
therapeutic in inflammation induced skin cancer (142, 152). The expression of D6 in the 
placenta appears to play a vital role in the survival of the foetus under inflamed 
conditions (151). As well as limiting inflammatory responses, D6 may play a role in the 
initiation of adaptive immune responses, shown by the accumulation of DCs at the site of 
injection, in D6 null mice, using the EAE model, which results in impaired T cell responses 
(153). Future work analysing the promoter of D6 will shed more light on how D6 is 
regulated and how D6 may potentially be involved in a wide range of inflammatory 
conditions and diseases.  
1.8.2 DARC 
DARC (Duffy antigen receptor for chemokines) was originally identified as the cellular 
entry point for Plasmodium vivax, and has subsequently been characterised as the only 
mammalian receptor which is capable of binding chemokines from more than one family 
(162). DARC can bind to 11 different inflammatory CXC and CC chemokines, shown in 
table 1.2 (163). DARC shares very little sequence similarity to other chemokine receptors, 
or even with other members of the atypical receptor family. The expression of DARC is 
restricted to red blood cells and vascular endothelial cells, as well as Purkinje cells, kidney 
epithelial cells and type II pneumocytes. A significant proportion of the human population 
have suppressed red blood cell expression of DARC, which is caused by polymorphisms in 
GATA1 sites in the promoter, but endothelial cell expression of DARC is unaffected (164).  
DARC expressed by erythrocytes is though to act as a chemokine ‘sink’ which prevents the 
activation of leukocytes in the blood, which has been shown using studies in DARC KO 
mice (165, 166). DARC has also been shown to maintain chemokine levels in the blood, 
acting as a chemokine reservoir (167, 168). Erythrocyte expression of DARC has also been 
proposed to be anti-angiogenic in a model of prostate cancer, clearing angiogenic 
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chemokines from the tumour circulation (169). The difficulty with using DARC KO mice to 
try to define its role, is separating the relative roles of DARC expressed by red blood cells 
and endothelial cells (170). On endothelial cells, DARC has been shown to transport 
chemokines from the apical to the basolateral side of endothelial cell monolayers, and 
retain chemokine on the surface of cells (168, 171). This function of DARC has been 
suggested to be involved in leukocyte recruitment, using transgenic mice which only 
express DARC on endothelial cells (168, 172).  
1.8.3 CCX-CKR 
CCX-CKR (Chemocentryx chemokine receptor) was originally identified by a group at 
Chemocentryx, hence the name (173). CCX-CKR (which has also been referred to as 
CCR11) can bind to CCL19, CCL21 and CCL25, internalise these chemokines and target 
them for degradation (174). It falls into the atypical receptor group as it fails to 
demonstrate signalling after ligand binding. The expression of CCX-CKR is highest in the 
heart and lung, and was found to be expressed by stromal cells in the thymus (175). CCX-
CKR has been shown to internalise, retain and degrade CCL19 much more efficiently than 
CCR7, which is due to the fact that CCR7 undergoes ligand-induced desensitisation. The 
marked capacity of CCX-CKR to degrade ligand is not dependent on constitutive 
trafficking, shown by a lack of requirement for β-arrestins and clathrin. The internalisation 
of CCX-CKR has been shown to use caveolae, which could suggest potential roles in 
transcytosis, similar to DARC (176). DCs have been shown to have reduced lymph node 
migration in CCX-CKR null mice, as well as reduced migration if embryonic thymic 
precursors. CCX-CKR expression on stromal cells has been proposed to alter levels of 
chemokines in the extracellular space, which is required for DC and thymic precursor 
migration (175).  
1.8.4 CXCR7 
CXCR7 is the most recently discovered member of the atypical receptor family, and has 
been studied extensively with the use of zebrafish. CXCL12 was thought to bind a single 
chemokine receptor, CXCR4, until the discovery of CXCR7. CXCR7 (also known as RDC1) 
can bind to CXCL11 and CXCL12, without evidence of calcium flux or chemotaxis (177). 
Although no signalling has been demonstrated, expression of CXCR7 in transfected cells 
provides increased survival and adhesion, so it is possible that some form of signalling 
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may occur (177, 178). The expression of CXCR7 appears to be confined to development, 
although it has been shown to be expressed on a wide range of tumours. These include 
gliomas, colon, lung, breast and prostate cancer (177, 179-182). CXCR7 has also been 
shown to be increased on tumour associated vasculature and may be involved in the 
survival of tumour cells (183). The role of CXCR7 in development has been studied using 
zebrafish. These studies have shown that CXCR7 is involved in the migration of primordial 
gem cells in the lateral line primordium of the zebrafish. Primordial germ cells respond to 
CXCL12 produced during zebrafish development by expressing CXCR4. CXCR7 is expressed 
on the surrounding somatic cells, which can alter levels of CXCL12 and subsequently 
affect the migration of germ cells (184). As well as influencing germ cell migration in 
zebrafish, CXCR7 is expressed on emerging blood vessels and plays a role in cardiac 
development. Studies with CXCR7 null mice show that CXCR7 is essential for 
development, as these mice die at birth. Conditional CXCR7 KO mice, with a deletion of 
CXCR7 in endothelial cells, shows that CXCR7 is involved in heart valve formation, as well 
as having roles in endothelial cell growth and survival (185).  
1.8.5 ‘Functional’ Decoys 
The group of decoy receptors mentioned above differ from signalling chemokine 
receptors due to alterations in the key signalling motif, but typical chemokine receptors 
have the ability to act in an atypical manner. At the site of inflammation, LPS triggers the 
down-regulation of inflammatory chemokine receptors on DCs and causes up-regulation 
of CCR7. This chemokine receptor switching can be modulated by the presence of IL10. 
IL10 inhibits the down regulation of CCR1, CCR2 and CCR5 on dendritic cells and 
monocytes, following exposure to LPS. These receptors still remain on the cell surface, 
but have become ‘frozen’, i.e. they are uncoupled to signal pathways. This means that 
DCs no longer have the ability to migrate using these receptors, but these receptors are 
still able to bind chemokines. In this way, these ‘frozen’ receptors can help to clear 
inflammatory chemokines from the microenvironment, and they become what are known 
as ‘functional decoys’. These receptors may block excessive cellular recruitment and 
activation, as well as helping to resolve inflammation (186). Further evidence to suggest a 
regulatory role for signalling chemokine receptors comes from work showing that 
chemokine receptor null mice have increased levels of circulating chemokines. This 
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suggests that chemokine receptors are required to clear chemokines from the circulation 
and tissues (187).  
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1.9 Chemokines in Disease 
The chemokine system has vital roles during inflammation and as a result, chemokines 
can be associated with inflammatory diseases. The chemokine system is involved in many 
diseases and chemokines are essential in viral, parasitic and bacterial infections. 
Chemokines can have detrimental effects in diseases such as asthma, rheumatoid arthritis 
and MS (188). As well as being important in responses to pathogens, chemokines are also 
involved in responses against self, for example in autoimmunity. IFNγ activated CD4+ and 
CD8+ T cells and activated macrophages can create a Th1 environment which has been 
shown to contribute to diabetes, atherosclerosis and Crohns disease (188).  
1.9.1 HIV 
HIV infection involves interactions between viral surface proteins, CD4 and the 
chemokine receptors CXCR4 and CCR5. Initial infection occurs via CD4, with CCR5 as a co-
receptor, by M-tropic viruses, so called because they usually infect macrophages. As the 
disease progresses, the virus mutates and uses CXCR4 as a co-receptor (T-tropic), allowing 
infection of a wider range of cell (189, 190). CCR5 mutations can confer HIV resistance; 
about 1% of the Caucasian population have a mutation in CCR5 that is essentially a 
natural knock out for the receptor. This mutation is known as CCR5∆32, and appears to 
have no adverse effects for the carriers. (191).  CCR5 has become an attractive target for 
the development of HIV therapies, but targeting CCR5 may leave people susceptible for 
West Nile virus (WNV), as a lack of CCR5 has been shown to increase symptomatic WNV 
infection (192).  
1.9.2 Multiple Sclerosis 
Multiple sclerosis is an autoimmune disease that targets the central nervous system 
(CNS), causing demyelination of nerves, leading to a chronic debilitating condition. The 
pathology of MS is caused by the infiltration of the CNS by inflammatory leukocytes, 
which cause specific destruction of the myelin sheath. The murine model of MS is EAE, 
which is induced by immunisation of mice with a peptide specific for a component of the 
myelin sheath. This model causes symptoms similar to human disease, with progressive 
paralysis and cell infiltration of the CNS (154). The cell populations involved in EAE include 
CD4+ and CD8+ T cells, as well as macrophages. Chemokines implicated in cellular 
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recruitment in EAE pathogenesis include CCL1, CCL2, CCL3 and CXCL10 (193, 194). CCR6 
and its ligand CCL20 have also been implicated in EAE pathogenesis, with CCR6 KO mice 
having alterations in DC and CD4+ T cell migration (195, 196). CCR2 KO mice are 
completely protected from the development of EAE, illustrating that CCR2 is required for 
the development of disease (197).   
1.9.3 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory condition which is characterised by 
an inflammatory cell infiltrate into the joints, which causes bone and cartilage 
destruction. Many different leukocytes have been found in the synovial tissue of 
rheumatoid patients, and the chemokine receptors have been analysed on these 
infiltrating leukocytes. Common receptors expressed include CCR2, CCR3, CCR5, CXCR2 
and CXCR3 (198). A wide range of chemokines are also implicated in the pathogenesis of 
RA, these include CCL2, CCL3 and CCL5 (199-201), as well as members of the CXC 
chemokine family (198). Chemokines are though to play a role in the degradation of 
cartilage, through the induction of MMP expression, and by recruiting cells into the 
inflamed joint to cause further joint destruction (202).  
1.9.4 Cancer & Metastasis 
The role that chemokines and their receptors play in cancer and metastasis will be dealt 
with in more detail in section 1.10.3. In cancer, chemokine receptors can be upregulated 
and are involved in growth, and cell survival (38).  Chemokine receptors are also thought 
to play a role in organ specific metastasis.  
1.9.5 Therapies Targeting the Chemokine System 
Targeting chemokines and chemokine receptors may be a successful therapeutic strategy, 
useful in a wide range of diseases. Chemokines and receptors are involved in a wide 
variety of inflammatory disorders, for example, CCR1 is associated with MS, asthma and 
rheumatoid arthritis, whilst CXCR4 has roles in HIV infection and cancer (9). The 
antagonism of the chemokine system may have beneficial effects for a wide range of 
diseases, which could be achieved using neutralising antibodies, modified chemokines 
(antagonists) or using small molecule receptor antagonists. Studies have shown the 
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potential benefit of chemokine therapies. In mouse models, treatment with an anti-
CXCR3 antibody has the same effect in vivo as generating a CXCR3 null mouse, 
demonstrating that this antibody is very specific and potentially useful in transplantation 
(203). Use of a CCR1 inhibitor (BX741) in the rodent model of EAE shows a reduction in 
disease severity of 50%, illustrating that CCR1 blocking may be a potential therapeutic for 
MS (204). The use of an antagonist to human CCL2 is able to prevent disease 
development in a murine model of spontaneous arthritis (205). The results from these 
studies show that different methods of chemokine antagonism can be effective in various 
different diseases.  
Met-RANTES is a form of RANTES that has an extra methionine at the amino-terminal. It 
still has the capability to bind CCR1 and CCR5, but the presence of this methionine 
residue abolishes CCR3 binding (206). This single amino addition alters the function of 
RANTES, making it anti inflammatory in a model of Th2 inflammation (OVA induced lung 
inflammation). Modified forms of chemokines therefore may have some therapeutic 
potential. In addition small molecules that could inhibit chemokine receptors may be 
useful therapeutic agents. For example TAK779 blocks CCR5 binding to its ligands (CCL3, 
4, 5) in an allosteric manner by binding at a cavity near the surface, which is not where 
the ligand binds (207). There is a great deal of interest in creating therapies that target 
CCR5, which could potentially have roles in HIV treatment; the most successful therapy in 
recent years has been Maraviroc. Maraviroc is a CCR5 antagonist that can be tolerated in 
both healthy individuals and HIV infected patients, it was approved for use in 2007 (208). 
CXCR4 targeting has also had a great deal of interest, with respect to HIV, but the first 
CXCR4 antagonist to be approved was AMD3100, as a stem cell mobilisation drug, for 
stem cell transplantation in 2008 (209). Although research into therapies for HIV have 
been extensive, other chemokine targeting treatments have had varying success in clinical 
trials. For example CXCL8 targeting in COPD patients was not very successful, and trials 
have since been discontinued (210, 211), similar to trials with a monoclonal against CCR2, 
which had no beneficial effects in rheumatoid arthritis patients (212).  
There are many problems with designing anti-chemokine therapies – redundancy being 
the main one. The mouse may not be an ideal model organism as there are differences in 
the way that the chemokine genes are organised, but other alternatives are limited.  
Despite this, chemokine receptors still represent one of the most attractive targets on the 
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market for drug targeting and murine models are required for testing before human trials 
can be considered (38).   
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1.10 Tumour Growth 
Tumours arise from normal cells, which have undergone numerous mutations to allow 
them to grow uncontrollably and remain undetected by the immune system. Mutations 
occur over time and create a tumour that has unlimited proliferative potential, and can 
allow cells to survive with cell division defects (213). Cells are undergoing mutations on a 
regular basis, but usually the immune system can recognise these cells and eliminate 
them before they form tumours, or the mutations may cause the cells to die.  
Chronic inflammation can contribute to the development of many different forms of 
tumours, and appropriately NSAIDS (non-steroidal anti-inflammatory drugs) are 
associated with protection against various tumours (156). At the moment, there is limited 
evidence for their benefit with respect to melanoma treatment. Only two human studies 
have been conducted, these show that NSAIDs are associated with a reduction in 
melanoma incidence (in females) and in melanoma patients, they are associated with a 
lower incidence of new melanoma, recurrence and metastasis (214, 215). In most 
tumours, an inflammatory component is present, e.g. leukocytes, inflammatory cytokines 
and chemokines. There are two ways in which inflammation can be linked to cancer 
development. The intrinsic pathway, is when the developing tumour cells actually cause 
inflammation, creating an inflammatory microenvironment, or the extrinsic pathway, 
which is when inflammatory conditions facilitate cancer development, e.g. Helicobacter 
infection and gastric cancer (156). Inflammation in the tumour microenvironment can 
promote the recruitment of bone marrow derived cells to the tumour, which in turn can 
help promote its growth (216).  An inflammatory microenvironment has been shown to 
contribute to all aspects of tumour growth; the proliferation and survival of tumour cells 
(e.g. NFkB signalling (156)), angiogenesis (TNFα, IL1 and myeloid cells, amongst others, 
have been shown to contribute to angiogenesis (217-219)), and metastasis.  
Once cells have mutated and become cancerous, they may lie dormant for years, 
undergoing a steady balance of proliferation and apoptosis, without being detected by 
the immune system. The survival of these cells involves interactions between the tumour 
cells and the surrounding stroma, which evolve as the tumour develops. The 
microenvironment is essential for contributing to cell survival, e.g. the protective 
microenvironment of a mouse blastocyst can suppress the tumourigenicity of 
Claire L. Burt, 2011   68 
teratocarcinoma cells, but this protective microenvironment can be overridden by chronic 
inflammation (216). Stromal cells that can be involved in tumour development include 
endothelial cells (both blood and lymphatic), pericytes, fibroblasts, macrophages, 
neutrophils, mast cells, myeloid derived suppressor cells (MDSCs) and mesenchymal stem 
cells (MSCs). More details can be found below (216). An overview of cells involved in 
tumour growth is shown in figure 1.3. 
 
Figure 1-3: Chemokines and chemokine receptors involved in tumour growth 
As the tumour grows, it develops blood vessels through the process of neovascularisation. Chemokines 
play a vital role in the development of blood vessels and the recruitment of leukocytes such as T cells and 
macrophages. In the tumour microenvironment, leukocytes can have anti-tumour or pro-tumour effects. 
Blood vessels, and lymphatic vessels within the tumour provide ‘escape routes’ which tumour cells can 
use to metastasise to different sites. Chemokines and chemokine receptors are thought to play roles in 
determining the sites of metastasis, as shown above (described in detail in section 1.11). Tumour cells 
develop new blood vessels via the process of neovascularisation. Blood vessels allow T cells and 
macrophages to enter the tumour environment where they can help tumour growth. Tumour cells can 
leave via blood vessels and metastasise to various organs depending on chemokine receptor expression.  
1.10.1 Immunosurveillance & Immunoediting 
The evasion of the immune system is a crucial step for tumour growth, as tumour cells 
have undergone mutations and may be recognised as non-self. Evasion is made difficult 
by the presence of cells of the immune system with tumour killing capabilities, which are 
constantly surveying the body. In order to successfully grow, tumours have to escape 
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from this immunosurveillance (220). The process of immunosurveillance was originally 
suggested by Burnet in 1970 (221). He described the sentinel thymus dependent cells of 
the body (T cells) constantly surveying host tissues for transformed cells; this theory has 
been expanded as knowledge of the immune system increased. Immunosurveillance can 
detect tumour cells and eliminate them, but this killing may be inefficient, which may 
allow tumour cells to continue to grow and mutate, making them unrecognisable by the 
immune system. This process is known as immunoediting and can be characterised by a 
period of immune mediated latency, when the remaining tumour cells can still proliferate 
and may eventually escape this latency and tumour re-growth may occur (222, 223) 
1.10.1.1 Immunosurveillance and Destruction 
The cells of the immune system which are responsible for immunosurveillance include 
cells of both the innate and adaptive systems, in particular γδT cells, αβT cells, NKT and 
NK cells, all of which can eliminate tumour cells completely (224-226). NK and NKT cells 
are involved in innate control of the tumour, they can produce IFNγ which has numerous 
anti-tumour effects including activating NK cell cytotoxicity, the enhancement of CD8+ 
cell killing, Th1 cell differentiation, reducing the rate of cell proliferation and up-
regulating MHC molecules. Tumour cells can down-regulate their expression of MHC 
molecules, in order to evade the immune system, but NK cells are able to recognise 
tumour cells that do not express MHC molecules. They can recognise tumour cells using 
non-classical MHC molecules such as NKG2D (227, 228). Other cells involved in anti-
tumour responses include γδT and αβT cells, which can also produce IFNγ, mediate direct 
cell killing, as well as being able to recognise tumour cells via both NKG2D (γδ T cells) and 
classical MHC (αβT cells)(223).  
During the process of tumour development, mutations can be acquired which can cause 
the up-regulation of tumour specific antigens; these are usually self-proteins, which have 
undergone alterations during the tumour growth phase. These antigens may be 
expressed by cells which would not normally express them, for example testes associated 
antigens can be expressed by tumour cells. These tumour antigens can be classified as 
differentiation antigens (melan-A), mutational antigens (abnormal p53), over-expressed 
or amplified antigens (Her-2/Neu), cancer-testis antigens (MAGE), or viral antigens (EBV 
or HPV) (229, 230). As well as being able to express tumour specific antigens, tumour cells 
can over-express other molecules, e.g. MICA/B (which bind NKG2D), which are highly 
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polymorphic non-classical MHC molecules, also known as stress molecules. These can be 
induced by heat shock, CMV infection or E.coli, and can also be expressed during the 
process of cell transformation (231). Despite expression of tumour-associated antigens 
and the expression of non-classical MHC molecules, tumours still may not be recognised, 
which may be due to the tumour microenvironment. The tumour microenvironment may 
not produce a classical ‘danger signal’ (e.g. LPS activating TLR4), but work has shown that 
substances such as uric acid, heat shock proteins and ECM derivatives can all act as 
danger signals, as well as the presence of a pro-inflammatory microenvironment (224). 
1.10.1.2 Equilibrium 
As mentioned above, after immune mediated destruction, tumour cells may survive 
which can undergo low levels of proliferation and apoptosis, and this permits the 
development of new mutations. This acquisition of new mutations may allow tumour cells 
to grow undetected, or an immunosuppressive microenvironment may allow these cells 
to proliferate (223). This low level of cell proliferation is described as immune mediated 
latency. Examples supporting tumour latency include a case of metastatic melanoma 
occurring 1-2 years after two patients received a kidney from the same donor. It was 
discovered that the donor had melanoma 16 years previously, but melanoma cells still 
existed in the kidney. When placed in to an immunocompromised host, the tumour cells 
were able to grow (232). Despite evidence that latency occurs, it is probable that tumours 
can be successfully eliminated on a regular basis.  
Examples of mutations that can occur in tumour cells to facilitate the escape of immune 
detection, include altering antigen processing or presentation. Evidence has shown that 
when patients with metastatic melanoma were given MART-1 specific T cells, this 
treatment led to the loss of MART-1 expression on tumour cells (233). As well as being 
able to alter antigen presentation, tumour cells may create an immunosuppressive 
environment by producing IL10, TGFβ, soluble NKG2D ligands, galectin 3, and IDO. This 
microenvironment may permit the tumour to grow and remain undetected by the 
immune system (231, 234, 235).  
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1.10.2 Leukocyte Infiltration 
Tumour cells, stromal cells and leukocytes populate the tumour microenvironment, as 
shown in figure 1.3. A wide variety of immune cells have been found to infiltrate tumours, 
these include cytotoxic T cells (CTLs), NK cells, neutrophils, mast cells, immature myeloid 
cells, macrophages and granulocytes. Leukocytes can contribute to the tumour 
microenvironment by producing cytokines and chemokines, which can cause remodelling 
of the ECM and create a pro or anti inflammatory microenvironment (216, 236, 237). As 
well as being able to influence the local microenvironment, leukocytes can also be 
affected by the microenvironment, e.g. a hypoxic environment can alter chemokine 
receptor expression (29). Infiltrating leukocytes have the potential to be both pro and 
anti-tumourigenic, depending on the extent of cell infiltration and the types of cytokines 
and chemokines they produce. In this way, leukocyte infiltration has the ability to 
influence angiogenesis, tumour cell invasion, metastasis and tumour survival (29, 216, 
236, 238).  
1.10.2.1 Tumour Associated Macrophages 
One major leukocyte population known to have wide ranging effects on tumour 
development are macrophages. In animal models they have been shown to promote 
angiogenesis, invasion, intravasation and metastasis (239). The presence of macrophages 
in tumours can have either tumour promoting or suppressing actions, but this is cancer 
subtype dependent (29). The infiltration of macrophages appears to be essential for 
tumour growth, as shown with studies in CSF (colony stimulating factor) KO mice. These 
mice lack normal macrophage numbers, and as a result tumours in these mice have 
reduced growth and reduced angiogenesis (240). Tumour associated macrophages 
(TAMs) can produce CCL2, which can influence tumour progression depending on the 
concentration; in melanoma, high CCL2 levels are associated with increased TAM 
infiltration (good prognosis), low CCL2 is associated with a reduced TAM infiltrate (bad 
prognosis) (29, 238).  
The numbers of macrophages and their phenotype can influence the tumour; M1 
macrophages typically have anti-tumour effects (produce IL12, IFNγ, pro-inflammatory 
cytokines and increase MHC expression) whilst M2 macrophages have pro-tumour effects 
(angiogenesis, matrix remodelling and immunosuppressive actions). The majority of TAMs 
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commonly have a M2 like phenotype (238, 241, 242). As well as producing cytokines and 
chemokines which can recruit cells and influence tumour growth, TAMs can produce 
VEGFs (vascular endothelial growth factors) and proteases, which have been shown to 
influence angiogenesis in breast cancer (236). It may be possible to alter the phenotype of 
macrophages within the tumour microenvironment, to promote tumour regression. NFkB 
has been shown to maintain the immunosuppressive phenotype of M2 macrophages, 
when NFkB is inhibited, TAMs change phenotype from M2 to M1, allowing tumour 
regression (243).  
1.10.3 Chemokines and Receptors 
The expression of chemokines in tumours has been extensively studied and chemokine 
expression has been shown to contribute to tumour growth, angiogenesis, cell survival 
and metastasis. The production of chemokines can be induced by cytokines secreted by 
tumour cells and infiltrating leukocytes, e.g. VEGFA, TGFβ and TNFα (222). With respect 
to chemokine receptor expression, one of the most common chemokine receptors 
expressed in tumours is CXCR4, which has been detected in 23 different human cancers, 
and its ligand, CXCL12 has also be found in the tumour microenvironment (29). Stromal 
cells, tumour cells and infiltrating leukocytes, may produce CXCL12. The centre of 
tumours tends to have a hypoxic environment and this can influence CXCR4 expression, 
via the upregulation of HIF-1 (hypoxia inducible factor), which can up-regulate CXCR4 on 
normal and tumour cells (244). The expression of CXCL12 produced in the tumour 
microenvironment can also promote survival of CXCR4+ cells (29). Numerous other 
chemokines have been detected in tumours, these include CCL2, CCL5, CCL17, CCL22, 
CXCL1, CXCL8 and CXCL13 (238).  
1.10.4 Angiogenesis 
The growth of tumour cells can reach ~1-2mm diameter before a blood vasculature must 
develop, in order for the tumour to survive (245). The development of vasculature 
involves interactions between tumour cells, stromal cells and infiltrating leukocytes. 
Angiogenesis is essential to provide growth factors for the tumour and can allow 
haematogenous metastasis. The process of angiogenesis can be regulated by chemokines 
in particular the CXC family of chemokines are important in the development of blood 
vessels within tumours. The CXC chemokine family can be broadly divided into two 
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groups, those that are angiogenic (‘ELR’ positive) and those that are angiostatic (‘ELR’ 
negative). Angiogenic chemokines include CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and 
CXCL8, and these bind to CXCR1 and CXCR2 (only CXCR2 in mice). Angiostatic chemokines 
include CXCL4, CXCL9, CXCL10, CXCL11 and CXCL14, which exert their effects by binding 
CXCR3 (246). Chemokines which promote angiogenesis have been detected in almost all 
human tumours, CXCL1, 2, and 3 were discovered in cultures of melanoma cells (247). 
Initially, it appeared that all angiostatic chemokines bound to CXCR3, but CXCR3 has been 
shown to undergo alternative splicing, which creates three new isoforms, CXCR3A, 
CXCR3B and CXCR3-alt. Each isoform of CXCR3 differs in its ligand specificity; CXCL9, 10 
and 11 can bind to CXCR3A and CXCR3B, whilst CXCL4 can only bind to CXCL3B. CXCR3-alt 
has a reduced binding affinity for CXCL9 and CXCL10 but retains high affinity for CXCR11 
(248, 249).  
1.10.5 Lymphangiogenesis 
As well as the development of blood vessels, tumours can often develop lymphatic 
vessels. The development of lymphatics within a tumour can allow metastasis to the local 
draining lymph node, which can lead to more disseminated spread. The extent of 
lymphangiogenesis in primary cutaneous melanoma may be a prognostic factor to predict 
the presence of sentinel lymph node metastases. Lymphatics can be induced by the 
expression of VEGFC expression, which is correlated with lymphatic vessel density in 
primary melanomas; it can influence tumour and lymphatic endothelial cell interactions. 
Lymphangiogenesis can also be induced in lymph nodes, if VEGFA produced by the 
tumour drains into the lymph node (250).  
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1.11 Metastasis 
When a tumour has developed a blood and lymphatic supply it is possible for tumour cells 
to enter the blood stream and lymphatics. Once tumour cells have entered the 
vasculature, they can reach and colonise distant organs, in a process known as 
metastasis. Not all tumours have the ability to metastasise, but often when they do it is a 
poor prognostic factor. In order to metastasise, genetic changes in tumour cells have to 
occur to allow the cells to survive in the circulatory or lymphatic system. As soon as a 
tumour develops vasculature, tumour cells can be found in the blood, but not all of these 
cells have the ability to form metastases. The same can be said about organs, whilst 
metastatic cells may be present in many organs, they will usually only form metastases in 
some of these organs. This is illustrated by the presence of disseminated tumour cells 
(DTCs) which can be detected in the blood of cancer patients, but not all of these develop 
to become metastases (245).  
1.11.1 Stages of Metastasis 
Similar to tumour development, metastasis is a multi-step process. Cells from the primary 
tumour must invade the vasculature or lymphatics, be able to survive in the circulation, 
extravasate in distant organs and have the ability to colonise the new organ. Genetic 
changes can occur in metastatic cells, which permit these stages to occur, certain genes 
are associated with different stages of metastasis. Initiation genes are involved in cell 
motility, immune system evasion and ECM degradation. Metastasis progression genes 
allow entry and survival in the new organs. These genes may have the same role in the 
primary tumour as they do in the metastatic cells, or they may have different roles (213). 
During tumour growth, the exact stage at which metastases occur is unknown; there are 
differing theories that have been described. A linear progression model has been 
described, which defines a stepwise accumulation of mutations in the primary tumour 
that leads to cells acquiring a metastatic phenotype. This means that metastatic cells have 
much of the same characteristics of the primary tumour, and the extent of metastasis can 
be linked to the primary tumour size (245). The parallel progression model (originally 
described in 1956 (251)) describes tumour cells leaving the primary tumour whilst it is 
small, so before any symptoms are evident. This allows cells to grow in distant organs, 
which leads to the acquisition of distinct phenotypes different from the primary tumour. 
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This theory indicates that metastasis must occur before the primary tumour is clinically 
detectable (245).  
1.11.1.1 Survival and Growth 
In order to metastasise, tumour cells must be able to survive the haemodynamic forces in 
the bloodstream and remain undetected by the immune system. Detection by the 
immune system may be prevented by tumour cells interacting with platelets in the blood, 
which can act as a shield. This platelet aggregation may have two roles; it can shield 
tumour cells from the immune system and platelet aggregation can increase the size of 
metastatic colonies (252, 253).  An increased platelet count has been correlated with a 
decrease in cancer survival (216).  
Metastasis can occur via the blood and lymphatics, but lymphatic metastasis can occur 
without spread in the blood. Once metastasis occurs in the sentinel lymph node (the first 
lymph node which metastasis occurs), further lymph node metastasis can occur in a 
sequential manner due to the lymphatic drainage (250, 254, 255). The likelihood of 
lymphatic metastasis can be predicted by certain markers expressed in the primary 
tumour, e.g. VEFC or VEGFD expressed in primary breast, colon and lung tumours is 
associated with lymphatic metastasis (256).  
There are two theories as to how organs are ‘chosen’ as sites for metastasis. In 1889 
Paget described the seed and soil theory, which likens tumours cells as ‘seeds’ that 
require the correct ‘soil’ (i.e. organ environment) to grow. This theory was used to 
describe the pattern of metastasis in breast cancer (257). A differing theory was proposed 
in 1928 by Ewing, which suggested that circulatory patterns were responsible for the 
patterns of metastasis and the organs colonised were determined by the site of the 
primary tumour (258). Elements of both theories are though to explain the location of 
metastases, and can be supported by expression of chemokine receptors in metastasis 
that are associated with colonisation of specific organs. For example, in human breast 
cancer and malignant melanoma, the same pattern of metastasis occurs as cells have 
been shown to express CCR7, CXCR4 and CCR10 (256). This could fit with the seed and soil 
theory, but whilst the sites of metastasis may be chosen due to chemokine receptor 
expression, certain organs are thought to be common metastatic sites as they have small 
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capillary beds, e.g. liver and lungs (236, 259), which would fit with the theory suggested 
by Ewing.  
1.11.1.2 Pre-Metastatic Niche 
However tumour cells decide which organs to colonise during metastasis, evidence exists 
that the primary tumour can pre-condition organs to become receptive to metastasis 
creating, what is known as the pre-metastatic niche. Factors secreted by the primary 
tumour, such as VEGFA, TGFβ and TNFα, can help create this niche in distant organs, by 
increasing fibronectin expression (260, 261). As well as increasing fibronectin expression, 
these cytokines cause the recruitment of VEGFR1+ VLA4+ haematopoietic cells to areas 
with increased fibronectin expression. The newly recruited cells interact with the 
surrounding stromal cells to produce chemokines and growth factors, such as the 
chemokines S100A8 and S100A9, which have been found to be up regulated specifically in 
the lungs, in response to VEGFA and TNFα from primary tumours in mice. This up-
regulation only occurs in the lungs, the organ where the tumour cells specifically 
metastasise, using the B16 F10 model of metastasis. Neutralising S100A8 and S100A9 was 
able to reduce the number of metastatic lung colonies, indicating that this niche was 
required for their development (261, 262). As well as causing chemokine expression, 
VEGFA from the primary tumour can cause the expression of MMP9 at the pre-metastatic 
niche (261). This causes remodelling of the lung parenchyma which allows metastatic cells 
to colonise (236, 263). The ability of the primary tumour to induce these pre-metastatic 
niches may be essential for metastasis to occur, but this may be dependent on the type of 
cancer. 
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1.12 Melanoma 
Skin cancer can fall into two classes, non-melanoma and malignant melanoma. Malignant 
melanoma is the most fatal type of skin cancer that is on the increase, with cases in the 
past 30 years increasing more than five fold (Statistical Information Team, Cancer 
Research UK, 2006). One of the major risk factors for developing melanoma is intense 
exposure to UVR (ultra violet radiation), but there is a significant genetic component to 
the disease (264). UVR can initiate a stress response in the cells of the skin, which induces 
numerous signalling pathways and genes that can cause cellular proliferation, apoptosis, 
DNA repair and survival (264). If caught at the early stages, melanoma can be treated with 
surgery, but late stage melanoma (which has often metastasised) has a 6 month survival, 
irrespective of treatment (264). Current treatments include adjuvant therapy with high 
dose IFNα, which has some benefit in advanced disease, but currently there are no 
effective treatments for melanoma (265).  
As previously described, with respect to tumour development, melanoma develops in a 
stepwise manner, beginning as a benign nevus, which is a clonal population of 
melanocytes in the epidermis.  These cells can then mutate to become a hyperplastic 
lesion, which does not progress due to senescence. If this senescence is overcome, it 
leads to dysplasia and superficial spreading of the cells. This spreading leads into the 
dermis, which can then cause metastasis. Murine melanoma differs from human 
melanoma due to the distribution of melanocytes; in humans they are throughout the 
basal layer of the epidermis, in mice they can be found in hair follicles in the dermis (264).  
1.12.1.1 Leukocyte Infiltration 
As described in section 1.10.2, the infiltration of leukocytes can influence tumour 
progression. Leukocytes have been detected in melanoma, both in primary tumours and 
metastases, including T cells, B cells, neutrophils, DCs and macrophages (266). In humans, 
specific melanoma cytotoxic T cells can be found in the blood, and within primary 
tumours there are areas with high numbers of localised T cell clones, which provides 
evidence that T cells can enter and proliferate within the tumour (266). The presence of 
neutrophils may enhance melanoma cell adhesion to endothelium, which may aid 
extravasation of melanoma cells via integrin expression (267).  
Claire L. Burt, 2011   78 
Melanomas typically have a macrophage content of between 0-30%, melanoma 
metastases have less than 10% macrophages. Murine models have supported this 
observation. There seems to be an inverse correlation between the macrophage content 
of melanoma and the capacity to metastasise (268). The level of macrophage infiltration 
can correlate with tumour stage and angiogenesis (269).  As mentioned previously, 
macrophages can be growth promoting in melanoma, they are able to produce MMP9 
under the influence of CCL2, CCL4 and CCL5, which can promote ECM breakdown and 
promote tumour invasion (270). On the other hand, macrophages can have anti-tumour 
effects if activated by IL2, IL12 and IFNγ (222). Other cells identified in melanoma include 
NK cells; the expansion of peripheral NK cells has been tested as a therapeutic agent, with 
limited success (222).  Dendritic cells have also been identified in human primary 
melanomas, plasmacytoid DCs in particular. Often there are more immature DCs than 
mature within a tumour. Similar to TAMs, it is thought that DCs can have both pro- and 
anti-tumour effects. Anti-tumour plasmacytoid DCs can be suppressed by the tumour 
microenvironment (255, 271), and indeed the presence of leukocytes may alter the 
tumour microenvironment. Melanoma cells have been shown to evade the immune 
system by retaining MICA inside the cell which prevents NK cell recognition (272). A pro-
inflammatory environment can be detrimental to melanoma growth, as melanoma 
proliferation has been shown to be inhibited by IL2, IL12, IFNγ, TNFα and IL6 (267). 
1.12.1.2 Chemokines & Chemokine Receptors 
In melanoma, chemokines can recruit leukocytes, which can increase growth and survival 
factors as well as inducing angiogenesis (as described in section 1.10.3). The expression of 
a wide range of chemokines and their receptors have been found to be expressed by 
melanoma cells, including CXCR1, CXCR2, CXCR3, CXCR4, CXCR6, CXCR7, CCR1, CCR2, 
CCR5, CCR7, CCR9 and CCR10 (241, 273, 274). Chemokines expressed by melanoma cells 
include CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL10, CCL2, and CCL5 (274, 
275). This wide range of chemokines may have roles in promoting melanoma growth, 
angiogenesis, recruiting leukocytes to the tumour and promoting metastasis. For 
example, CXCL1 is an essential autocrine growth factor for melanoma cell lines (originally 
called MGSA – melanoma growth stimulatory activity), which is constitutively expressed. 
Blocking of CXCL1 or its receptor CXCR2 prevents melanoma cell growth in vitro (274). 
The expression of CXCR1, CXCR2 and CXCL8 correlates with vessel density and 
aggressiveness in human melanoma, and in murine models, over expression of CXCR1 or 
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CXCR2 increases tumour cell survival (276, 277). Other chemokine receptors expressed in 
melanoma include CXCR3, which is correlated with an absence of tumour infiltrating 
lymphocytes and a poorer prognosis (278). CCR5 and CCR7 can be expressed by primary 
melanoma and metastases; CXCR4 and CCR1 are expressed in melanocytes, melanoma 
cell lines, primary tumours and metastases (279). 
In human studies, melanomas have been found to be CCR10 positive, which may promote 
their survival, as CCL27 binding of CCR10 on melanoma cells has been shown to increase 
cell survival in a model of murine melanoma (273). UVB irradiation of human skin can 
cause inflammation which results in the production of CXCL8, which has been shown to 
promote tumour growth and cell migration in human melanoma cells (280). Other 
chemokines involved in melanoma include CCL2, which promotes the infiltration of the 
tumour by macrophages (the level of CCL2 can determine the level of macrophage 
infiltration); the degree of macrophage infiltration can correlate with tumour stage and 
angiogenesis in human melanoma. (281) 
1.12.2 Melanoma Metastasis 
Melanoma metastasis is the main cause of death in cases of melanoma. The location of 
the primary tumour often predicts where metastasis is likely to occur, but this is not 
always the case. For example in melanoma, the most common site of metastasis is the 
lungs, but metastases can also be found in lymph nodes, brain, skin, liver, bone marrow 
and small intestine (213, 267). The expression of chemokine receptors by melanoma cells 
are thought to play a role in determining the organs in which metastasis can occur, e.g. in 
human melanoma CCR9 expression is associated with metastasis to the small intestine 
(282). As mentioned above melanoma cells are CXCR4, CCR7 and CCR10 positive, and this 
chemokine receptor expression can correlate with the site of metastasis, to the lungs, 
lymph nodes and skin respectively (274). Much of the work relating to melanoma growth 
and metastasis has been performed using the B16 model of murine melanoma, which will 
be discussed below.   
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1.13 B16 Murine Model of Melanoma 
The B16 murine model of melanoma growth and metastasis has been extensively 
characterised and is the ‘gold standard’ for melanoma metastasis models (283). B16 cells 
are derived from a tumour that spontaneously developed in a C57Bl/6 mouse in 1954. 
This model is still used widely today as a model for studying human malignant melanoma 
(284). B16 cells can be grown in vitro and can induce tumours when injected 
subcutaneously into syngeneic mice. The size of the tumours increase in size as the cell 
number administered increases, and they can cause death with no obvious metastasis 
(284). Other models of tumour growth involve injecting human cancer cells into SCID 
(severe combined immunodeficient) mice, but syngeneic tumour models are better, as 
the role of the immune system in tumour development can be more accurately defined 
and metastatic cells from humans will not always grow in mice (283). Different variants of 
B16 cells exist, the original cell line isolated is known as B16 F0. B16 F0 cells from the 
original tumour were cultured in vitro, injected intravenously into C57Bl/6 mice and then 
lung colonies were selected and grown in culture. This process was carried out ten times 
to create a B16 variant which is highly specific for the lungs, known as B16 F10 (more 
details can be found in section 1.13.2) (285). 
1.13.1 B16 F0 Tumour Growth 
Subcutaneous administration of B16 F0 cells causes tumour growth in the skin, which is 
easy to identify as B16 cells produce melanin (286). B16 cells are histocompatible with the 
host, and they express tumour-associated antigens, which has been shown by immunising 
mice with irradiated B16 cells; this leads to partial immunity against rechallenge (284, 
287). The immunisation must be performed before tumour challenge, as immunisation 
strategies fail if the animal has a pre-established tumour (287). B16 cells are lacking, or 
have very low levels of MHC I and II, which means despite tumour antigen expression, 
they have low immunogenicity. IFNγ can up-regulate MHC I on B16 F0 cells, which can 
cause lysis of tumour cells by CTLs and NK cells, as well as increasing CD95 and CD95L 
expression, which can lead to apoptosis (288).  
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1.13.1.1 Chemokines & Cytokines 
The B16 tumour model has been used to analyse the role of chemokines and their 
receptors in tumour growth, often using transfected cells. CCL2 is associated with 
macrophage recruitment and its role in melanoma growth has been studied by 
transfecting B16 cells with CCL2. This increases macrophage infiltration, which reduces 
tumour growth. This effect is dependent on the level of CCL2 produced, low levels of CCL2 
recruit low macrophage numbers which has pro-tumour growth effects (289). Blocking of 
CCL2 production causes a reduction in tumour volume, reducing angiogenesis as well as 
reducing TAM infiltration (290). Other chemokines associated with metastasis and cell 
infiltration include CXCL12, which when over-expressed causes a reduction in the level of 
T cell infiltration in B16 tumours, which can be restored following CXCR4 blocking. The 
effect of CXCL12 is concentration dependent, similar to that of CCL2, low levels of CXCL12 
can attract tumour specific T cells to the tumour and reduce growth, but high levels of 
CXCL12 may cause chemo-repulsion of T cells, and permit tumour growth (291). When 
tumour cells express CXCR4 this causes an increase in metastasis to the lungs, with no 
effect on tumour size (292). 
Chemokines have also been shown to be involved in angiogenesis, tumour growth and 
metastasis. B16 F0 cells produce the membrane bound form of fractalkine; RNAi 
inhibition of fractalkine causes a reduction in tumour size, with a reduction in tumour 
vessels. This suggests fractalkine has a role in tumour angiogenesis (293). Transfection of 
CCL20 inhibits the growth of B16 tumours by increasing CD8+ CTL responses, as does 
transfection with CCL21 which acts to inhibit tumour growth (294, 295). The over-
expression of CCR10 in B16 cells slightly increases the size of tumours developing in the 
footpad, and CCL27 treatment of these cells caused protection against IFNγ stimulated 
Fas mediated death (273). Transfection with CCR7 increases metastasis to the draining 
lymph node, which can be blocked by CCL21 inhibition, and causes increased tumour 
growth (296).   
Chemokine receptors can influence tumour growth and metastasis, for example CXCR2 
KO mice have a reduced tumour growth, as well as reduced lung metastasis. These 
tumours have increased apoptotic cells, reduced micro vessels and reduced neutrophils 
(297). Whilst mice which over express CXCR2 have larger tumours showing increased 
levels of angiogenesis (298). 
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Cytokines, as well as chemokines, can affect different aspects of tumour growth. IFNα 
treatment of B16 cells in vitro inhibits cell proliferation in a dose and time dependent 
manner. In vivo, IFNα can reduce the size of subcutaneous tumours, by reducing cell 
proliferation and increasing the inflammatory infiltrate (299). Transfection of cells with 
IRF3 (transcription factor which regulates type I IFNs, CCL5 and IFN stimulated genes), 
inhibits tumour development by causing an increase in inflammatory cell recruitment 
(300). Other cytokines which can influence tumour growth include IL12 produced by T 
cells, NK cells and macrophages, which can have anti-tumour and anti-angiogenic (via 
IFNγ mediated CXCL9 and CXCL10 production) activity (301). ECM degrading enzymes 
have a crucial role in tumour growth, these have been transfected into B16 cells. MMP 13 
is produced by B16 tumours and has a role in tumour growth, angiogenesis and 
metastasis, as shown by tumour development in MMP13 KO mice (302). 
1.13.2 B16 F10 Metastasis 
As mentioned above, the B16 cell line has variants that can be used in tumour growth 
models and variants that can be used in experimental metastasis models. The B16 F10 cell 
line was derived from the B16 F0 cell line, but has underwent in vitro and in vivo selection 
to create a cell line which is highly specific for lung metastasis (286). Intravenous 
administration of B16 F10 cells causes metastatic colony formation in the lungs. This type 
of model is known as a model of experimental metastasis, which differs from 
spontaneous metastasis models in that there is no requirement for primary tumour 
formation. Models of experimental metastasis, such as the B16 F10 model, have fewer 
variables, and can be carried out over a shorter time compared to spontaneous 
metastasis models, and these models allow manipulation of the cells, by transfection for 
example (283).   
The B16 F10 cell line is very stable in vitro; the potential to form metastatic colonies is still 
present after 60 passages (both in vivo and in vitro) (303). Whilst all B16 cell lines have 
the ability to grow on lung tissue extracts in vitro, this does not correlate with 
colonisation in vivo, only B16 F10 cells have this ability (304). Compared to B16 F1 cells, 
B16 F10 cells have increased glycoslyltransferase activity, which makes them more likely 
to form aggregates with lung cells. Few other differences have been identified between 
B16 F0 cells and B16 F10 cells which can explain their lung specificity (286, 305-307).  
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When B16 F10 cells are injected intravenously, more than 80% of F10 cells survive in the 
circulation and make it to the lungs. These cells develop into metastases in the lungs, in 
particular at the surface and near major structures in the lungs. The initial distribution of 
cells is random, but preferential growth of B16 F10 cells occurs adjacent to blood vessels 
and the pleural surface (308). Parabiosis experiments has confirmed the lung specificity of 
B16 F10 cells (309).  
As with the B16 tumour growth model, the B16 F10 metastasis model has been 
extensively characterised and is commonly used as a murine model of melanoma 
metastasis. Treatment of metastasis in humans often includes surgery, but (with respect 
to pulmonary metastasis) re-growth is common. Mice that underwent surgical resection 
of lungs had 2-3 times more B16 F10 metastatic colonies after surgery, which was 
associated with rapid lung growth.  This suggests that surgery may not be the ideal 
method of treatment for melanoma metastasis, as wound repair environments appear to 
be beneficial for metastatic growth (310).  
The B16 F10 model requires an immune response to form metastasis, shown by 
performing experiments in immunosuppressed mice, which causes a reduction in 
pulmonary metastasis (311). Evidence also exists to show that inflammation can affect 
metastasis in this model. B16 F10 cells express TLR2 and TLR4; the expression of both can 
be increased by LPS treatment. Modulation of TLR expression has been shown to 
modulate pulmonary metastasis; TLR2 knock down reduces metastasis, whilst TLR4 knock 
down increases metastasis. After B16 F10 cells are injected intravenously, levels of IFNγ 
decrease, which causes TGFβ and IL10 production in the lungs. The knock down of TLR2 
reduces TGFβ and IL10 levels, which are required for lung colonisation. TLR4 knock down 
enhances Stat3 activation which can increase T regs and facilitate metastasis (312). IFNγ 
has also been shown to increase MHC expression on B16 F10 cells. When injected 
intravenously, IFNγ can reduce lung metastasis, which is thought to be due to activation 
of NK cells and CTLs, which inhibit B16 F10 cell proliferation and cause apoptosis (313, 
314). Other evidence supporting inflammation in metastasis development come from the 
use of the OVA model of allergic lung inflammation, along with the B16 F10 metastasis 
model. The combination of the two models causes an increase in the level of metastasis 
by B16 F10 cells. This can be reduced by depleting CD4+ cells and treating with 
corticosteroids to reduce inflammation (315). Other pro-inflammatory cytokines, such as 
TNFα can increase metastatic colonies by increasing VCAM-1 expression on lung 
Claire L. Burt, 2011   84 
endothelium, which can binds to VLA4 on B16 F10 tumour cells (256).  The role of 
inflammation in metastasis seems to be complicated, it will depend on the cytokines 
produced and their potential downstream effects on the lungs, and it may depend on the 
type of inflammation, e.g. Th1 or Th2.  
1.13.2.1 B16 F10 & Cell Interactions 
Cell interactions can play a role in metastasis, as mentioned in section 1.12.1.1. B16 F10 
cells can form emboli with each other and with host cells such as lymphocytes and 
platelets. When B16 F10 cells cluster with lymphocytes, this causes an increase in the 
level of metastatic colonies on the lungs (286, 306). Interactions with other cell types can 
influence metastasis; these include B1 cells. The pleura and the peritoneal cavity are 
environments rich in B1 cells. These are described as innate B cells, which express IgM+ 
and CD5+, have a limited antibody repertoire and are capable of self renewal (316, 317). 
When B1 cells are co-cultured with low metastatic B16 cells, their metastatic potential 
increases. This effect is cell contact dependent, and induces increased levels of CXCR4 and 
MMP9 on the B16 cells (318). When B1 cells are depleted the development of metastatic 
colonies is inhibited. The role of B1 cells in human metastatic melanoma has been 
investigated and B1 cells have been identified in sections from human melanoma 
samples. Their presence correlates with MUC18 expression, which is though to be 
responsible for the interactions between melanoma cells and B1 cells (319).  
As mentioned above, platelet interactions with cancer cells can protect them from rapid 
clearance in the blood stream. The production of thrombin, tissue factor, fibrinogen, vWF 
and PAF (platelet activating factor) by tumour cells can activate platelets and cause 
platelet binding to tumour cells (267). PAF is responsible for platelet aggregation and has 
been shown to mediate angiogenesis as well as having roles in tumour growth and 
metastasis (320). When PAF is inhibited, tumour growth is reduced in the B16 model 
(321). The production of PAF by B16 F10 cells can be caused by IFNγ which can also inhibit 
B16 F10 growth in vitro (322). In the B16 F10 model of metastasis, a single injection of 
PAF increases the number of metastatic colonies, by increasing expression of MMP9 in 
the lungs (323).  In vitro, B16 F10 cells form aggregates with platelets, and platelets have 
a role in metastasis – thrombocytopoenia reduces metastasis (324). Platelets can coat 
circulating cancer cells, facilitating adhesion to endothelium (325). Mice lacking Gp 1b-1x 
(the primary adhesion receptor for platelets) have a reduction in B16 F10 metastasis 
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(326).  B16 F10 cells produce low levels of PGD2 (prostaglandin D2) which can cause 
platelet aggregation and is though to increase metastasis (327).  
1.13.2.2 Chemokines & Chemokine Receptors in B16 Metastasis 
Chemokines and chemokine receptors have long been associated with metastasis. As 
mentioned previously (section 1.13.1.1), transfection of a single chemokine receptor gene 
can increase organ specific metastasis in the B16 tumour model. Chemokines and their 
receptors can also affect the development of colonies in the B16 F10 experimental 
metastasis model.   
CCR5 expression by non-haematopoietic cells is important in metastatic colony 
development, shown using bone marrow chimera studies in CCR5KO mice, which have 
reduced metastatic colonies (328). These data suggests that B16 F10 cells may be creating 
a pre-metastatic niche, by recruiting pulmonary fibrocytes, via CCR5, which is essential to 
the development of metastatic colonies as they produce MMP9 (329).  When CXCR4 is 
over-expressed in B16 F10 cells, the number of metastatic colonies increases, and CXCR4 
can also promote cell survival in vitro (292, 330).  The enhanced metastasis to the lungs 
caused by CXCR4 can be blocked using T22, an inhibitor of CXCR4 (330). These results 
show that chemokine receptors may play a role in the development of the pre-metastatic 
niche, and determining where metastasis occurs.  
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1.14 Cancer Immunotherapy 
The main difficulty with treating cancer cell is that cancer cells are essentially ‘self’ cells 
that have mutated. This makes it difficult to design specific therapies that will not cause 
autoimmunity. Current treatments such as radiotherapy and chemotherapy, target 
actively dividing cells, rather than tumour cells specifically, which means they have many 
undesirable side effects. Problems identifying the stage of growth the tumour is in can 
make it difficult to determine whether or not metastasis has occurred (259). Breaking 
self-tolerance is an attractive therapy for treating cancer, but again this runs the risk of 
inducing autoimmunity. Mechanisms to break self tolerance include triggering 
inflammation, e.g. injecting live BCG (Bacille Calmette Guerin) into the tumour, but this 
can cause pneumonia, hepatitis and BCG infection (331).  
Cytokines which are currently used in melanoma treatment, include high doses of IFNα 
and IL2, which unfortunately have high levels of cytotoxicity (267, 332, 333). Chemokines 
also have the potential to be used as cancer therapeutics; in particular there has been 
interest in using angiostatic chemokines (CXCL9-11) to inhibit tumour growth. In vitro 
studies have shown that CXCL10 can inhibit human melanoma cell growth in vitro. In vivo 
studies have shown that IL12 therapy, along with IFNγ can induce the production of 
CXCL9-11, which can have anti-tumour effects, possibly by inhibiting tumour growth (241, 
334). Monoclonal antibody therapies have been shown to be effective against breast 
cancer and melanoma, but these are often toxic to host (332). There are currently trials 
using anti-CTLA4 and anti-α4β7 monoclonal antibodies as treatments for melanoma, but 
these have had limited success (267).  
Other types of cancer immunotherapies include vaccines against tumour antigens. In 
melanoma, potential antigens include gp100, MART-1, TRP1 and TRP2. Unfortunately 
tumour vaccines do not come without problems; they have limited efficacy and can cause 
autoimmunity. Regrettably, the presence of autoimmunity seems to be associated with 
treatment success (333). Cellular therapies have been successful in haematogenous 
malignancies, e.g. stem cell transplants. Infusion of tumour specific lymphocytes has had 
good results in 50% of melanoma cases, but this is limited to a defined set of patients 
(333). It may be impossible to eliminate the side effects attributed to cancer therapies, 
unless more specific targets can be defined and treatments become more refined. 
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1.15 Aims & Objectives 
D6 has been shown to be involved in the resolution of inflammation and studies have 
suggested that D6 may play roles in chemotaxis and tumour development. This thesis 
aims to define the role of D6 in cell movement and to clarify the role of D6 in tumour 
development. The experiments within this thesis set out to do the following: 
1. Determine the role that D6 plays in chemotaxis, in response to inflammatory and 
constitutive chemokines 
2. Determine the role of D6 in melanoma growth and metastasis 
These aims will be investigated using a variety of experimental approaches: 
1. Analysis of D6 in chemotaxis will be performed using in vitro chemotaxis 
assays with cells that either over-express (transfected cell lines) or with cells 
lacking D6 (primary murine cells) 
2. Analysis of D6 in neutrophil chemotaxis will be analysed in vivo using a well 
characterised skin inflammation model with a neutrophil adoptive transfer 
protocol 
3. The role of D6 in melanoma growth will be analysed using a murine model of 
melanoma, the B16 F0 model, comparing tumour growth in WT mice and 
D6KO mice 
4. The B16 F10 murine model of experimental melanoma metastasis will be used 
to determine the role that D6 plays in melanoma metastasis 
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2 Materials & Methods 
2.1 Cell culture and transfection 
2.1.1 Cell Lines 
The B16 murine melanoma cell lines (B16 F0 and B16 F10) were acquired from Dr Mike 
Edward (Dermatology, Glasgow University) and maintained in DMEM (Dulbecco’s 
modiﬁed Eagle's medium), plus 10% FCS, 10 units pen/strep and 2mM glutamine 
(complete DMEM). All tissue culture reagents were purchased from Invitrogen, Paisley, 
UK.  
2.1.2 Primary Cells 
2.1.2.1 Neutrophils 
Neutrophils were isolated by first dissecting the femur and the surrounding muscle from 
129/Bl6 D6KO and WT mice. In a laminar flow hood, the surrounding muscle was 
removed from the femur, and the bone placed in sterile PBS (Phosphate Buffered Saline). 
The ends of the bone were trimmed off using dissecting scissors, and the bone marrow 
was flushed with ~2ml sterile PBS using a 25G needle. The resulting cell suspension was 
disaggregated by passing through an 18G needle at least ten times, followed by passing 
through a 70μm, then a 40μm cell filter (BD Falcon, UK). Cells were counted using a 
haemocytometer (Sigma Aldrich, UK) before neutrophils were isolated by positive 
selection using the Ly6G Isolation kit (Miltenyi Biotec, UK). Neutrophils were isolated to 
~96% purity using this kit (see figure 3.12).  The average yield of neutrophils isolated from 
murine bone marrow is discussed further in section 3.2.  
An alternative method of isolating the bone marrow from the femurs was used, which 
involved crushing the bones in a sterile mortar and pestle. The muscle was stripped from 
the bones which were then placed in the mortar, with ~10ml sterile PBS. Bones were 
crushed with the pestle until the bones appeared clear (this meant all the bone marrow 
had been removed from the bones). The cell suspension was then passed through filters 
and underwent magnetic selection for neutrophils, as described above.  
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2.1.3 Transfection 
2.1.3.1  Fugene HD 
B16 F0 and B16 F10 cells were transfected using Fugene HD lipofection reagent (Roche 
Diagnostics GmbH, Mannheim Germany) according to the manufacturers’ protocol. The 
optimal DNA:Fugene reagent ration was calculated by performing an optimisation 
experiment with B16F0 cells and a GFP expressing plasmid. The optimal ratio was 
determined to be 4μl Fugene HD to 2μg DNA. The day before transfection, B16F0 cells 
were harvested by trypsinisation and added to a 6 well culture plate at a concentration of 
5 x 105 cells per well. The plasmids to be used in the transfection reaction (murine D6 in 
pcDNA 3 (Rob Nibbs) and pmax GFP) were diluted to a concentration of 2μg in 100μl 
sterile water. 4μl Fugene HD reagent was added to the DNA and incubated at room temp 
for 15 mins. The DNA:Fugene complex was added to the appropriate wells in a ‘drop wise’ 
manner. The cells were incubated at 37ºC for 24 hours before GFP expression was 
analysed to determine transfection efficiency. Transfected cells were then transferred 
into the appropriate concentration of G418, described below. 
2.1.4 Kill Curve 
For all cell lines used, a kill curve was created using G418 (Promega, UK) as the selective 
antibiotic. G418 was chosen as all plasmids used for transfection contained a gentamycin 
resistance gene. For all cell types, a known cell concentration was plated into a six well 
tissue culture plate with the appropriate media, plus G418 in a range of concentrations 
from 0mg/ml up to 2 mg/ml. Fresh media and antibiotics were added halfway through 
the incubation period. Once the incubation period was over, the cells were harvested, 
stained with Trypan blue (Sigma Aldrich, UK) and dead cells were counted. The 
percentage cell death was calculated after 7-14 days for each cell type. The G418 
concentration that killed 90-100% of un-transfected cells for each cell type was used 
when trying to create stable transfectants. The selection of stable transfectants of both 
B16 F0 and B16 F10 cells was carried out using 2mg/ml G418.  
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2.1.5 FACS analysis of D6 Expression 
2.1.5.1 D6 Function Analysis 
B16 F0 and B16 F10 cells were analysed for stable D6 expression using a FACS based 
chemokine competition assay developed by Chris Hansell. At the time, there was no 
available antibody against murine D6, so the only way to show expression was at the 
mRNA level, which gives no indication of protein levels.  This assay uses a fluorescently 
labelled version of CCL2, with an Alexa-fluor labelled lysine residue at the C-terminus 
(Almac, UK) that can bind to CCR2 and D6. Cells of interest are incubated with PM2 (a 
mutant of CCL3 which does not form aggregates at high concentrations(12)) that can bind 
to CCR1, CCR5 and D6. Due to the nature of D6, if a vast excess of PM2 is added to the 
cells before the addition of labelled CCL2, all the D6 will bind PM2 and will be unable to 
bind to the fluorescent CCL2. The uptake of CCL2 in the absence of PM2 is compared to 
the uptake in the presence of PM2, and if addition of PM2 abrogates CCL2 binding, then 
this shows that CCL2 uptake must be through D6, as there is no other chemokine receptor 
that binds to both of these chemokines. The cells of interest were harvested and 
resuspended in binding buffer (20mM HEPES in RPMI) to a concentration of 1 x 106 cells 
per 100μl. 2.5 μl of PM2 (0.1mg/ml) was added to the cells and the whole volume was 
mixed. 0.5μl of CCL2-Alexa 647 (Almac, UK) was added to the cells and mixed. Cells were 
incubated for 40 minutes at 37ºC, with periodic re-suspending. Following incubation with 
chemokines, cells were washed twice with FACS buffer before fixing with 2% 
paraformaldehyde. Cells were analysed using the FACS Calibur.  
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2.2 Neutrophil Adoptive Transfer 
2.2.1 Maintenance of mice 
Mice were housed within the animal facility at the Central Research Facility at Glasgow 
University. All procedures performed on mice were in accordance with United Kingdom 
Home Office guidelines and were in accordance with the appropriate project and 
personal licenses. 
2.2.2 Neutrophil Isolation and Labelling 
Differential labelling of 129/Bl6 D6KO and WT neutrophils was performed using CFSE 
(Carboxyfluorescein succinimidyl ester) and CMTMR (5-(and6-)-(((4-
chloromethyl)benzoyl)amino)tetramethylrhodamine) or TAMRA (Tetramethyl-6-
Carboxyrhodamine) (Molecular Probes, Invitrogen, UK). Neutrophils were isolated from 
129/Bl6 mice, as described in section 2.1.2.1.  For CFSE labelling, neutrophils were 
resuspended at a concentration of 1 x 106 per ml in PBS 0.1%/BSA. 2μl of 5mM CFSE stock 
was added per ml of cells to give a final concentration of 10μM, and the cells were 
incubated at 37ºC for 10 minutes. The staining was quenched by adding 5 volumes of ice 
cold PBS, and incubating for 5 minutes on ice. Cells were centrifuged at 1200rpm for 5 
minutes and washed 3 times in fresh media (RPMI). TAMRA staining was performed as 
described for CFSE staining, but 0.5μl of 10mM TAMRA was added per ml of cells to give a 
final concentration of 5μM, and cells were incubated for 20 minutes at 37ºC. Quenching 
and washing was performed as per CFSE staining. CMTMR was used to stain neutrophils 
at a concentration of 5μM in RPMI. Cells were incubated in the staining solution for 30 
minutes at 37ºC. Stained neutrophils were washed in PBS before counting on a 
haemocytometer then re-suspending at the appropriate cell concentration (cell numbers 
are described in tables 3.1 and 3.2)  
2.2.3 Neutrophil Adoptive Transfer 
129/Bl6 mice were shaved and dorsal skin was painted with TPA (12-tetradecanoyl 13-
phorbol acetate, 150μl of 50μM TPA in acetone). WT and D6KO labelled neutrophils were 
mixed together in equal concentrations (numbers described in tables 3.1 and 3.2) in a 
maximum volume of 200μl sterile PBS. At indicated time points after TPA treatment, 
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fluorescently labelled neutrophils were administered into the tail vein of the treated 
mice. For all neutrophil adoptive transfer experiments, mice were on a 129/Bl6 mixed 
background, were aged between 6-8 weeks, and age matched. 
2.2.4 Frozen Sections 
After sacrifice, 5mm punch biopsies of the inflamed dorsal skin from mice that received 
labelled neutrophils, were collected and snap frozen in liquid nitrogen. Skin biopsies were 
embedded in OCT (Optimal Cutting Temperature, Thermo Shandon, Cheshire, UK). 4μm 
frozen sections were either cut at the Vet School (University of Glasgow, UK), or cut in-
house using the cryostat (Bright, UK). Frozen sections were stored at -80ºC prior to use. 
Frozen sections were left to thaw and air dry before mounting in Vectashield plus DAPI 
(4'-6-Diamidino-2-phenylindole, Vector Laboratories, UK), before adding a coverslip and 
sealing with nail varnish, or permanent mount (Sub X Mounting Media, SurgiPath, UK).  
2.2.5 Confocal Analysis 
Frozen sections, mounted using Vectashield with DAPI as described above, were analysed 
on the LSM 510 Meta (Zeiss, Germany) confocal microscope. The 200x objective was used 
to take pictures of the entire skin section. This allowed an ‘overlay’ picture to be 
generated; using which the whole skin section could be viewed in one picture (see figure 
3.31). Positive cells were identified and the distance from their position to the epidermis 
was measured using Axiovision software.  
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2.3 Melanoma Model 
2.3.1 Tumour Model 
B16 F0 murine melanoma cells were cultured in DMEM before harvesting during log 
phase, by adding trypsin (Trypsin EDTA 0.25%, Sigma Aldrich, UK) to the cells in culture 
flasks (2ml for T25 flask, 4ml for T75 flask). After five minutes incubation, cells were 
collected by addition of 2-8ml complete DMEM. Cells were counted using a 
haemocytometer, centrifuged and resuspended in PBS at the desired concentration. 
C57Bl/6 mice housed in the Central Research Facility (Glasgow University) were used for 
tumour models. Mice were between 6-8 weeks old at the time of experiment, and were 
age and sex matched. Mice were shaved and received 5 x 105 B16 F0 cells in 200μl PBS 
subcutaneously in the dorsal skin. The injection site was monitored daily until signs of 
tumour formation became visible. When the tumour became palpable, it was measured 
using callipers on a daily basis. Two tumour lengths were measured and the mean 
diameter was calculated as the average of the two lengths. Mice were sacrificed when the 
mean tumour diameter reached greater than 1.2 cm (according to Project licence). 
Tumours were excised and fixed in 10% NBF (neutral buffered formalin) (Surgipath, UK) 
for a minimum of 24 hours before processing for histology, as described in section 2.4.6.  
2.3.2 Metastasis Model 
The B16 F10 melanoma cell line was cultured as described above for B16 F0 cells. C57Bl/6 
mice were between 6-8 weeks old at the time of experiment (mice were sex and age-
matched). B16 F10 cells were harvested in trypsin, as described above, counted and 
resuspended in PBS to get a final concentration of 5 x 105 cells in 200μl. Mice were placed 
into a heat box to dilate the tail vein, before 200μl of the B16 F10 cell suspension in PBS 
was injected into the tail vein. The mice were left for up to two weeks (with daily 
monitoring) at which point they were sacrificed by CO2 overdose. The ribcage was 
exposed and removed to expose the lungs. A 25G needle was introduced into the trachea 
and the lungs were slowly filled with PBS or NBF until they were fully inflated. The trachea 
was tied with suture thread to prevent the fluid escaping and the lungs were removed ‘en 
bloc’. The lungs were placed into 10% NBF for later histological analysis, or in cold RPMI 
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for FACS analysis. Melanoma colonies on the lungs surface were counted using a 
dissecting microscope.  
2.3.2.1 Pleural Washes 
C57Bl/6 mice that had received melanoma cells intravenously, or untreated mice (both 
WT and D6KO mice) were sacrificed by CO2. The ribcage was exposed and ~5 ml of sterile 
PBS was injected into the pleural cavity, between two ribs, being careful not to puncture 
the lungs. The fluid was removed, placed on ice, and the protein concentration measured 
by NanoDrop (Thermo Scientific, UK). Pleural wash samples had to be concentrated into a 
smaller volume using an Amicon Ultra-15 Centrifugal filter device (Millipore, UK), which 
retained all protein samples above 3,000 kDa. This concentrated the samples, to give a 
range of protein concentrations from 0.06mg/ml-1.57mg/ml, compared to 0.01mg/ml-
0.36mg/ml prior to concentration.  
2.3.2.2 Luminex 
Pleural wash samples were analysed for the presence of 11 different chemokine and 
cytokines (see table 5.1), using a custom designed mouse cytokine/chemokine Milliplex 
kit (Millipore, UK). The assay was carried out according to the manufacturers protocol. 
This involved preparing the Luminex plate by adding 200μl wash buffer to each well, this 
was left to incubate for 10 minutes at room temperature on a plate shaker. The wash 
buffer was removed by vacuum and excess buffer was blotted from the bottom of the 
plate. Standards and controls (both provided with the kit) were added onto the plate 
(25μl), following the plan described below in table 2.1. 25μl of assay buffer was then 
added to each sample well, followed by 25μl of PBS (which was the appropriate matrix 
solution), which was added to all wells. Finally 25μl of sample was added to the 
appropriate wells. This was followed by the addition of the mixed beads (one per 
cytokine/chemokine to be analysed), to each well (25μl). The plate was sealed and 
incubated at 4ºC with agitation overnight.  
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1 2 3 4 5
A 0 pg/ml 
standard
400 pg/ml 
standard
QC-2 control KO1 
untreated
WT3 F10
B 0 pg/ml 
standard
400 pg/ml 
standard
QC-2 control KO1 
untreated
WT3 F10
C 3.2 pg/ml 
standard
2000 pg/ml 
standard
WT 1 
untreated
KO2 
untreated
KO1 F10
D 3.2 pg/ml 
standard
2000 pg/ml 
standard
WT 1 
untreated
KO2 
untreated
KO1 F10
E 16 pg/ml 
standard
10,000 pg/ml 
standard
WT2 untreated WT1 F10 KO2 F10
F 16 pg/ml 
standard
10,000 pg/ml 
standard
WT2 untreated WT1 F10 KO2 F10
G 80 pg/ml 
standard
QC-1 control WT3 untreated WT2 F10 KO3 F10
H 80 pg/ml 
standard
QC-1 control WT3 untreated WT2 F10 KO3 F10
    
Table 2-1: Layout of Milliplex plate for analysis of pleural washes 
The chemokine and cytokine content of pleural washes was analysed using a custom-designed Luminex 
kit from Millipore. The table above shows the plate outline, with the standards provided by the company 
in the first two rows, followed by two quality control samples. (QC= quality control). The remainder of 
the plate was used by another member of the lab. This was used for the analysis of pleural wash samples.  
The following day, the fluid was removed from the plate by vacuum and washed twice 
with 200μl of wash buffer. Excess wash buffer was blotted from the plate and then 25μl 
of detection antibodies were added into each well. The plate was then sealed and 
incubated for an hour with agitation at room temperature. 25μl of streptavidin-PE was 
then added to each well containing detection antibodies; the plate was sealed and 
incubated with agitation for 30 minutes at room temperature. All the contents of the 
plate were removed by vacuum, and the plate was washed twice with 200μl wash buffer 
per well. Finally, 150μl sheath fluid was added to all the wells and the beads were 
resuspended on a plate shaker for 5 minutes. The plate was run using the Bioplex System 
(Biorad, UK), with the help of Ashley Gilmour.  
2.3.2.3 AMD 3100  
After receiving intravenous injections of B16F10 cells, as described above, C57Bl/6 mice 
were treated with the specific CXCR4 antagonist AMD3100. AMD3100 is a bicyclam 
molecule that was initially developed as a potential treatment for HIV. It specifically 
interacts with CXCR4, and as a result, has effects on HIV replication, stem cell mobilisation 
from the bone marrow and cancer metastasis (335). Mice that had received B16 F10 cells 
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intravenously were given twice daily doses of AMD3100, or PBS control, for the duration 
of the metastasis experiment (14 days). AMD3100 was administered subcutaneously, at 
60μg per dose in 50μl PBS. Mice were sacrificed and organs were taken for histological 
analysis after 14 days.  
2.3.3 Tissue Processing 
Tumours and lungs were processed for histology using the Shandon Citadel 1000 (Thermo 
Shandon, Cheshire, UK). The processing cycle is described in table 2.2. After processing, 
tissues were embedded using the Shandon Histocentre 3. For histological analysis all 
tissue sections were cut at 4μm thick using a Shandon Finesse 325 microtome. Sections 
were floated in a water bath at 40ºC before placing onto polysine-coated slides (VWR, 
UK). Sections were left overnight at 65ºC on a hot plate before staining.  
Solution Time
Neutral Buffered 
Formalin
30 minutes
70% Alcohol 1 hour
90% Alcohol 1 hour
95% Alcohol 1 hour
100% Alcohol 1 hour
100% Alcohol 2 hours
100% Alcohol 2.5 hours
Xylene 1 hour
Xylene 1 hour
Xylene 1.5 hours
Wax 4 hours
Wax 5 hours                                                             
Table 2-2: Tissue processing protocol. 
The above processing protocol was used to process tissues from both the B16 F0 tumour model and the 
B16 F10 metastasis model. The program was created and stored on the Shandon Citadel 1000. After 
tissue processing using the above program, samples were embedded in paraffin wax using the Shandon 
Histocentre 3, in order to allow cutting of paraffin embedded sections.  
2.3.4 Histological Analysis 
Haematoxylin and eosin (H&E) staining was carried out as follows. Sections were de-
waxed and rehydrated by incubating in xylene for 3 minutes, followed by 10 dips in 100% 
alcohol, another 10 dips in fresh 100% alcohol, 10 dips in 70% alcohol followed by 
washing in running water. Slides were placed in haematoxylin (CellPath, UK) for 7 
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minutes, followed by rinsing in running water until clear. Slides were then dipped in 1% 
acid alcohol for 12 dips, washed in running water, placed in Scotts tap water substitute 
(CellPath, UK) for 2 minutes, washed in running water then placed in Putts Eosin 
(CellPath, UK) for 4 minutes. Slides were washed in running water for 2 minutes, followed 
by 10 dips in 70% alcohol, 10 dips in 100% alcohol, another 10 dips in fresh 100% alcohol 
followed by 3 washes in xylene for 1 minute each. Sections were then permanently 
mounted using DPX (Di-n-butyl Phthalate in xylene, VWR, UK).  
2.3.5 Immunohistochemistry 
2.3.5.1 Von Willebrand Factor 
Von Willebrand factor (vWF) antibody staining was performed on tumour and lung 
sections using a rabbit anti-human antibody from Dako (UK). Sections were de-
paraffinised and rehydrated using the following protocol: 
 5 minutes in Xylene (times 2) 
3 minutes in 100% alcohol (times 2) 
3 minutes in 90% alcohol (times 2) 
3 minutes in 70% alcohol (times 2) 
This was followed by washing sections in tris-buffered tween (TBT 10mM pH 7.5) for 3 
minutes. Slides were incubated in 0.5% hydrogen peroxide in methanol for 3 minutes to 
block endogenous peroxidase activity. This was followed by two 5-minute washes in TBT. 
Antigen retrieval was performed by boiling Tris EDTA buffer in a microwave, placing slides 
in the solution and boiling them in the microwave for 30 minutes, followed by 20 minutes 
cooling time. Slides were then washed in distilled water for 5 minutes, followed by a 5-
minute wash in TBT. A wax ring was drawn around the section using an ImmEdge pen 
(Vector Laboratories, UK). To prevent non-specific binding of the antibody, sections were 
incubated in a solution of 20% normal goat serum (Vector Laboratories, UK) in PBS for 30 
minutes. Slides were washed briefly in TBT before adding the primary antibody diluted in 
antibody diluent (Dako, UK). The antibody was used at a 1 in 300 dilution and incubated 
at 4ºC overnight. Sections were brought to room temperature then washed twice in TBT 
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for 5 minutes each wash. The secondary antibody was added to the sections (Envision kit, 
Dako, UK) and incubated at 37ºC overnight. Secondary antibody was drained from the 
sections that were then washed in TBT for two 5-minute washes. The peroxidase 
substrate Nova Red (Vector Laboratories, UK) was added to the sections and incubated 
for 5 minutes. Washing sections in distilled water terminated the peroxidase reaction. 
Sections were then counterstained by placing in haematoxylin for 20 seconds, followed by 
washing in running water until the water ran clear. Sections were then dehydrated by 
placing in 70% alcohol for 30 seconds, 90% alcohol for 1 minute, 100% alcohol for 3 
minutes, then 3 x 3 minute incubations in Xylene. The sections were then mounted using 
DPX.  
2.3.5.2 LYVE-1 
LYVE-1 (Lymphatic Vessel Endothelial Receptor 1) antibody staining was performed using 
a biotinylated anti-mouse LYVE-1 antibody (R& D Systems, UK). Sections were de-
paraffinised and rehydrated as for the vWF antibody staining. Peroxidase blocking and 
antigen retrieval was performed as described above. The blocking step involved 
incubating the sections in 20% normal horse serum (Vector Laboratories, UK) in PBS for 
30 minutes. After briefly washing in TBT, the primary antibody was added at a final 
concentration of 10μg/ml and incubated overnight at 4ºC. The primary antibody was 
washed off with TBT and streptavidin HRP (Horseradish Peroxidase, Dako, UK) was added 
at a concentration of 1 in 500; this was incubated overnight at 37ºC. Sections were 
washed in TBT for two 5 minute washes before adding DAB (3, 3'-
diaminobenzidine,Vector Laboratories, UK) for 5 minutes. The sections were 
counterstained, dehydrated and mounted as described above.  
An alternative protocol was used for LYVE-1 staining. Sections were de-paraffinised, 
dehydrated, and underwent peroxidase blocking and antigen retrieval as described 
above. After antigen retrieval, sections were fixed in ice-cold acetone for 5 minutes 
before air-drying. This was followed by three 5-minute washes in PBS. A further blocking 
step was performed by incubating the sections in 2% fish gelatine (Sigma Aldrich, UK) in 
PBS, with the addition of 10μg/ml rat IgG (VectorLabs, UK), for 20 minutes at room 
temperature. Avidin and biotin blocking was performed using a kit available from 
VectorLabs (UK). This involved adding 4 drops of avidin blocking solution per ml of 
blocking solution (2% fish gelatine in PBS) and incubating for 5 minutes followed by a brief 
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rinse in PBS. Biotin blocking was performed in the same manner, adding 4 drops of biotin 
blocking solution per ml of blocking buffer and incubating for 5 minutes. Sections were 
then incubated overnight at 4ºC with 10μg/ml LYVE-1 antibody prepared in 1% fish 
gelatine/PBS. Following primary antibody incubation, sections were washed 3 times (5 
minutes each) with PBS/Tween (0.05%). Streptavidin conjugated to Cy-5 (Invitrogen, UK) 
was added to the sections at a concentration of 1:30 in 1% fish gelatine/PBS. This was 
incubated for 30 minutes at room temperature. Sections were then washed with 
PBS/Tween for 3 times 5 minutes, followed by three 5-minute washes in PBS. Sections 
were then mounted using Vectashield plus DAPI (VectorLabs, UK); a coverslip was placed 
over the section and sealed with nail varnish.  
2.3.5.3 Mac-2 
The protocol for macrophage staining was adapted from a protocol by Robert Macdonald 
(Cardiovascular Research Centre, Glasgow University). Sections cut at 4μm were left on 
the heat block overnight before placing in xylene for two times 5 minute washes, then 
rehydrated by placing in 100% ethanol for 5 minutes, 70% ethanol for 5 minutes, then 
running water for 5 minutes. Wax rings were drawn around the section, followed by 
addition of 3% hydrogen peroxide in distilled water for 5 minutes to block endogenous 
peroxidase activity. Sections were washed in PBS for 2 minutes, twice. Blocking was 
performed with 20% normal goat serum in PBS for 30 minutes. The primary antibody was 
rat anti-mouse Mac-2 (Cedarlane, USA), which was diluted 1 in 6000 in PBS/1% BSA, 
added to sections and left overnight at 4ºC. Sections were washed in PBS for 3 times 5 
minute washes. The secondary antibody was goat anti-rat IgG (Vector Laboratories, UK), 
which was diluted 1 in 200 in PBS/1% BSA. The secondary antibody was added to the 
sections and was incubated for 30 minutes. Sections were washed in PBS 3 x five minutes 
before adding Extravidin Peroxidase LSAB reagent (Sigma Aldrich, UK) diluted 1 in 200 in 
PBS/1%BSA and incubated for 30 minutes. Sections were washed in PBS 3 x five minutes 
before adding DAB reagent (3, 3'-diaminobenzidine,Vector Laboratories, UK) and 
incubating for 5 minutes. The reaction was quenched with distilled water (5 minutes) and 
counterstained in haematoxylin for five dips. Sections were rehydrated by placing in 70% 
ethanol for two times 1 minute, 100% ethanol for one minute, xylene for two times 2 
minutes, then permanently mounting with DPX.  
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2.3.5.4 TUNEL 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labelling) staining was 
performed using the Dead End colorimetric TUNEL system from Promega (UK), according 
to manufacturers instructions. Tissue sections were cut at 4μm as described previously. 
Slides were de-paraffinised by placing in xylene for two 5-minute washes. This was 
followed by five minutes in 100% ethanol, then 3 minutes in fresh 100% ethanol. Slides 
were then placed into 90% ethanol for 3 minutes, followed by 70% ethanol for 3 minutes. 
Slides were then washed in 0.85% NaCl for 5 minutes at room temperature. This was 
followed by a 5-minute wash in PBS. Sections were then fixed by placing in 10% NBF for 
15 minutes at room temperature. Two 5-minute washes in PBS followed this step. Whilst 
sections were washing, a 20μg/ml proteinase K solution was prepared using stock 
solution provided with the kit. 100μl of proteinase K was added to each slide and 
incubated for 10 minutes at room temp. Slides were washed in PBS for 5 minutes, before 
re-fixing in 10% NBF for 5 minutes at room temp. Another two five minute PBS washes 
followed, and then excess fluid was removed from the sections. Samples were then 
covered with 100μl equilibration buffer and incubated for 5-10 minutes. Whilst the 
sections were equilibrating, the biotinylated nucleotide mix was thawed on ice, and the 
rTdT (recombinant Terminal Deoxynucleotidyl Transferase) reaction mix was prepared for 
all sections and kept on ice (98μl equilibration buffer, 1μl biotinylated nucleotide mix and 
1μl rTdT enzyme per section). Areas around the sections were blotted with a tissue to 
remove equilibration buffer, and 100μl of rTdT mix was added to each section. These 
were covered with a plastic coverslip and incubated at 37ºC for 1 hour in a humidified 
chamber. The reaction was terminated by immersing the slides in SSC (saline sodium 
citrate) buffer for 15 minutes at room temperature. Slides were then washed three times 
in PBS for 5 minutes each. Endogenous peroxidase activity was then blocked by 
immersing slides in 0.3% H2O2 in PBS for 5 minutes at room temperature. This was 
followed by another three 5 minute washes in PBS. 100μl of streptavidin HRP solution 
was added to each sample and incubated for 30 minutes at room temperature, followed 
by another three 5 minute washes in PBS. DAB components (provided with the kit) were 
prepared prior to use and kept in the dark until needed. 100μl of DAB solution was added 
to each sample and the reaction was left to develop for 10 minutes. Rinsing several times 
in deionised water terminated the reaction. Slides were mounted using aqueous 
mounting media (Vectamount AQ aqueous mounting media, VectorLabs, UK).  
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2.3.5.5 CD3 
CD3 staining was used to identify T cells in tissue sections. Sections were deparaffinised 
and rehydrated with a series of xylene and alcohol washes: 
Xylene for 5 minutes 
100% ethanol for 1 minute 
100% ethanol for 1 minute 
70% ethanol for 1 minute 
Tap water for 5 minutes 
Endogenous peroxidase activity was blocked by incubating sections in 0.5% H2O2 in 
methanol for 30 minutes at room temperature. Sections were then washed in TBT for 5 
minutes. Antigen retrieval was performed by boiling Tris EDTA buffer in a microwave, 
placing slides in the solution and boiling them in the microwave for 30 minutes, followed 
by 20 minutes cooling time. Slides were then washed in distilled water for 5 minutes 
followed by a 5-minute wash in TBT. Non-specific binding was blocked by incubating 
sections in ready to use 2.5% horse blocking serum (ImmPRESS anti-rabbit peroxidase kit, 
VectorLabs, UK) for 45 minutes at room temperature. The blocking serum was ‘tapped’ 
off the slides and the primary antibody; a polyclonal rabbit anti human CD3 (Dako, UK) 
was added to the sections, at a concentration of 1/1000 in Dako antibody diluent solution 
containing 2.5% horse serum (VectorLabs, UK) and 2.5% mouse serum. The primary 
antibody was incubated on the sections overnight at 4ºC. The primary antibody was 
removed and sections were washed in TBT for 5 minutes, twice. Sections were then 
incubated with the rabbit ImmPRESS reagent for 30 minutes. Slides were then washed for 
5 minutes with TBT. Sections were then incubated with Novared for 5 minutes, this 
reaction was terminated by the addition of distilled water. Sections were then washed 
with TBT for 5 minutes, followed by a 5-minute wash in distilled water. Sections were 
then counterstained by dipping twice into haematoxylin, rinsing in tap water and 
dehydrating by placing in 70% ethanol for 30 seconds, 100% ethanol for 1 minute and 
100% ethanol for 3 minutes. Sections were placed in 2 washes of xylene for 5 minutes and 
mounted permanently using DPX.  
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2.3.6 Flow cytometry 
Lungs from C57Bl/6 mice, with and without intravenous administration of B16 F10 cells, 
were perfused with PBS and placed into 5ml RPMI on ice. The lung tissue was cut into 
small pieces (mm2) with dissecting scissors. The resulting tissue suspension was incubated 
in 1mg/ml collagenase D in PBS (Roche Diagnostics GmbH, Mannheim, Germany), for 1 
hour at 37ºC with constant shaking. The remaining lung pieces were placed into a 70μm 
cell strainer, and any remaining tissue fragments were pushed through with the end of a 
syringe into a 50ml tube. The resulting cell suspension was passed through a 40μm cell 
strainer and centrifuged at 300g for five minutes at 4ºC. The cell pellet was resuspended 
in red blood cell lysis buffer and incubated for 1 minute. The reaction was stopped by 
adding 20ml RPMI and centrifuged for 5 minutes. Cells were washed twice with PBS and 
counted using a haemocytometer. Lung cells were resuspended at a final concentration of 
1 x 106 cells per 150μl PBS, before proceeding to antibody labelling. Fc block (Miltenyi 
Biotec, UK) was added to the cells at a dilution of 1:10 and incubated for 10 mins to block 
non-specific antibody binding. A panel of lineage markers were used to stain lung cell 
populations. 10μl each of CD3-FITC, CD19-Cy5, CD11b-APC, CD11c-Cy7, Ly5.2-PE (All 
antibodies from eBioscience, UK, except CD11b-APC which was from Abcam, UK) were 
added to the cells and incubated for 20 minutes on ice. The stock concentration for all 
antibodies was 0.2mg/ml. Cells were washed in PBS before adding to FACS tubes and 
analysed using the MACSQuant (Miltenyi Biotec, UK) with the help of Alasdair Fraser. 
Results were analysed using CAP software (Miltenyi Biotec, UK) 
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2.4 Molecular Biology 
2.4.1 PCR 
PCR reactions were performed using ReddyMix PCR Master Mix (Abgene, Surrey, UK). 
Each reaction contained 0.2 mM of each dNTP and 1.5 mM MgCl2. Primers were added to 
the master mix at varying concentrations (from 0.4μM to 0.5μM final primer 
concentration). Primers used were from VHBio (subsequently became IDT DNA, UK); 
sequences are shown in table 2.3.  
Gene Forward Primer Reverse Primer Annealing 
Temp
Murine 
CCR1
GCCCTCATTTCCCCTACAA CGGCTTTGACCTTCTTCTCA 50.81ºC 
52.07ºC
Murine 
CCR2
AGAGAGCTGCAGCAAAAAG
G
GGAAAGAGGCAGTTGCAA
AG
55.8ºC 
54.5ºC
Murine 
CCR3
TTTCCTGCAGTCCTCGCTAT ATAAGACGGATGGCCTTGT
G
56ºC    
54.8ºC
Murine 
CCR4
ATTTGCTGTTCGTCCTGTCC CGTGTGGTTGTGCTCTGTGT 55.5ºC 
58.1ºC
Murine 
CCR5
TTTGTTCCTGCCTTCAGACC TTGGTGCTCTTTCCTCATCT
C
54.9ºC 
54.6ºC
Murine 
CCR7
GTGTGCTTCTGCCAAGATGA CCACGAAGCAGATGACAGA
A
55.5ºC 
54.9ºC
Murine 
D6
TTCTCCCACTGCTGCTTCAC TGCCATCTCAACATCACAG
A
57.5ºC 
54.9ºC
Murine 
GAPDH
TGTCTCCTGCGACTTCAA TGCAGCGAACTTTATTGAT
G
53.5ºC 
51.2ºC
 
Table 2-3: Nucleotide sequences used for PCR. 
Primer sequences used for all PCR reactions. Primers were designed using Primer 3 software. The melting 
temperatures for each primer pair is shown, which was used to calculate the ideal annealing temperature 
for the PCR programs.  
Two different PCR programs were used throughout, with different annealing 
temperatures depending on the primers used (described for each PCR reaction). PCR 
program 1: (referred to as CLIVE program) 95ºC for 3 minutes, 95ºC for 15 seconds, 
59.5ºC for 20 seconds, 72ºC for 30 seconds (step 2 through 4 repeated 35 times), 
followed by a final 72ºC for 7 minutes. PCR program 2:  (CBPCR1 program) reactions using 
this PCR program were started with a ‘hot start’. This meant the samples were heated to 
95ºC before adding the final component (this could be primers or template DNA). This 
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PCR program started with 95ºC for 3 minutes, 95ºC for 15 seconds, 60ºC for 20 seconds, 
and 72ºC for 40 seconds (step 2 through 4 repeated 35 times), followed by 72ºC for 7 
minutes. PCR program 3: (CBPCR2 program) 95ºC for 2 minutes, 95ºC for 1 minute, 55ºC 
for 30 seconds, 72ºC for 2 minutes (step 2 to 4 repeated 30 times), followed by 72ºC for 7 
minutes.  
PCR products were analysed on agarose (Invitrogen, UK) gels, varying from 1-2% (in TAE 
(tris acetate EDTA) buffer). Ethidium bromide (Invitrogen, UK) was added to the molten 
agarose to a final concentration of 0.5μg/ml. Once the gel was set, 5-8μl of each PCR 
product was added to each well of the gel, along with a DNA ladder (Hyperladder IV, 
Bioline) in at least one of the wells. The gel was allowed to run for 30-40 minutes at 100-
110 volts. The gel was imaged using the AlphaImager (AlphaInnotech, UK). 
2.4.2 RNA Extraction 
For RNA extraction from cell lines, cells were harvested, counted and pelleted. The pellet 
was kept frozen at -80ºC until the RNA was extracted. RNase free filter tips and plastics 
were used throughout all RNA work. Before RNA was isolated, surfaces were wiped down 
with 70% ethanol and RNase ZAP (Ambion, UK) to remove endonucleases. The RNA was 
extracted using the RNeasy mini kit (Qiagen, UK) following the manufacturers protocol for 
animal cells. On column DNase digestion (Qiagen, UK) was performed for all samples 
following the manufacturers instructions. RNA was eluted in RNase-free water and stored 
at -80ºC.  RNA was isolated from mouse tissues by placing the tissue of interest in RNA 
Later (Qiagen, UK), or snap freezing the tissue in liquid nitrogen. The tissue was crushed 
to a fine powder using liquid nitrogen and a mortar and pestle. RNA was then extracted 
using the RNeasy mini kit, following the manufacturers protocol for animal tissues. RT-
PCR 
cDNA was generated from RNA using the Superscript II (or III) kit (Invitrogen, UK). 5µg of 
RNA was mixed with 1 µl (0.5 µg) oligo-dT primer, 1 µl dNTPs (10 mM with respect to 
each / 40 mM total). The reaction mix was denatured at 65oC for 5 minutes then placed 
on ice for 5 minutes. A master mix was made up containing the following; 4 µl 5X buffer, 2 
µl 0.1 M DTT, 0.5 µl RNasin (RNase inhibitor). 6.5 µl of master mix was added to each 
denatured RNA sample and incubated for 2 minutes at 42oC.  50 units (1 µl) of Superscript 
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II (or III) was added and incubated for 60 minutes at 42oC, followed by a 15-minute 
inactivation step at 70oC.  
Some cDNA samples were generated using the Affinityscript kit (Stratagene, UK). It was 
decided to start using this kit as it was more cost effective and worked just as well as 
Superscript kit. cDNA was generated using Affinityscript according to the following 
protocol. 1ng-5μg of RNA was added to an RNase free micro centrifuge tube along with 
1μl oligo dT primers (0.5μg/μl) and RNase free water to a final volume of 15.7μl. The 
reaction was incubated at 65ºC for 5 minutes, then left to cool for 10 minutes at room 
temp to allow the primers to anneal to the RNA. The following components were added 
to the reaction: 2μl 10x Affinityscript buffer, 0.8μl dNTP mix (25mM each dNTP), 0.5μl 
RNase block ribonuclease inhibitor (40U/μl) and 1μl AffinityScript Multiple Temperature 
RT. The reaction was incubated at 42ºC for 5 minutes followed by 55ºC for 55 minutes. 
Incubating at 70ºC for 15 minutes terminated the reaction. The resulting cDNA was 
diluted 1 in 5 in DEPC treated water (Ambion, UK) and stored at -20ºC to be used for 
future experiments 
2.4.3 Ethanol Precipitation 
Plasmid DNA was purified by Miniprep (Qiagen), and ethanol precipitation was performed 
before using the plasmid DNA for transfection. 1/10 volume of 3M NaAc was added to the 
DNA solution that was to be precipitated. This was followed by adding 2 volumes ice cold 
100% ethanol. The DNA solution was placed into the -80ºC freezer for 30 minutes, 
followed by centrifugation at high speed (10,000rpm) for 10 minutes. The supernatant 
was discarded and the pellet resuspended in 70% ethanol and spun for another 3 
minutes. The supernatant was discarded under sterile conditions and the pellet was left 
to air dry, before re-suspending in the buffer of choice for use in transfection 
experiments. 
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2.5 Statistical Analysis 
Statistical analysis was performed using Graphpad Prison software version 4.0. Results 
shown throughout are mean +/- standard error of the mean (SEM) unless stated in the 
figure legend. Statistical tests used were unpaired students t test, two way ANOVA with 
Bonferroni’s post test and the Logrank test. Values of p less than or equal to 0.05 were 
considered to be statistically significant. 
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3 In vivo migration of neutrophils  
3.1 D6 and chemotaxis 
As mentioned in the introduction, chemotaxis is essential in a wide variety of cellular 
processes. During development, chemotaxis allows stem cells and progenitors to migrate 
to the correct position in the embryo, and it is required for the development of organs 
and the immune system (336). Chemokines and their receptors play an essential role in 
development, as revealed by studies using KO mice. CXCL12 and CXCR4 are believed to be 
the primordial chemokine ligand and receptor – KO for both are perinatally lethal with 
defects in B cell lymphopoiesis, haematopoietic stem cell development, primordial germ 
cell development, cardiogenesis and neural development (61, 337).  
In addition, the immune system relies on cell movement for the initiation and 
maintenance of immune responses. In the innate response, neutrophils, monocytes and 
DCs must be able to enter the site of inflammation and infection in order to try to clear 
the pathogen and resolve the inflammation (48). Defects in cell movement cause diseases 
such as leukocyte adhesion deficiency, which results from a deficiency in the β2 integrin 
subunit. This results in the development of persistent infections (338). In the case of DCs, 
they must be able to migrate in response to inflammatory stimuli, and once at the site of 
inflammation, their chemokine receptors have to switch from inflammatory chemokine 
receptors such as CCR 1 and CCR2 to CCR7 (94). This is required to allow them to migrate 
to the draining lymph node, where they interact with T cells and help to mount an 
adaptive immune response, which involves numerous other cells.  
As well as expression of conventional signalling chemokines receptors, leukocytes have 
been shown to express D6, an atypical chemokine receptor. In particular, DCs and B cells 
have high levels of D6 expression (144, 145). Work using D6KO mice has suggested that 
D6 may play a role in cell movement. In the EAE model, DCs are unable to leave the site of 
inoculation in D6KO mice, which appears to result in reduced T cell activation, and a 
reduced disease severity (153). In the TPA model of skin inflammation, D6KO mice display 
an aberrant localisation of neutrophils compared to WT mice. In D6KO skin, neutrophils 
are found at the dermal/epidermal junction, whilst in WT mice neutrophils are found in 
the dermis (140, 152). As neutrophils have been shown to express D6, it has been 
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suggested that D6 may somehow influence their migration into inflamed skin. In vitro 
work, using transfected cell lines, shows that cells which co-express CCR4 and D6 have 
reduced chemotactic abilities to CCL22. When D6 is co-expressed with CXCR4, migration 
to CXCL12 is unaffected. These data suggest that D6 may compete for ligand with 
signalling CC chemokine receptors, or may interfere with the signalling mechanism for 
CCR4 (141). These results were obtained using transfected cell lines, which are likely to 
express the transfected receptors at levels higher than those found in vivo, so this data 
needs to be analysed with that caveat in mind.  
Taken together, these data suggest that D6 may act on a cell autonomous basis to 
influence cell movement. Looking more in detail at the aberrant location of neutrophils in 
inflamed skin from D6KO mice, there are two possible explanations of the role of D6 in 
cell movement. D6KO neutrophils may be found at the dermal epidermal junction due to 
increased levels of chemokines in this area (i.e. as a secondary effect of the inflammatory 
response and not due to a defect in neutrophil movement), allowing neutrophils to 
migrate here (A in figure 3.1). Alternatively, a lack of D6 on neutrophils may mean that 
they are able to enter the skin normally under the influence of signalling chemokine 
receptors, but once there, these neutrophils are unable to halt their movement and 
continue moving to the dermal/epidermal junction (B in figure 3.1). These two 
hypotheses are illustrated in figure 3.1.  
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Figure 3-1: Potential mechanisms of D6 influencing neutrophil migration into the skin 
Hypothesis A: A lack of D6 in the skin means that increased levels of chemokines at the dermal/epidermal 
junction allows both WT and D6KO neutrophils to localise here. Hypothesis B: A lack of D6 on neutrophils 
means they are unable to halt their migration in response to chemokines, meaning they continue moving 
towards the dermal/epidermal junction.  
These data led us to investigate if this phenomenon was receptor or cell type specific, i.e. 
could D6 affect migration in response to other D6 ligands when co-expressed with the 
appropriate signalling receptor. This hypothesis was tested using in vitro chemotaxis 
assays, with cells that stably over-express D6, primary murine cells and eventually using in 
vivo models of cell movement. Initially attempts were made at creating cell lines that 
stably expressed D6 to analyse the effects, if any, that D6 would have on in vitro 
chemotaxis towards both inflammatory and constitutive chemokines. Unfortunately 
these experiments failed repeatedly, due to a failure to generate stably transfected cell 
lines, and problems with the initial optimisation of chemotaxis assays.  
An alternative approach was taken, which involved isolating different cell populations 
from WT and D6KO mice, and analysing their chemotaxis in vitro, using two types of 
chemotaxis assays, the Transwell assay and the Neuroprobe chamber (a modified Boyden 
chamber). Again, these experiments were unsuccessful as, despite some early results 
using these assays, the results were extremely variable and as a result, no clear 
conclusions could be drawn. These results have been omitted from the thesis.  
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3.2 Neutrophil Adoptive Transfer 
3.2.1 Neutrophil movement in inflammation 
Using the well-characterised TPA skin inflammation model (339, 340), D6KO mice have 
shown an exaggerated inflammatory response, typified by the development of a psoriasis 
like pathology in the dorsal skin. This model, and the features unique to D6KO mice, have 
been discussed in further detail elsewhere, and in the introduction (152). The main 
pathology caused by the lack of D6 is due to a failure to clear CC chemokines from the site 
of inflammation, in this case the skin.  The presence of these chemokines in the skin of 
D6KO mice is thought to promote an exaggerated influx of T cells and dermal mast cells, 
which are thought to contribute to the development of the psoriasis-like pathology. 
Although there were no observed differences in neutrophil numbers, when comparing 
D6KO skin to WT, there was a difference in the location of neutrophils in D6KO mice. In 
WT mice, neutrophils were situated primarily in the dermal layer of the skin (picture A 
figure 3.2), whilst in D6KO mice, neutrophils were present at the dermal/epidermal 
junction, as shown in picture B of figure 3.2.  
Two alternative hypotheses have been proposed to explain the differences in neutrophil 
localisation in D6KO skin. A lack of D6 in the skin has been shown to increase levels of 
chemokines, and these chemokines may localise to the dermal/epidermal junction, 
allowing both WT and D6KO neutrophils to localise to this area. Alternatively, a lack of D6 
in neutrophils may prevent neutrophils from being able to halt their migration, meaning 
they are found at the dermal/epidermal junction (illustrated in figure 3.1).  
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Figure 3-2: Differential positioning of neutrophils in the skin of TPA treated D6KO mice 
The skin of WT and D6KO 129/Bl6 mice was inflamed with one treatment of TPA, which was then 
processed for histological analysis. Staining for neutrophils was performed using an antibody against 
myeloperoxidase. A: WT skin, B: D6KO skin. More neutrophils are present at the dermal/epidermal 
junction in D6KO mice (manuscript submitted, 137).  
To try to address these possibilities, the TPA skin inflammation model was used, along 
with adoptive transfer of labelled neutrophils. This would allow identification of the 
genotype of the neutrophils, as D6KO and WT neutrophils are labelled with different 
fluorescent dyes, and would allow analysis of the position of neutrophils in the inflamed 
skin. These experiments would illustrate if a lack of D6 on neutrophils is responsible for 
their positioning at the dermal/epidermal junction – if this is the case, more D6KO 
neutrophils would be expected at the dermal/epidermal junction in the inflamed skin of 
D6KO mice, whilst WT neutrophils would remain lower down in the dermal compartment 
of the skin.  
D6KO and WT neutrophils were isolated from 129/Bl6 mice (materials and methods 
section 2.2.2), fluorescently labelled and injected into the tail vein of 129/Bl6 D6KO mice 
that had received a single TPA treatment to the dorsal skin. The treated skin was sampled 
at various time points after neutrophil transfer, ‘snap frozen’ in liquid nitrogen, and skin 
sections were analysed for the presence and location of labelled neutrophils.  
3.2.1.1 Fluorescent Labelling - Optimisation 
Initial optimisation experiments were performed using THP-1 cells, rather than 
neutrophils, to determine the ideal concentration for each fluorescent dye to be used. 
These cells were used as they were easy to grow in culture and meant that mice would 
not need to be sacrificed for the optimisation of the fluorescent dyes. Initially CFSE and 
CMTMR were the fluorescent dyes used. CFSE fluoresces green and CMTMR fluoresces 
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orange/red. These dye combinations were used, as they allow easy identification of 
labelled neutrophils, without interfering with the DAPI staining of nuclei.  
 
Figure 3-3: Optimisation of neutrophil staining.  
Following optimisation of staining using THP1 cells, neutrophils were stained using the same protocol. 
CFSE staining could be detected on both WT and D6KO neutrophils (picture A and B respectively). Images 
were taken at 200x magnification using the Axiostar plus microscope. CMTMR stained neutrophils are 
shown in picture C, taken at 400x magnification. TAMRA stained neutrophils are shown in picture D, with 
DAPI counterstain, this image was taken at 200x using the LSM 510 Meta Zeiss confocal microscope.  
A dose response curve was obtained to determine the optimal concentration of CFSE and 
CMTMR; labelled THP-1 cells were analysed using both flow cytometry and fluorescent 
microscopy. The concentration of fluorescent dye which gave a strong signal using the 
fluorescent microscope, in the appropriate channel, without too much ‘bleed-through’ 
into other channels (e.g. the lowest bleed through in the rhodamine channel for the CFSE 
and the lowest bleed through in the FITC channel for CMTMR.) was the concentration 
used (CFSE 10μM, CMTMR 5μM) (data not shown). After the optimal concentration was 
determined using THP1 cells, this concentration was then tested on neutrophils and used 
for adoptive transfer experiments, see figure 3.3.  
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3.2.1.2 Neutrophil Adoptive Transfer - Optimisation 
Neutrophils are one of the first cell types recruited to a site of inflammation and can 
appear as early as 2 hours after the induction of inflammation (341). The initial neutrophil 
adoptive transfer experiment was carried out in order to try to determine the optimal 
time after cell injection when neutrophils could be detected in the inflamed skin. 
Experiments were named according to the date they were carried out; the initial 
experiment was carried out on the 15/01/07. A summary of all neutrophil adoptive 
transfer experiments can be found in tables 3.1 and 3.2. All mice used in these 
experiments were on a 129/Bl6 background, both WT and D6KO.  
 
Figure 3-4: Giemsa stained murine neutrophils 
Murine neutrophils were isolated from murine bone marrow using the Ly6G kit from Miltenyi (materials 
and methods section 2.1.2.1), put onto a slide by cytospin and stained with Giemsa. This allowed 
assessment of the purity of neutrophil preps by light microscopy. Neutrophil preps were consistently 
~96% using this kit. 200x magnification, Axiostar plus microscope 
 
Claire L. Burt, 2011   114 
Date of 
Experiment
Time of 
TPA 
painting
Time of 
neutrophil 
injection
Time of 
sampling
Type of cell 
staining
No. of cells 
injected
15/01/2007 8am 3pm 8am (24hours 
after TPA)
CFSE and 
CMTMR 
(reciprocal)
1 x 106 of each 
genotype (2 x 106 
total)
29/01/2007 8am 3pm 7pm (11 hrs 
after TPA) 9pm 
(13 hrs after 
TPA)
CFSE and 
CMTMR
1.25 x 106 of each 
genotype (2.5 x 
106 total)
05/03/2007 8am 3pm 9pm (13 hrs 
after TPA)
CFSE 4 x 106 of any one 
genotype (either 
D6KO or WT)
27/03/2007 5pm 12pm 
(following 
day)
3pm (22hrs 
after TPA) 5pm 
(24 hrs after 
TPA)
CFSE 1 x 107 of D6KO 
neutrophils
03/05/2007 8am 1pm 7pm (11hrs 
after TPA) 8am 
(24hrs after 
TPA)
CFSE and 
TAMRA
1 x 107of each 
genotype (2 x 107 
total neutrophils)
26/07/2007 8am 1pm 7pm (11hrs 
after TPA) 8am 
(24hrs after 
TPA)
CFSE and 
TAMRA
1 x 107of each 
genotype (2 x 107 
total neutrophils)
Table 3-1: Summary of neutrophil adoptive transfer experiments  
This table shows the details for each neutrophil adoptive transfer experiment which was performed 
during the optimisation stages. The time course of TPA treatment, neutrophil administration and 
sampling are shown for each experiment. The fluorescent dyes used, the total number of neutrophils 
injected, and their genotype, are also described here. 
For the initial experiment, 129/Bl6 D6KO mice were treated with TPA once (which has 
been shown to induce an inflammatory response in the skin (152)), then 7 hours later, a 
total of 2 x 106 labelled neutrophils were injected into the tail vein of these TPA treated 
mice. Each mouse received a 50:50 mixture of labelled WT and D6KO neutrophils. All 
neutrophils were isolated from 129/Bl6 mice, either WT or D6KO, and all mice receiving 
neutrophils were 129/Bl6 background. Two mice received WT neutrophils labelled with 
CFSE and D6KO neutrophils labelled with CMTMR, whilst the remaining two mice received 
the same number of cells, with the opposite staining combination (WT labelled with 
CMTMR and D6KO labelled with CFSE). Neutrophils were isolated using the Ly6G isolation 
kit from Miltenyi (materials and methods section 2.1.2.1). Initial optimisation experiments 
were performed to determine the percentage purity of neutrophil preparations. These 
were determined by performing cytospins of neutrophil preps, staining with Giemsa, and 
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calculating the percentage of neutrophils by light microscopy, see figure 3.4. Consistently 
neutrophil preps were 96% neutrophils, with few mononuclear cells contaminating the 
preparations.  
Experiment 
Date
No. mice 
sacrificed
No. mice receiving 
cells
Method of bone 
marrow cell 
extraction
Yield (neutrophils 
per mouse)
15/01/2007 7 WT 7 
D6KO
4 D6KO Flushing WT: 1.23 x 106 
D6KO: 9.5 x 105
29/01/2007 9 WT 9 
D6KO
8 D6KO (4 D6KO 
CFSE WT 
CMTMR, 4 WT 
CFSE D6KO 
CMTMR)
Crushing WT: 1.11 x 106 
D6KO: 1.44 x 106
05/03/2007 12 WT 12 
D6KO
8 D6KO (4 WT 
CFSE, 4 D6KO 
CFSE)
Crushing WT: 2.9 x 106 
D6KO: 2.225 x 106
27/03/2007 12 D6KO 4 D6KO Crushing D6KO: 3.94 x 106
03/05/2007 12 WT 12 
D6KO
4 D6KO (2 WT 
CFSE D6KO 
TAMRA, 2 WT 
TAMRA D6KO 
CFSE)
Crushing WT: 3.33 x 106 
D6KO: 3.33 x 106
26/07/2007 12 WT 12 
D6KO
4 D6KO (2 WT 
CFSE D6KO 
TAMRA, 2 WT 
TAMRA, D6KO 
CFSE)
Crushing WT: 4.05 x 106 
D6KO: 3.56 x 106
  
Table 3-2: Summary of neutrophil adoptive transfer experiments – neutrophil isolation details.  
The number of mice that were treated with TPA, and the cell labelling combinations used are detailed 
here. The method of isolating bone marrow from murine femurs was either flushing of crushing (further 
details can be found in materials and methods section 2.1.2.1). The average yield of neutrophils per 
mouse is shown for each adoptive transfer experiment. 
Mice were sacrificed 24 hours after TPA painting and 5mm punch biopsies of the inflamed 
dorsal skin were snap frozen in liquid nitrogen. Skin sections were cut to 6μm thickness 
and mounted on polysine-coated slides, before mounting using Vectashield plus DAPI (to 
label the nuclei of the skin cells). Slides were analysed initially using the Axiostar plus 
microscope with fluorescent filters.  Neutrophils were checked for successful fluorescent 
labelling by performing cytospins (data not shown)  
Upon analysing the skin sections using the fluorescent microscope, it was discovered that 
under the UV light, hair follicles auto-fluoresce. This made it very difficult to identify any 
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labelled cells in the skin (see figure 3.5-A and B). The skin sections from the first 
neutrophil adoptive transfer experiment were re-analysed using the LSM 510 Meta 
confocal microscope, as this could be used to help reduce the auto fluorescence. The 
main difference between these two types of microscopy is that in fluorescence 
microscopy the whole image is illuminated which can create a haze, and can result in high 
background. With confocal microscopy a laser is used to focus the illumination, which 
gives a higher intensity and, as the illumination is focused onto a smaller area, it reduces 
background fluorescence. Another advantage of using the confocal microscope was that 
all three colours, orange for CMTMR, green for CFSE and blue for DAPI, could be shown 
on the same picture, which could not be done using the fluorescent microscope. The 
more precise wavelength of the confocal allowed identification of labelled cells.  
The confocal images shown in figure 3.5 (C and D) show that labelled neutrophils can be 
detected in the skin of treated mice following neutrophil adoptive transfer. These labelled 
cells could not be detected with the fluorescent microscope, due to the hair follicle auto-
fluorescence. Very few labelled neutrophils, either WT or D6KO could be detected using 
the confocal microscope, so it was decided to alter the adoptive transfer protocol.  
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Figure 3-5: Inflamed skin from a mouse (15/01/07) that had received CFSE and CMTMR labelled WT and 
D6KO neutrophils.  
Pictures from D6KO 129/Bl6 mouse that received one dose of TPA followed by tail vein injection of 1x10
6
 
CFSE and CMTMR labelled neutrophils (D6KO and WT neutrophils at 1:1 ratio) 7 hours later. Skin samples 
were taken 24 hours after TPA painting, frozen sections were cut and analysed for the presence of 
labelled neutrophils. A – image taken at 200x magnification with Axiostar plus microscope, with the CFSE 
filter, showing autofluorescent hair follicles. B – same skin section taken with the DAPI filter on the 
Axiostar plus microscope, showing skin cells and hair follicles. C& D – skin sections analysed using the 
LSM 510 Meta confocal microscope, showing CMTMR labelled neutrophils (C) and CFSE labelled 
neutrophils (D). These images were taken at 200x magnification. N = 4 (2 received CFSE D6KO neutrophils 
with CMTMR WT neutrophils, 2 received the reciprocal staining combination).  
The second neutrophil adoptive transfer protocol was altered to add more neutrophils at 
the injection stage and sampling the skin less than 24 hours after TPA painting, as very 
few neutrophils could be detected at 24 hours after TPA painting. The details of this 
experiment (29/01/07) can be found in tables 3.1 and 3.2. For this experiment, femurs 
from WT and D6KO mice were crushed using a mortar and pestle, rather than flushing the 
bone marrow, to try to increase the neutrophil yields. This method increased neutrophil 
numbers; these are detailed in table 3.2. Confocal analysis of frozen skin sections showed 
that cells stained with both fluorescent dyes could be detected in the skin, and that both 
cell genotypes could be detected (figure 3.6). The results from this experiment showed 
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that neutrophils could be detected in the skin, but indicated that more may be needed at 
the time of transfer, as only a few cells could be detected per picture. As neutrophils tend 
to have a short half-life in vivo (342), it is possible that a large number of neutrophils are 
dying before they reach the skin. Using a large number of neutrophils in the adoptive 
transfer protocols we hoped to overcome the problem of the neutrophils dying. The 
protocols were optimised to try to minimise the length of time that neutrophils were ex 
vivo, unfortunately analysis of the proportion of live to dead neutrophils was not carried 
out before injection. It is likely that a large number of cells die during the process of 
labelling, but by injecting a large enough number of neutrophils, we hoped to overcome 
this effect.  
 
Figure 3-6: Skin sections from mouse treated with neutrophil adoptive transfer protocol 29/01/07 
Skin sections from 129/Bl6 D6KO mice that received a 1:1 mixture of WT and D6KO neutrophils, labelled 
with CFSE and CMTMR.  Each mouse (n = 8) received 2.5 x 10
6
 labelled neutrophils, at a 1:1 mix WT to 
D6KO, with reciprocal staining combinations. Frozen sections were mounted with Vectashield plus DAPI 
to visualise skin cells, images were taken at 200x magnification on the LSM 510 Meta confocal. A – 
CMTMR labelled neutrophils are identified, B – CFSE labelled neutrophils are identified. These skin 
sections are from the 9pm sampling point (see tables 3.1 and 3.2 for further details). Control skin sections 
consistently showed no fluorescently labelled cells (not shown).  
These results show that neutrophils can be detected in inflamed skin 13 hours after the 
induction of inflammation, but very few neutrophils (relative to the number of cells 
injected) were detectable. For the next adoptive transfer experiment (05/03/07), the 
same general timeline as the previous experiment was used, with only the later 9pm time 
point (see table 3.2) used for sampling, as this was when fluorescent cells could be 
detected in the skin. To further increase the number of neutrophils that could be injected 
into treated mice, more mice were sacrificed (12 of each genotype) and crushing of the 
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femurs was used to isolate the bone marrow. Crushing the femurs increased the 
neutrophil yield, which allowed 4 x 106 neutrophils to be injected per mouse. For this 
experiment, mice received either CFSE labelled D6KO neutrophils or CFSE labelled WT 
neutrophils alone. 
 
Figure 3-7: Fluorescent images of inflamed skin from D6KO mice receiving CFSE labelled neutrophils 
according to protocol 05/03/07 
Representative images of inflamed skin from 129/Bl6 D6KO mice that received 4 x 10
6
 CFSE labelled 
neutrophils, either WT or D6KO. Skin sections are mounted with Vectashield plus DAPI to stain nuclei. A – 
confocal image showing CFSE labelled neutrophils in the subdermal region of the skin, 200x 
magnification. B – same skin section as A at 400x magnification. C – CFSE labelled WT neutrophils in the 
subdermal region of D6KO inflamed skin, 200x magnification. N = 4 per group receiving either CFSE WT 
neutrophils or CFSE D6KO neutrophils.  
CFSE labelled neutrophils could be detected for both cell genotypes injected, but with the 
D6KO neutrophils the majority of cells were present below the dermis (in the fatty layer) 
of the inflamed skin (see figure 3.7). Fewer cells were obvious in the sections from mice 
that had received WT neutrophils. The cell number for this experiment (05/03/07) 
seemed to be better for detecting labelled neutrophils in the inflamed skin, but there may 
be a problem with the time point of sampling. D6KO neutrophils may require longer 
getting from the sub dermal area to the site of inflammation (13 hour time point).  
As a result, the next adoptive transfer experiment (27/03/07) was re-designed, so that 
mice received TPA treatment at 5pm on the day before neutrophil administration. 
Neutrophils were isolated, labelled and injected at 12pm the following day. Mice were 
sacrificed at both 22 hours and 24 hours after TPA treatment in the hope that letting the 
inflammation develop for longer would attract more neutrophils into the skin. For this 
experiment, only D6KO neutrophils were labelled with CFSE and transferred into TPA 
treated D6KO mice. More than double the number of neutrophils (see tables 3.1 and 3.2) 
were injected intravenously.  
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Figure 3-8: Fluorescent skin sections from neutrophil adoptive transfer protocol 27/03/07 
129/Bl6 D6KO mice received 1 x 10
7
 CFSE labelled D6KO neutrophils following TPA painting, 22-24 hours 
after injection, mice were sacrificed and dorsal skin samples were taken. A – CFSE labelled D6KO 
neutrophils at the edge of the skins surface, 200x magnification. B – CFSE labelled D6KO neutrophils 
detected beside a hair follicle, 200x magnification. C – picture B at 400x magnification. Images are 
representative of 4 mice.  
The skin sections from the adoptive transfer experiment performed on the 27/03/07 (see 
figure 3.8) show that CFSE labelled D6KO neutrophils could be detected in the skin 22 and 
24 hours after TPA treatment. Even though a higher number of neutrophils were 
administered intravenously, this does not seem to correspond with higher numbers of 
labelled neutrophils present in the inflamed skin. It appears (see picture A of figure 3.8) 
that some of the labelled cells may be reaching the outer edge of the skin, but this was 
not seen in every mouse. These results suggest that this time point may be too late to 
fully analyse the location of D6KO neutrophils in inflamed skin. 
The results of the neutrophil adoptive transfer experiments performed on the 05/03/07 
and 27/03/07, suggested that the ideal time point for analysing neutrophil location in this 
model was between 11 and 24 hours. The experiment was repeated; following the 
protocols detailed in tables 3.1 and 3.2 (03/05/07), and transferring a 50:50 mixture of 
CFSE and TAMRA labelled D6KO and WT neutrophils. It was decided to start using TAMRA, 
rather than CMTMR because very few CMTMR positive cells had been detected in 
previous experiments, and it was thought that an alternative dye, which fluoresces in a 
similar wavelength, might be more suitable. Other groups had used this cell dye 
combination in adoptive transfer experiments successfully (343). Skin samples were taken 
at 11 hours and 24 hours after TPA painting, in the hope that these time points would be 
suitable to identify labelled neutrophils entering the inflamed skin.  
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Figure 3-9: Fluorescent skin sections from D6KO mice that received neutrophils according to protocol 
04/05/07 
129/Bl6 D6KO mice received tail vein injections of a total of 2 x 10
7
 labelled neutrophils, a combination of 
CFSE and TAMRA labelling, at a 1:1 ratio. N = 2 mice received CFSE WT neutrophils, TAMRA D6KO 
neutrophils, n= 2 mice received CFSE D6KO neutrophils and TAMRA WT neutrophils. Mice were sacrificed 
and skin samples taken at 11 and 24 hours post TPA treatment. Skin sections were mounted with 
Vectashield plus DAPI, as described previously. A – control skin section, B – skin from a D6KO mouse that 
received TAMRA labelled D6KO neutrophils and CFSE WT neutrophils, C – Skin section from D6KO mouse 
that received TAMRA WT neutrophils and CFSE WT neutrophils. All sections were taken at 200x 
magnification and show a high red background, making identification of TAMRA positive cells difficult. 
Skin sections were cut on the cryostat and mounted on polysine slides. Vectashield plus 
DAPI was added to the sections and they were analysed on the confocal microscope as 
described previously. The majority of the sections analysed from this experiment had a 
very high red background, which could not be reduced using the confocal microscope (see 
figure 3.9). This made it very difficult to identify TAMRA positive cells. The whole area of 
the skin section was searched for positive cells, but very few (of either TAMRA or CFSE 
labelled cell populations) could be identified.  
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Figure 3-10: Fluorescent skin sections from neutrophils adoptive transfer protocol 26/07/07.  
The 03/05/07 protocol was repeated on 26/07/07 (4 129/Bl6 D6KO mice received TPA painting followed 
by 2 mice receiving 2x10
7
 labelled neutrophils, 1:1 mixture of TAMRA WT and CFSE D6KO neutrophils, 
and 2 mice receiving the reciprocal staining combination).  Skin sections were mounted using Vectashield 
plus DAPI; skin sections from this repeated experiment lacked the high red background shown previously 
(figure 3.10). A – Skin section from D6KO mouse that received TAMRA D6KO neutrophils and CFSE WT 
neutrophils. B – Skin section from D6KO mouse that received TAMRA labelled WT neutrophils and CFSE 
D6KO neutrophils. Images taken at 200x magnification, LSM 510 Meta confocal microscope.  
This experiment was repeated (26/07/07) with the same combination of dyes and time 
course. Skin sections from the adoptive transfer performed on 26/07/07 were mounted 
using Vectashield and analysed as before. Upon analysing the skin sections from this 
experiment, it was discovered that all of the sections again had a substantial red 
background, which made it difficult to see any TAMRA labelled cells. CFSE cells could still 
be detected, as shown in figure 3.10.  More sections were cut from this experiment to 
determine if the high red background was present throughout the skin samples. The 
second batch of sections had a reduced red background that allowed identification of 
CFSE and TAMRA labelled neutrophils (representative images are shown in figure 3.11)  
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Figure 3-11: Skin sections showing labelled neutrophils from neutrophil adoptive transfer protocol 
26/07/07 
Skin sections from 129/Bl6 D6KO mice that received TPA painting followed by tail vein injection of 
labelled WT and D6KO neutrophils (protocol 26/07/07, more details in tables 3.1 and 3.2). Skin sections 
were mounted with Vectashield plus DAPI and analysed using the LSM 510 Meta confocal microscope. A 
& B – skin sections from D6KO mouse that received TAMRA labelled D6KO neutrophils and CFSE labelled 
WT neutrophils, following induction of inflammation with TPA. C &  D – Skin sections from D6KO mice 
that received CFSE labelled D6KO neutrophils and TAMRA WT neutrophils following TPA painting. Images 
taken at 200x magnification, n = 2 per group.  
Analysis of labelled neutrophils could now be carried out, using the skin sections from the 
adoptive transfer performed on 26/07/07. Control skin sections, from mice that received 
inflammation but no fluorescent neutrophils consistently showed no fluorescent cells, 
suggesting that the cells we were seeing in the skin of these mice were labelled 
neutrophils. The lungs of treated mice were taken throughout these experiments, to 
check for the presence of labelled cells. This was carried out as the lungs are the first 
capillary bed that cells will encounter after being injected into the tail vein, so it is 
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possible they may become trapped here. No fluorescent cells could be detected in the 
lungs, see figure 3.12. 
 
Figure 3-12: Control skin and lung sections from neutrophil adoptive transfer experiments.  
Picture A: All neutrophil adoptive transfer experiments included control mice that received no 
fluorescent neutrophils, but underwent TPA treatment. These skin sections were analysed for the 
presence of fluorescent cells and were consistently negative. Picture B: Lung sections from treated mice 
were analysed for the presence of fluorescent neutrophils, as the cells may become trapped here after 
injection. Again, these sections were consistently negative. 200x magnification, LSM 510 Meta confocal 
microscope.  
The entire skin section for each mouse was analysed (see figure 3.13) and the total 
number of labelled neutrophils was counted using the Axiovision software. At 11 hours 
after TPA painting, an average of 24.75 (+/- 29.6) WT neutrophils could be found in skin 
sections, compared to 15.5 (+/- 9.94) D6KO neutrophils. At the 24 hour timepoint, 16 (+/-
16.43) WT neutrophils could be detected in skin sections, compared to 10.25 (+/-15.1) 
D6KO neutrophils. Figure 3.14 shows that, at both time-points after TPA treatment (11 
hours and 24 hours), more WT neutrophils can be detected in the skin than D6 KO 
neutrophils, but this difference was not significant. Both neutrophil genotypes showed a 
drop in number at the 24-hour time-point, but again this difference was not significant.  
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Figure 3-13: Entire skin section from a D6KO mouse showing labelled neutrophils 
Representative image of the skin from a 129/Bl6 D6KO mouse that was treated with neutrophil adoptive 
transfer protocol 26/07/07. Skin sections were mounted with Vectashield plus DAPI. Images taken at 
200x magnification using the LSM 510 Meta confocal could be ‘overlaid’ to create an image of the entire 
skin section. TAMRA labelled D6KO neutrophils and CFSE labelled WT neutrophils have been highlighted.  
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 In order to determine if D6KO neutrophils had any differences in migration into inflamed 
skin (suggested by results from TPA skin painting shown in figure 3.2), the distance from 
labelled neutrophils to the epidermis was measured using the Axiovision software for all 
mice. 11 hours after TPA treatment, WT neutrophils were significantly closer to the 
epidermis, with an average distance of 168.37μm (+/-58.6), than D6KO neutrophils that 
had an average distance of 191.81 μm (+/- 63.51) from the epidermis. This difference was 
statistically significant, p=0.0179 (Students unpaired t test). At 24 hours after TPA 
painting, there was no significant difference in the location of neutrophils, with respect to 
the distance from the epidermis. WT neutrophils had an average distance of 202.49μm 
(+/-21.8) from the epidermis, compared to 185.5μm (+/- 68.98) shown by D6KO 
neutrophils. At the 24 hour timepoint, WT neutrophils were significantly further away 
from the epidermis, compared to their location at 11 hours, (p<0.0001, Students unpaired 
t test) suggesting that these cells may be moving away from the site of inflammation, or 
simply dying off, as graph A shows reduced neutrophil numbers at the 24 hour timepoint.  
 
Figure 3-14: Analysis of labelled neutrophil number and location in inflamed D6KO skin.  
Skin sections from neutrophil adoptive transfer protocol 26/07/07, showed both WT and D6KO 
fluorescently labelled neutrophils could be detected in the inflamed skin of 129/Bl6 D6KO mice. A – the 
total number of labelled neutrophils was determined using the Axiovision software on full length skin 
sections from each treated mouse. These results are expressed as the total neutrophil number in a full 
skin section from an 8mm punch biopsy, n = 4, NS – Students unpaired t test. B – the distance between 
labelled neutrophils and the epidermis could be measured using Axiovision software and is expressed as 
the average distance of neutrophils from the epidermis, n = 4, WT vs D6KO at 11 hours p= 0.0179, 
Students unpaired t test, WT 11 hours vs 24 hours, p <0.0001, Students unpaired t test.  
These results show that fluorescently labelled neutrophils can be detected in TPA treated 
skin of D6KO 129/Bl6 mice. At 11 hours after TPA painting, WT neutrophils are 
significantly closer to the epidermis than D6KO neutrophils, suggesting that a lack of D6 
on neutrophils does affect their position in inflamed skin. A lack of D6 on neutrophils 
means that neutrophils are further from the epidermis, suggesting that in the results 
shown in figure 3.2, the differential positioning of neutrophils is not due to a lack of D6 on 
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these cells. These results suggest that it may be the location of chemokine production 
that affects the placement of neutrophils in TPA inflamed D6KO skin.  
3.3 Summary 
Initially this chapter set out to analyse the role that D6 may play in cell chemotaxis, this 
was going to be analysed using both in vitro and in vivo techniques. Unfortunately the in 
vitro experiments were unsuccessful. These experiments used two different types of 
chemotaxis assay, the Transwell assay and the Neuroprobe assay. The Transwell assay is a 
24 well disposable plate that has 12 wells for the analysis of chemotaxis. The Neuroprobe 
assay is a modified version of the chamber assay initially described by Boyden in 1962 
(344),  which contains 48 wells for the analysis of chemotaxis. In comparison to the 
Transwell assay, the Neuroprobe chamber would allow the use of smaller volumes of 
chemokines and reduced cell numbers. Attempts were made to create cell lines that 
would stably express D6, along with their own endogenous chemokine receptors – cells 
were chosen carefully to include those that had inflammatory CC chemokine receptors 
and homeostatic CC chemokine receptors. The plan was to use these cells in chemotaxis 
assays towards a range of inflammatory and homeostatic CC chemokines to determine 
the effect, if any, D6 would have on chemotaxis towards these ligands. These assays failed 
due to repeated technical problems.   
An alternative approach was taken, involving isolating various cell populations from WT 
and D6KO mice, and analysing their chemotactic responses in vitro. This approach had the 
benefit that no cell manipulation, other than the isolation protocol, would be required, 
and would allow examination of the influence of D6 on these responses. Unfortunately, 
the use of chemotaxis assays, both the Transwell assay and the modified Boyden chamber 
(Neuroprobe) gave extremely variable results. The inconsistencies in these results can be 
attributed to problems with the technical aspects of these assays, and as a result, these 
data have been omitted as they failed to meet the aims of this thesis. After abandoning 
this approach, subsequent data has emerged suggesting that D6 may influence neutrophil 
migration in the chemotaxis assay system. These results show that in a Boyden chamber 
system, the migration of D6KO and WT neutrophils remains the same towards CXCL8 and 
CCL4, but migration towards CCL3 is enhanced in D6KO neutrophils. These data suggest 
that on neutrophils, D6 may limit chemotactic responses towards CCL3, and is supported 
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by an in vivo model of intraperitoneal injection of CCL3, which shows increased 
neutrophil accumulation in D6KO mice, compared to WT (140).  
Rather than continue with the in vitro analysis of the affect of D6 on chemotaxis, an in 
vivo approach was taken. This used the well characterised model of TPA skin 
inflammation, and was based on observations that neutrophils in D6KO skin are 
aberrantly located at the dermal/epidermal junction, compared to the position of 
neutrophils in WT skin. Experiments were designed which aimed to determine if D6 on 
neutrophils affects their position in inflamed skin. Optimisation of these experiments took 
some time, but a successful neutrophil adoptive transfer protocol was designed, and 
allowed the detection of labelled neutrophils in the inflamed skin of D6KO mice. These 
results show that both WT and D6KO neutrophils can be detected in the skin, at both 11 
hours and 24 hours after TPA painting. At the 11 hour timepoint, there is a significant 
difference in the location of labelled neutrophils, with WT neutrophils being significantly 
closer to the epidermis than D6KO neutrophils. These results suggest that D6 on 
neutrophils does not affect their location in the skin, the differences in location exhibited 
in D6KO skin (shown here (137)) is likely to be due to altered chemokine localisation, 
affecting neutrophil positioning, which requires further investigation.  
In order to improve this experimental protocol, it would have been desirable to test the 
labelling of neutrophils prior to transfer, using a flow cytometer. Unfortunately due to the 
short time course, and lengthy neutrophil isolation procedure, there was not enough 
time, or enough cells to perform this control. Any spare labelled neutrophils were spun 
down onto a slide and labelling was checked using the confocal microscope (data not 
shown). Another control that would be desirable for these experiments would be to stain 
the skin sections with an antibody specific for neutrophils, to be entirely sure that the 
labelled cells are indeed neutrophils. Skin sections from mice that did not receive 
fluorescently labelled neutrophils showed no features that resemble those shown in 
figures 3.11 and 3.13, suggesting that the cells shown in these skin sections are indeed 
labelled neutrophils. 
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4 Tumour Development 
4.1 B16 Melanoma  
Tumour growth and development is a complex process, which involves interactions with 
stromal cells, angiogenesis, lymphangiogenesis and interactions with immune cells. 
Chemokines and inflammatory cells are known to play a role in melanoma development 
(220, 275), more details of which can be found in the introduction (section 1.12 and 1.13). 
Previous work in our group has shown that D6 can be protective in the inflammatory 
driven model of skin carcinoma (142). Since D6 is expressed in the skin, and has been 
shown to have an effect on squamous cell carcinoma, it seems feasible that D6 may play a 
role in other models of skin carcinogenesis, e.g. melanoma. In order to investigate the 
broader role of D6 in other models of skin cancer, it was necessary to find a model that 
was easy to manipulate and differed in action to the model of inflammatory driven skin 
cancer.   
The B16 model has been well characterised and can be used as a model of melanoma in 
the mouse. The murine B16 cell line was originally discovered in the 1950s from a 
spontaneously arising melanoma in a C57Bl/6 mouse (284). Cells from this tumour were 
cultured in vitro and in vivo to create variations on the original F0 cell line, with different 
organ colonising capabilities. B16 F0 cells retain the ability to form melanomas when 
injected subcutaneously into syngeneic mice (284, 311). It was decided to use this model 
of melanoma in WT and D6KO mice to determine if D6 has a role in regulating tumour 
growth. This model is easy to manipulate and will allow extensive analysis into the roles 
that D6 may play in tumour growth. 
4.1.1 Tumour Growth 
B16 F0 cells grow rapidly in culture and are easily maintained. The tumour model involves 
subcutaneously injecting cells into syngeneic mice and monitoring the growth of the 
resultant tumour. WT and D6KO C57Bl/6mice received a subcutaneous injection of 5 x 105 
B16 F0 cells (as described in materials and methods, section 2.3.1) and were monitored 
daily for tumour growth. Once the tumour became palpable, as shown in figure 4.1 the 
mean diameter was measured using callipers (two diameters measured each time). The 
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tumours were allowed to grow until they reached a mean diameter of 1.2cm, at which 
point the mice were sacrificed, in accordance with Home Office regulations.  
                                                          
Figure 4-1: WT C57Bl/6 mouse that received a subcutaneous injection of B16 F0 cells 12 days previously.  
WT and D6KO mice on a C57Bl/6 background received B16 F0 cells subcutaneously, in the dorsal skin. 
Mice were monitored daily for the development of tumours, the skin was shaved to aid identification. 
Once tumours began to appear, two diameters were measured using callipers, and the mean tumour 
growth was calculated. The dorsal skin has been shaved for ease of identifying and measuring the 
tumours.  
The average tumour growth rate was plotted for WT and D6KO mice against time, and the 
results are shown in figure 4.2. Graph A shows the average tumour growth plotted 
against time. Tumours began to appear in D6KO mice (day 8) before they appeared in WT 
mice (day 10). The tumours in D6KO mice grew at a faster rate, which resulted in a delay 
in tumour growth in WT mice, but this difference was not significant (two way ANOVA) At 
day 13, WT tumours had an average diameter of 0.63cm, compared to D6KO tumours 
which had an average diameter of 1.03cm. At day 16 the average diameter of tumours in 
WT mice reached their peak at 1.05 cm, compared to 1.32 cm in tumours that developed 
in D6KO mice. At day 17, WT tumours remained with an average diameter of 1.05cm 
whilst D6KO tumours had an average diameter of 1.33 cm.   
This increased growth rate meant that tumours developing in D6KO mice reached the 
point where mice had to be sacrificed before WT mice, resulting in a decreased survival 
rate, as shown in graph B (figure 4.2). Tumours reached the size that resulted in sacrifice 
at the same time in WT and D6KO mice at day 11, but the increased growth rate in D6KO 
mice resulted in all D6KO mice being sacrificed by day 19. The final mouse in the WT 
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group was sacrificed at day 28.  Although the survival curve data was not statistically 
significant (p=0.1786, Logrank test), the results were reproducible. In summary, B16 F0 
tumours developing in D6KO mice display a faster growth rate than tumours developing 
in WT mice, although this difference was not significant.   
 
Figure 4-2: B16 F0 tumour growth in WT and D6KO C57Bl/6 mice 
Following injection of B16 F0 tumour cells, mice were monitored daily for the development of tumours. 
Tumours appeared in D6KO mice before WT mice, which meant that D6KO mice had an increased tumour 
growth rate (graph A), although this is not significant (Two way ANOVA). When tumours reached 1.2cm 
mean diameter, mice were sacrificed. As tumours in D6KO mice grew faster than in WT, this resulted in a 
reduced survival rate (graph B) but again this is not significant (Logrank test). Results are pooled from 3 
separate experiments, n = 12 per group. Results shown are mean tumour diameter +/- SEM.  
4.1.2 B16 F0 Tumour Histology 
In order to try to determine what could be causing this difference in growth rate, tumours 
from both WT and D6KO mice were analysed by histology to determine if there were any 
differences in the tumour structure or histological characteristics. When tumours reached 
a mean diameter of 1.2cm, they were excised from WT and D6KO mice and placed in 10% 
NBF for at least 24 hours before processing as described in the materials and methods 
(section 2.3.5). Tumour sections were cut (4μm) and were stained with H&E to analyse 
the histological characteristics of the tumours. In both genotypes, tumours developed 
close to the site of injection at the dorsal skin. When the tumours were removed, the 
surrounding skin was also removed, which allowed orientation of tumour sections. Figure 
4.3 shows representative H&E stained tumour sections from WT and D6KO mice. 
Tumours were well defined, with obvious blood vessels and distinct areas of tumour cells 
and ‘necrotic looking’ areas.  
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Figure 4-3: H&E stained B16 F0 tumour sections.  
Tumours were excised from mice when they reached 1.2 cm mean diameter, and were processed for 
histology. Numerous features could be identified in H&E stained sections, including blood vessels, skin 
and melanin. The tumours could be divided into two distinct areas which appeared to contain ‘necrotic 
looking’ cells (1) and areas of densely packed tumour cells (2). A & B – tumours from WT and D6KO mice 
respectively, taken at 100x magnification. C – image from D6KO tumour taken at 400x magnification 
illustrating the presence of melanin. D – D6 KO tumour showing densely packed tumour cells, 400x 
magnification.  
Tumours from both WT and D6KO mice have areas that appeared necrotic, along with 
areas of densely packed tumour cells.  These areas are indicated in figure 4.3, pictures A 
and B, with 1 representing areas of cell death and 2 representing areas of densely packed 
tumour cells Picture D in figure 4.3, shows a higher magnification image of densely 
packed tumour cells. Melanin could be detected throughout the tumours, often 
concentrated in specific areas (see figure 4.3 C). Overall the histological features for both 
WT and D6KO tumours were similar. Although at first it appeared that D6KO tumours had 
increased areas of cell death, this was not consistently seen throughout tumour sections.   
Claire L. Burt, 2011   133 
 
Figure 4-4: TUNEL stained B16 F0 tumours 
B16 F0 tumours from WT and D6KO mice were stained using TUNEL to identify areas of dying cells within 
the tumour sections. A- D6KO tumour section, B- WT tumour section, images taken at 200x magnification 
In order to try and confirm that the areas that looked like areas of cell death did contain 
dead cells, TUNEL staining was performed (see materials and methods section 2.3.5.4). 
This staining technique identifies DNA strand breakages, which defines apoptotic cells. 
Figure 4.4 shows that the dark stained TUNEL positive areas correlated with the ‘necrotic 
looking’ areas in the H&E stained tumour sections. Although TUNEL staining is routinely 
used for identification of apoptotic cells, it may also stain necrotic cells, as they undergo 
DNA fragmentation (345). As a result, areas of positive TUNEL staining in these tumours 
are referred to as areas of cell death. When the areas of cell death were measured, using 
the Axiovision software, no differences were found comparing D6KO tumours to WT, and 
there were no differences in the location of dying cells (data not shown). 
4.1.3 B16 F0 Tumour Immunohistochemistry 
The tumour growth results showed that D6KO mice developed tumours faster than WT 
mice, although this difference is not significant. As mentioned previously, tumour 
development is a complex process. The tumour cells must interact with stromal cells in 
order to create an environment conducive to their growth. Inflammatory cell infiltration is 
known to play a role in tumour growth and tumour associated macrophages (TAMs) in 
particular can influence tumour growth (see section 1.10.2.1). Angiogenesis must occur, 
once the tumour reaches a certain size, to allow cells within the tumour to survive (more 
detail can be found in section 1.10.4). The complexity of tumour growth means that there 
could be a wide range of factors causing the difference in tumour growth exhibited in 
D6KO mice. To try to characterise the cell populations present in B16 F0 tumours that 
developed in WT and D6KO mice, immunohistochemical analysis was used.  
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4.1.3.1 Blood Vessel Staining 
Von Willebrand factor (vWF) is a glycoprotein that is produced by endothelial cells and 
megakaryocytes which is commonly used as a marker for blood vessels (346). An antibody 
against vWF was purchased from Dako and was used to stain blood vessels in tumours 
from WT and D6KO mice (as described in section 2.3.5.1 of materials and methods). The 
staining protocol required extensive optimisation. Various different steps were altered 
throughout optimisation; antigen retrieval methods, antibody incubation time, 
peroxidase blocking, and antibody concentration. Initially DAB was used as the peroxidase 
substrate, but even with the addition of nickel to make the DAB darker, melanin positive 
cells made identification of positively stained blood vessels difficult. An alternative HRP 
substrate, Novared, was purchased which gives a red product rather than brown. The 
Novared gave a lot of non-specific background on the tissue sections. The antibody was 
tested on human tonsil tissue (which should give positive staining with the vWF 
antibody). Positive staining was evident but the non-specific background was still high. 
Despite this, positive vessels can still readily be identified, in the tonsil section shown in 
figure 4.5.  
 
Figure 4-5: Optimisation of vWF staining 
Initial optimisation of the vWF antibody, which was used to identify blood vessels within tumour 
sections, was performed using human tonsil sections, as this antibody cross-reacts with human vWF. A – 
vWF stained blood vessels within human tonsil. B – isotype control for vWF antibody showing unstained 
blood vessels. Images taken at 200x magnification  
An optimised vWF protocol was therefore developed and used to stain all tumour 
sections from WT and D6KO mice. Novared was used as the HRP substrate to stain 
positive vessels red. Despite the high background, mentioned above, it was still possible 
to identify vWF positive vessels within tumour sections. Representative images from 
D6KO and WT tumours are shown in figure 4.6. Positive vessels can be easily recognised 
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in both D6KO and WT tumour sections. The morphology of the blood vessels varies, as 
can be seen in figure 4.6, depending on the plane at which the sections were cut. Blood 
vessels could also be confirmed by the presence of red blood cells within vWF stained 
vessels (not shown). The extent of blood vessel development in tumours was quantified 
by counting the number of positive vessels in eight random fields within the tumour at 
200x magnification. 
 
Figure 4-6: vWF stained B16 F0 tumour sections 
Blood vessels were identified in B16 F0 tumours from WT and D6KO mice using an antibody against vWF. 
A – D6KO tumour section, B – WT tumour section. Images were taken at 400x magnification and are 
representative of 3 separate experiments  
A quantitative analysis of vWF staining is shown in graph A, figure 4.7, and shows that B16 
F0 melanomas developing in WT or D6KO mice have the same number of blood vessels 
within the tumour, with a mean of 2.44 positive vessels per 200x field (+/- 1.80) for WT 
tumours, and a mean of 3.28 positive vessels (+/- 1.19) for D6KO tumours. These data are 
pooled from three separate experiments and the p value is 0.1951 (students unpaired t 
test). 
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Figure 4-7: Analysis of blood vessels in B16 F0 tumours 
A- B16 F0 tumour sections from both WT and D6KO C57Bl/6 mice were stained for vWF to identify blood 
vessels. The number of positive vessels were counted per random 200x magnification field and are 
expressed as the average number of vessels per field. B- optimisation of vWF staining was taking some 
time, so H&E stained tumour sections were used to analyse areas containing red blood cells, which could 
be used as a surrogate for vWF staining. Areas containing red blood cells were measured using Axiovision 
software, results are expressed as a percentage of the entire tumour section. Results are pooled from 3 
experiments, n = 12 per group. NS – Students unpaired t test 
As optimisation of vWF was ongoing for quite some time, an alternative method of 
measuring the extent of haemorrhage was also used in parallel. Areas within the tumours 
that contained red blood cells (as identified with H&E staining) were measured using 
Axiovision software. The total area of each tumour was measured and the percentage of 
‘red areas’ (i.e. areas which contained blood) was calculated. Although this was not a 
specific measurement of blood vessels, it gave an indication of the distribution of blood 
throughout the tumours. This technique had the advantage that it would pick up areas of 
haemorrhage within the tumour, which may not be identified by vWF staining. These can 
also be called ‘blood lakes’, and can be found within tumours (347). The results from this 
analysis are shown in graph B, figure 4.7 and these show no significant difference in the 
percentage red areas in WT and D6KO tumours, which correlates well with the vWF data. 
In WT tumours the mean percentage red areas was 2.46% (+/- 3.71) and in D6KO tumours 
the mean percentage was 3.5% (+/- 3.17).  The results from blood vessel analysis of WT 
and D6KO tumour have shown that the difference in tumour growth in D6KO mice is not 
due to, or associated with, a difference in blood vessel number, or areas of blood within 
the tumours. 
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4.1.3.2 Macrophage Staining 
Macrophages are known to play a crucial role in tumour development, especially in the 
B16 model (269, 281, 289). The balance of macrophages is essential; too few 
macrophages can help promote tumour growth, but too many may promote tumour 
killing (289). The level of macrophage infiltration was analysed to determine if a 
difference in macrophage number could account for the altered tumour growth seen in 
D6KO mice. Tumour sections were stained with a Mac-2 antibody, which recognises a 
galactose specific lectin, expressed on mature macrophages (348). The staining protocol is 
described in materials and methods (section 2.3.5.3). DAB could be used as the HRP 
substrate for this protocol as it was easy to tell the difference between melanin and DAB 
staining, as their distribution was different. Mac-2 positive cells appeared rounded, whilst 
melanin, distributed throughout the tumour, appeared thread-like.  
 
Figure 4-8: Identification of macrophages in B16 F0 tumours 
B16 F0 tumour sections from WT and D6KO mice were stained for the presence of macrophages using an 
antibody against Mac-2. Macrophages are shown in brown (DAB) and counterstained with haematoxylin. 
Images are representative of 3 separate experiments, taken at 200x magnification. A – D6KO tumour 
section, B – WT tumour section.  
Representative sections from D6KO and WT mice are shown in figure 4.8, showing Mac-2 
positive cells within D6KO (picture A) and WT tumours (picture B). Similar to vWF staining 
analysis, the extent of Mac-2 staining was quantified by counting the number of positive 
cells in at least eight random fields throughout the entire tumour section at 200x 
magnification.  
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Figure 4-9: Analysis of macrophage staining of B16 F0 tumours.  
WT and D6KO B16 F0 tumours were stained for macrophages using an antibody against Mac-2. Positive 
cells were counted in at least 8 random 200x magnification fields, results are expressed as the average 
cell number per field. Results are pooled from 3 separate experiments, n= 12 per group. NS – students 
unpaired t test.  
The results from Mac-2 analysis of tumour sections are shown in figure 4.9. WT tumour 
sections had on average 47 macrophages per 200x field (+/- 28.16) and D6KO tumour 
sections had on average 46 macrophages per 200x field (+/- 20.13). Statistical analysis 
(students unpaired t test) shows that there is no difference between the number of 
macrophages in tumours developing in D6KO mice, compared to tumours in WT mice (p = 
0.9441). These results show that the level of macrophage infiltration is not altered in 
D6KO tumours, compared to WT tumours. 
4.1.3.3 T Cell Staining 
Another cell type known to play a role in tumour development are T cells, more details of 
this can be found in section 1.10. It was decided to stain for all T cell populations to 
determine if there were any differences in T cell numbers in WT and D6KO tumours. T 
cells were stained using an anti-CD3 antibody, which identified both CD4+ and CD8+ T 
cells which may have been infiltrating the tumour. The staining was carried out as 
described in materials and methods (section 2.3.5.5). Figure 4.10 shows an example of 
CD3 staining in WT (picture A) and D6KO (picture B) tumours. Positive cells were stained 
with Novared. Analysis of T cell numbers within the main tumour mass was performed by 
counting positive cells in at least eight random fields, at 400x magnification using the 
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Axiovision software. In separate sections it appeared as if there were T cells infiltrating at 
the very edge of the tumours, so positive cells around the edge of the tumours were 
counted separately, and were expressed as the number of positive cells per μm of tumour 
edge.  
 
Figure 4-10: CD3 stained B16 F0 tumour sections 
CD3 staining was used to identify T cells in WT and D6KO B16 F0 tumours. A – WT tumour section, B – 
D6KO tumour section. Images taken at 400x magnification  
Figure 4.11 shows the results from the quantitation of the CD3 staining analysis. The 
numbers of CD3+ cells within the tumour (graph A) are similar in WT (mean 17.63 +/- 
8.04) and D6KO mice (mean 14.72 +/- 6.06), but the numbers of CD3 cells at the edge of 
the tumours (graph B) were slightly reduced in D6KO tumours. The mean number of CD3 
+ cells per μm tumour was 0.01536 (+/- 0.009026) in WT tumours and 0.010906 (+/-
0.006758) in D6KO tumours, however this difference is not significant (p= 0.1850 students 
unpaired t test).  
Claire L. Burt, 2011   140 
 
Figure 4-11: Analysis of T cells within B16 F0 tumours 
A – CD3 positive cells were counted in at least 8 random 400x magnification field per section and are 
expressed as the average positive cells per 400x field.  NS – Students unpaired t test. B – the distance 
around the tumours edge was measured using Axiovision software, then the number of CD3+ cells along 
the tumours edge were counted. Results are expressed as the average number of cells per μm. NS – 
Students unpaired t test. Results are pooled from 3 experiments, n = 12 per group.  
 
4.1.3.4 Other Staining 
Numerous attempts were made to stain tumour sections for the presence of neutrophils, 
using an antibody to myeloperoxidase and using Naphthol AS-D Chloroacetate (which 
turns a pink colour when neutrophils are present in tissue sections). Unfortunately both 
methods were repeatedly unsuccessful. LYVE-1 staining for lymphatic vessels was also 
performed (using both protocols described in materials and methods, section 2.3.5.2) but 
again this consistently failed to work on tumour sections, despite extensive optimisation.  
It is possible that the tumours do not express any lymphatic vessels, but each tumour was 
removed with the overlying skin still attached, this skin sample would contain lymphatics 
which would act as a positive control for lymphatic vessel staining. This staining protocol 
was later optimised for lung sections as shown in figure 5.15.  
4.1.4 Summary 
To summarise these results, B16 F0 tumours that develop in D6KO mice grow at a faster 
rate than in WT mice, although this difference is not significant. Immunohistochemical 
analysis of B16 F0 tumours from WT and D6KO mice, show that there are no differences 
in the number of blood vessels, the level of macrophage or CD3+ T cell infiltration. 
Analysis of the contribution of lymphatic vessels to the development of these tumours 
could not be performed, so this could not be ruled out. 
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4.2 D6 Expressing Tumours 
4.2.1 B16 F0 Chemokine Receptor Expression 
The results shown above, demonstrate that B16 F0 tumours appear to grow slightly faster 
in D6KO compared to WT mice, which suggests that D6 may play a role in tumour 
development. As a lack of D6 displayed a mild effect on delaying tumour development, it 
seemed plausible that D6 over-expression may have the reverse effect on tumour growth. 
In order to examine this, B16 F0 cells were stably transfected with D6. Prior to 
transfection, the chemokine receptor profile of B16 F0 cells was analysed by RT-PCR. This 
was performed to try and identify chemokine receptors that may be influenced by over-
expression of D6, for example inflammatory CC chemokine receptors, as previous 
evidence has suggested that D6 over-expression may affect chemotactic responses to 
CCL4 (141).  This was carried out as described in materials and methods, section 2.4. 
Briefly, RNA was extracted from B16 F0 cells, cDNA was generated and the expression of 
chemokine receptors was analysed by routine PCR.  
 
Figure 4-12: Chemokine receptor expression by B16 F0 cells.  
The chemokine receptor profile of B16 F0 cells, was analysed by extracting RNA and performing RT-PCR.  
Primer sequences are detailed in table 2.6. RT-PCR reactions for CCR1, 2, 3, 4, CXCR4 and D6 were all 
negative (not shown).  
RT-PCR results showed that B16 F0 cells did not express CCR1, 2, 3 and 4 (data not 
shown). They were also negative for D6. The only two chemokine receptors that were 
found to be expressed by B16 F0 cells were CCR5 and CCR7 as shown in figure 4.12, which 
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were present at the expected size (189bp for CCR5 and 154bp for CCR7).  β-actin was 
used as a control to confirm the presence of cDNA. At the same time the chemokine 
receptor profile of the metastatic B16 F10 cells was analysed by PCR and these results are 
shown in section 5.1.7.1. These results, taken together with evidence from the literature 
(141), suggest that there is no potential for D6 to interact with any chemokine receptors 
expressed by B16 F0 cells.  
B16 F0 cells were transfected with a plasmid containing murine D6, under the control of 
the CMV promoter (with a G418 resistance gene), using Fugene HD reagent, as described 
in materials and methods (section 2.1.3.1). The concentration of G418 used for selection 
of stable transfectants was determined by performing a ‘kill curve’, as described in 
materials and methods. Figure 4.13 shows the percentage of live B16 F0 cells remaining 
after culture with increasing G418 concentrations, for up to 2 weeks. 2mg/ml G418 was 
decided upon, as some cells were still alive after culture with 1.5 mg/ml G418.  
 
Figure 4-13: G418 kill curve for B16 F0 cells. 
B16 F0 cells were cultured in increasing concentrations of G418 for up to 2 weeks. The number of live 
cells were counted using Trypan blue staining. Results are expressed as the number of live cells remaining 
in culture +/- SEM.  
After selecting for stable transfectants (for at least 2 weeks) using 2mg/ml G418, pools of 
stable transfectants were tested for their ability to express D6. Analysis of D6 expression 
showed that un-transfected B16 F0 cells did not express D6. B16 F0 cells stably 
transfected with D6, were shown to be positive for D6 as shown by RT-PCR, see figure 
4.14. 
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Figure 4-14: B16 F0 transfectant expression of D6 
B16 F0 cells were transfected with a murine D6 plasmid and stable transfectants were selected by 
culturing in G418 containing media. RNA was extracted and D6 expression was confirmed by RT-PCR (un-
transfected B16 F0 cells were D6 negative)  
RT-PCR analysis shows that B16 F0 D6 cells express the mRNA for D6 (band size 98bp, 
figure 4.14), but expression at the mRNA level may not correspond to expression at the 
protein level. In order to be confident that D6 expressed in B16 F0 cells may have an 
effect on tumour growth, the D6 expressed by B16 F0 cells had to be functional. As there 
is no antibody available against murine D6, other methods had to be developed in order 
to assess D6 protein expression. A flow cytometry based assay was developed in our lab,  
which could be used to assess D6 function. This assay uses the principle that D6 is the 
only known chemokine receptor that can uptake both CCL2 and CCL3. CCL2 can bind CCR2 
and D6; CCL3 can bind CCR1, CCR5 and D6.  If the uptake of fluorescently labelled CCL2 
could be out-competed by adding an excess of CCL3 (in this case PM2, a non-aggregating 
mutant of CCL3 was used (12)), then this suggested that the CCL2 was being uptaken by 
D6 meaning that it was functional. B16 F0 cells and B16 F0D6 cells were tested for D6 
specific uptake, as described in materials and methods, section 2.1.5.1, the results are 
shown in figure 4.15. 
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Figure 4-15: D6 expressed by B16 F0 transfectants is functional  
B16 F0 D6 transfectants were tested for D6 functionality using a flow cytometry based chemokine binding 
assay. Cells were incubated in the presence of fluorescently labelled CCL2 with or without the presence of 
excess PM2 (CCL3). As D6 is the only chemokine receptor which can bind both CCL2 and CCL3, if CCL3 
blocks CCL2 uptake then this indicates D6 is functional at binding chemokines. Untransfected cells are 
shown in the top two plots, showing no uptake of Alexa-647-CCL2. In contrast, D6 expressing B16 F0 cells 
shown uptake of Alexa-647-CCL2, which can be competed out with excess PM2, suggesting D6 expressed 
by these cells is able to bind chemokines.  
The results shown in figure 4.15 (top graphs) show that un-transfected B16F0 cells did not 
bind CCL2, which correlates with the RT-PCR data showing these cells were CCR2 and D6 
negative. When fluorescent-labelled CCL2 was added to B16 F0D6 cells, an increase in 
fluorescence intensity was evident (bottom graphs figure 4.15), showing that these cells 
were binding CCL2. There appears to be two populations of B16 F0D6 cells, one with a 
mean fluorescence intensity of 4.74 and the other population, which is binding 
fluorescent CCL2, has a mean fluorescence intensity of 35.14. When an excess of PM2 
was added to the cells along with CCL2, the fluorescence intensity decreased which 
meant that PM2 was blocking the binding of fluorescent CCL2. Since D6 is the only 
chemokine receptor that can bind to both of these chemokines, this shows that B16 F0D6 
cells were expressing functional D6. These results correlated with the RT-PCR results 
shown in figure 4.14, and confirmed the usefulness of these transfectants.  
4.2.2 B16 F0D6 Tumour Growth 
The results above show that the transfection of B16 F0 cells with D6 was successful and 
the D6 expressed by these cells is functional. B16 F0D6 cells were used to induce 
subcutaneous tumours, as described in materials and methods (section 2.3.1). Initially 
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B16 F0 and B16 F0D6 cells were injected subcutaneously into WT mice. The growth rate 
of the tumours were plotted against time and the data are shown in figure 4.16, graph A. 
Tumours in both groups appeared at day 9 after subcutaneous injection and by day 22, 
the majority of mice in both groups were sacrificed. One mouse that received B16 F0 cells 
had a slow growing tumour, which meant it survived until day 27. These data show that 
over-expression of D6 did not alter the growth rate of B16 F0 cells in WT mice – they grew 
at the same rate as B16 F0 cells, which resulted in similar survival in both groups as shown 
in graph B figure 4.16. In both groups, tumours reached the point of sacrifice at day 12 for 
B16 F0 cells, and day 14 for B16 F0D6 cells. The final mouse in the B16 F0D6 group was 
sacrificed at day 23, whilst the mouse with the slow growing B16 F0 tumour was 
sacrificed at day 27. The results from this experiment show that over-expression of D6 
has no significant effect on B16 F0 tumour growth in WT mice. 
 
Figure 4-16: Growth and survival of B16 F0 tumours compared to B16 F0 D6 tumours in WT C57Bl/6 mice.  
A – in WT C57Bl/6 mice the growth of tumours developing from B16 F0 cells was compared to B16 F0 D6 
cells.  The mean tumour diameter was measured after appearance of tumours and plotted against time. 
Results are expressed as mean tumour growth +/- SEM. NS – Two way ANOVA. B – mice were sacrificed 
when tumours reached 1.2cm mean diameter. Tumour growth was calculated by measuring the mean 
tumour diameter in cm each day from the first appearance of the tumours.  NS – Logrank test. N = 5 per 
group  
The above results show that there was no significant difference in growth rate when B16 
F0 tumour cells over-express D6 in WT mice. B16 F0 D6 cells showed no difference in 
tumour growth rate in WT mice, compared to B16 F0 tumours in a WT background. These 
results suggest that D6 does not affect the growth of B16 F0 tumours. B16 F0 D6 tumour 
cells were injected into WT and D6KO mice, and the resultant tumour growth was 
compared. The growth rate of B16 F0D6 cells in WT and D6KO mice is shown in graph A of 
figure 4.17, and the relevant survival curve is shown in graph B of figure 4.17. These 
results show that in a D6KO background, tumours that developed from B16 F0D6 cells 
grow at a slower rate. This meant that tumours in D6KO mice were significantly smaller 
than D6 expressing tumours in a WT background. Tumours began to appear in D6KO mice 
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at day 6, and in WT mice at day 7. At day 7, B16 F0D6 tumours in WT mice had a mean 
diameter of 0.475cm (+/- 0.06455) whilst tumours in D6KO mice, which had a mean 
diameter of 0.4875 cm (+/- 0.326). By day 14, D6 expressing tumours in WT mice had a 
mean diameter of 1.056 cm (+/- 0.101), D6KO tumours had a mean diameter of 0.815 cm 
(+/- 0.114673). B16 F0D6 tumours developed at a significantly faster rate in WT mice, 
compared to B16 F0D6 tumours developing in D6KO mice (p<0.0001, Two way ANOVA 
test, with Bonferroni’s correction) 
 
Figure 4-17:  Growth and survival of B16 F0 D6 tumours in WT and D6KO mice.  
A – tumour growth is shown as the mean tumour diameter +/- SEM. D6 expressing tumours appeared in 
WT mice before D6KO mice, resulting in a reduced tumour growth rate. P <0.0001 2 way ANOVA. B – 
survival of mice that received D6 expressing B16 F0 cells. Mice were sacrificed when tumours reached 
1.2cm mean diameter. The delay in tumour growth shown in D6KO mice resulted in a significant 
difference in the survival of WT and D6KO mice that received D6 expressing tumour cells. p = 0.034, 
Logrank test. n= 5 per group.  
This delay in tumour growth meant that D6KO mice survived for longer, as it took longer 
for their tumours to reach 1.2cm mean diameter, as shown in graph B (figure 4.17). The 
last WT mouse was sacrificed at day 17, whilst the last D6KO mouse to be sacrificed was 
at day 21, which resulted in a significant difference in survival (p=0.034, Logrank test).   
The growth rate of B16 F0D6 tumours has been shown to be unchanged in WT mice, 
compared to B16 F0 tumours. In D6KO mice, B16 F0D6 tumours grow at a significantly 
slower rate compared to B16 F0D6 tumours in WT mice. B16 F0 and B16 F0D6 cells were 
injected subcutaneously into D6KO mice, to determine if B16 F0D6 cells grew at a slower 
rate in D6KO mice, compared to B16 F0 cells. The results from this experiment are shown 
in graph A, figure 4.18. These data show that in a D6KO background, D6 expressing 
tumours grow at a slower rate than un-transfected tumour cells. B16 F0 tumours began 
to appear in D6KO mice at day 8, whilst B16 F0D6 tumours did not appear in D6KO mice 
until day 11. The sample size in this experiment was small (3 mice for each cell group), so 
these results are not significant. One of the mice in the D6 transfected tumour group did 
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not develop a tumour until day 20, the inclusion of these results explains the large error 
bars in graph A. This was probably due to problems with the subcutaneous injections; this 
mouse may have received fewer cells than the others.  
 
Figure 4-18: Tumour growth and survival of B16 F0 and B16 F0 D6 tumours in D6KO mice 
A – Tumour growth is expressed as the mean tumour diameter +/- SEM. Each group had only 3 mice, one 
mouse in the B16 F0 D6 group did not develop a tumour until day 20, which accounts for the large error 
bars. NS – two way ANOVA. B – Survival of D6KO mice that developed B16 F0 and B16 F0D6 tumours. NS 
– Logrank test. n = 3 per group. 
The survival curve comparing B16 F0 cells to B16 F0D6 cells in D6KO mice is shown in 
graph B of figure 4.18. Mice in the B16 F0 cell group were sacrificed between 12 and 14 
days, whilst mice in the B16 F0D6 cell group were sacrificed between 13 and 23 days. The 
mouse that did not develop a tumour until day 20 has been included in the survival curve 
graph. It appears from these data that in D6KO mice, B16 F0D6 tumours develop later 
than B16 F0 tumours, and may grow at a faster rate, but the sample size is too small here 
for this difference to be significant.   
To summarise these results; D6 expression on B16 F0 cells has no effect on the tumour 
growth in WT mice. However, in D6KO mice, D6 over-expression causes a reduction in 
tumour growth, when compared to B16 F0 tumour growth. B16 F0D6 tumours develop at 
a significantly slower rate in D6KO mice compared to D6 expressing B16 F0 cells in WT 
mice. These results suggest that in a D6KO background, D6 expressing cells are causing 
changes to the tumour microenvironment or cells within the tumour, to alter tumour 
growth. This experiment would need to be repeated to confirm the reproducibility of 
these results.  
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4.2.3 B16 F0D6 Tumour Histology 
The histology of tumours which developed from B16 F0D6 cells were analysed to 
determine if there were any differences in tumours which over-expressed D6 compared 
to un-transfected tumours, which could be contributing to the differential growth rate, 
seen in D6KO mice. As with previous tumour experiments, tumours were excised, 
processed for histology and stained with H&E. Representative tumour sections are shown 
in figure 4.19. There appeared to be no obvious differences in the histology of D6 
expressing tumours compared to un-transfected tumours. D6 expressing tumours had the 
same features as B16 F0 tumours; densely packed tumour cells, necrotic areas, blood 
vessels and melanin.  
 
Figure 4-19: Histological analysis of B16 F0 D6 tumours in WT and D6KO mice  
B16 F0 and B16 F0 D6 tumours were processed for histological analysis following sacrifice. D6 expressing 
tumours showed similar features to B16 F0 tumours, namely blood vessels, densely packed tumour cells 
and areas of necrosis. A – B16 F0 D6 tumour from WT mouse, B – B16 F0 D6 tumour from D6KO mouse. 
Images are taken at 50x magnification and ‘overlaid’ to show the entire tumour section  
4.2.4 B16 F0D6 Tumour Immunohistochemistry 
As mentioned above, tumour development is a complex process that involves growth of 
new blood vessels, macrophage and T cell infiltration (see section 1.10). Staining for vWF, 
Mac-2 and CD3 was performed on tumour sections from B16 F0D6 tumours, as described 
previously (materials and methods, section 2.3.5). vWF expression was quantified by 
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counting the number of positive vessels in at least eight random 200x fields throughout 
the tumour sections. Mac-2 analysis was carried out by counting the number of positive 
cells in at least eight random 200x fields. CD3 staining analysis was performed by counting 
the number of positive cells in at least eight random 400x fields within the tumour, as 
well as counting the total numbers of CD3+ cells at the edge of the tumour, which was 
expressed as the average cell number per μm. Representative staining is shown in figure 
4.20. Picture A shows a vWF stained D6 positive tumour section; a positive vessel is 
shown in red. Picture B shows a CD3 stained D6 positive tumour section, with red stained 
CD3+ cells throughout. Picture C shows Mac-2+ cells within a D6 positive tumour.  
 
Figure 4-20: Immunohistochemical staining of B16 F0 D6 tumours  
B16 F0D6 tumours from WT and D6KO mice were stained for A - blood vessels (vWF), B - T cells (CD3) and 
C - macrophages (Mac-2). Pictures shown are representative of three separate experiments. Taken at 
200x magnification (A) and 400x magnification (B and C).  
Analysis of vWF staining (graph A figure 4.21) suggested that there may be a trend 
towards a decrease in blood vessel number in D6 expressing tumours, in both WT and 
D6KO mice, but these differences were not significant. B16 F0 tumours in WT mice had an 
average number of 2.2 (+/- 1.59) vWF positive vessels per 200x field, in D6KO mice B16 F0 
tumours had an average of 4 (+/- 0.353) vWF positive vessels. Comparing B16 F0D6 
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tumours, in WT mice these tumours had on average 1.69 (+/- 1.08) positive vessels 
compared to 2.38 (+/- 1.96) positive vessels in D6 expressing tumours in D6KO mice.  
Results for Mac-2 staining, shown in graph B in figure 4.21, showed a significant 
difference in the number of macrophages in B16 F0 tumours. D6KO mice had a 
significantly higher number of macrophages than WT mice, with D6KO tumours having on 
average 40.33 (+/-10.01) positive cells per field, and WT tumours having 25.4 (+/- 5.23) 
positive cells per field. This difference was significant, p = 0.0158 (students unpaired t 
test). Looking at B16 F0D6 tumours in D6KO mice, they appear to have a slight increase in 
Mac-2 positive cells (43.19 cells +/- 11.47), compared to B16 F0D6 tumours in WT mice 
(31.63 cells +/- 10.28), but this difference is not significant (p = 0.0797 students unpaired t 
test). These data did not correlate with the previous results for Mac-2 staining in B16 F0 
tumours (see figure 4.9), where there was no difference in the number of macrophages in 
WT and D6KO mice. The difference may be significant here due to the small sample size 
(3-5 mice per group).   
Figure 4-21: Immunohistochemical analysis of B16 F0 D6 tumours  
B16 F0 D6 tumours that developed in WT and D6KO C57Bl/6 mice were stained with antibodies against 
vWF and Mac-2. Positive vessels and cells were counted in 8 random fields at 200x magnification, results 
are expressed as the average positive vessels (graph A) and average positive cells (graph B) per random 
field. Results are from 3 separate experiments , n  = 5 (B16 F0 tumours in WT mice); n = 9 (F0D6 in WT 
mice); n = 3 (B16 F0 in D6KO mice); n = 7 (B16F0D6 tumours in D6KO mice). A – NS, students unpaired t 
test. B – p = 0.0291, students unpaired t test 
The results from CD3 staining analysis are shown in figure 4.22. Graph A shows the results 
from quantifying the number of CD3+ cells within the tumour, and graph B shows the 
number of CD3+ cells present at the edge of the tumours, expressed as the average 
number of cells per μm of tumour edge. Graph A shows that there are no differences in 
the number of CD3 + cells within the tumours, irrespective of the expression of D6 by B16 
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F0 cells. B16 F0 tumours in WT mice had an average number of 17.25 (+/- 14.99) CD3 
positive cells, whilst B16 F0 tumours in D6KO mice had on average 19.25 (+/- 13.099) CD3 
positive cells. In B16 F0D6 tumours, those that developed in WT mice had on average 
18.33 (+/- 10.97) CD3 positive cells, whilst those that developed in D6KO mice had on 
average 18.85 (+/-13.12) CD3 positive cells within the tumour.  
 
Figure 4-22: Immunohistochemical analysis of T cell infiltration of B16 F0 tumours 
B16 F0 and B16 F0 D6 tumours, in WT and D6KO C57Bl/6 mice were stained for T cells using an antibody 
against CD3. A – positive cells were counted in at least 8 random 400x fields, and are expressed as the 
average cell number per 400x field. B- Positive cells were counted at the edge of the tumour and are 
expressed as the average cell number per μm of tumours edge. Results are pooled from 3 experiments, 
n= 4 (F0 in WT), 9 (F0D6 in WT), 4 (F0 in D6KO), 7 (F0D6 in D6KO). NS – Students unpaired t test  
Graph B shows the average number of CD3+ cells per μm of the tumours edge. B16 F0 
tumours developing in WT mice had on average 0.00649 (+/- 0.00263) cells per μm, 
compared to 0.00471 (+/-0.003711) cells per μm in D6KO mice. B16 F0D6 tumours had on 
average 0.008087 (+/- 0.003802) cells per μm in WT mice, and 0.007745 (+/- 0.00313) 
cells per μm in D6KO mice. These data show that there are no significant differences in 
the number of CD3+ cells infiltrating the tumour, or at the tumours edge, in D6 expressing 
tumours compared to un-transfected tumours. 
As with previous tumour experiments, staining for neutrophils and lymphatic vessels was 
carried out, but this was unsuccessful.  
In conclusion, these results show that D6 expressing tumours develop at a significantly 
slower rate in D6KO mice, compared to D6 expressing tumours in a WT background. In a 
D6KO background, D6 expressing tumours develop at a slower rate than B16 F0 tumours, 
but this difference was not significant. The results from immunohistochemistry show that 
there are no differences in the number of blood vessels within the tumour. The number 
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of macrophages and CD3+ T cells infiltrating the tumour showed no significant differences 
comparing B16 F0 tumours to B16 F0D6 tumours in WT or D6KO mice. This suggests that 
some other mechanism is likely to be responsible for the reduced growth rate.  
4.3 Summary 
The results presented in this chapter show that B16 F0 tumours developing in D6KO mice 
grow at a faster rate, although not significant, than B16 F0 tumours developing in WT 
mice. No differences could be found with respect to blood vessels, CD3+ T cell infiltration 
or macrophage number of location, when comparing tumours in WT and D6KO mice.  
The data presented here show that B16 F0 cells that have been transfected with D6 
express it in a stable and functional manner. B16 F0D6 tumours have no obvious 
differences in growth compared to their un-transfected counterparts, when injected in to 
WT or D6KO mice. When comparing B16 F0D6 growth in WT and D6KO mice, these 
tumours develop at a significantly slower rate in D6KO mice, compared to WT. Analysis of 
the tumours by histology shows that this difference in growth is not due to any gross 
morphological differences in D6 expressing tumours, nor any differences in T cell or 
macrophage infiltration. Initially it was hypothesised that D6KO mice were mounting an 
immune response against previously unseen D6, but this is unlikely to be the case, as 
tumour sizes are largely similar and no increase in T cell or macrophage infiltration has 
been shown. Ideally these experiments would be repeated with a more comprehensive 
study of the leukocyte populations infiltrating the tumours, by flow cytometry, to study 
the relative populations of B cells, T cells, NK cells and macrophages in more detail.  
The only other chemokine receptors that are expressed by B16 F0 cells are CCR5 and 
CCR7. D6 expression on B16 F0 cells is unlikely to affect CCR7 function, as CCR7 binds 
CCL19 and CCL21, which D6 cannot bind to. It is more likely that D6 may have an effect on 
CCR5, as the CCR5 ligands CCL3, CCL4 and CCL5 can also bind to D6. In B16 F0 tumours, 
which lack D6 expression, CCR5 may be influencing tumour cell survival, as CCR5 has been 
shown to be anti-apoptotic in macrophages and has been shown to promote the survival 
of lymphoma cells (349, 350). In D6KO mice, there may be a general increase in 
inflammatory chemokine levels, including the CCR5 ligands, CCL3-5. It is possible that in 
D6KO mice this increased level of inflammatory chemokines induces signalling via CCR5, 
which enhances survival and proliferation of B16 F0 cells, resulting in increased tumour 
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growth. In B16 F0D6 cells, the presence of D6 may reduce the levels of inflammatory 
chemokines in the local tumour environment of D6KO mice, which would result in 
reduced CCR5 signalling, as its ligands are being degraded by D6. This would cause a 
reduction in tumour cell proliferation, resulting in a reduced growth rate. Another 
possibility is that degradation of inflammatory chemokines by D6 causes some 
interference in CCR5 induced signalling, which results in reduced tumour cell growth. The 
importance of CCR5 expression could be tested by performing knock-down of CCR5 
expression in B16 F0 cells with siRNA, this would allow analysis of cell survival in vitro and 
these cells could be tested for their ability to induce tumour growth.  
The role of D6 has been investigated in the DMBA/TPA model of skin tumourigenesis, 
which acts by inducing mutations in the skin, followed by repeated rounds of 
inflammation, to drive tumourigenesis. In this model, tumour development is dependent 
on TNFα and T cells. A lack of D6 expression renders B6/129 mice (that are normally 
resistant to tumours in this model) susceptible, and in FvB/N mice (which are already 
susceptible) D6KO mice develop a higher tumour burden compared to WT. Tumours that 
develop in D6KO mice contain more mast cells and T cells (142). The data presented here 
shows that B16 F0 (whether D6 positive or negative) tumours developing in D6KO mice 
have no increase in CD3+ T cells. Mast cell populations were not examined in this model. 
The role of mast cells in tumourigenesis has conflicting reports, evidence exists to support 
both a pro-tumourigenic role, and evidence also suggests that mast cells may have anti-
tumour effects. In related B16 tumour models, mast cells have been shown to have anti-
tumour effects after activation via TLR2 (351), and mast cell deficient mice have been 
shown to have delayed tumour growth in the B16 BL6 model of tumour growth, 
suggesting they may be pro-tumourigenic (352). As mast cells are increased in D6KO mice, 
in both the model of skin tumourigenesis and the TPA skin inflammation model (142, 
152), in the B16 F0 model, mast cells may be increased in the skin of D6 KO mice, which 
may negatively influencing tumour growth when these cells express D6. This could be 
tested by looking at mast cell infiltration and localisation in B16 F0 tumours, by 
immunohistochemistry and flow cytometry.  
The results with over-expression of D6 in B16 F0 cells show similarities to the work with 
the DMBA/TPA skin tumour model. In the DMBA/TPA model of tumourigenesis, over-
expression of D6 in the epidermis was able to suppress tumour formation, in comparison, 
in the B16 F0 model, it appears that D6 expression on the melanoma cells is able to 
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suppress tumour growth, although not completely. If the K14 transgenic D6 mice used in 
this model were on a C57Bl/6 background then the contribution of epidermal expressed 
D6 to tumour growth could be compared to B16 F0 D6 expressing cells (142). In the 
DMBA/TPA model of skin tumourigenesis, the ability of D6 to suppress tumours was 
dependent on chemokine burden, D6 could be overwhelmed and tumours could still 
develop (142). No data exists as to the relative contribution of chemokines to the growth 
of “wild type” B16 F0 tumours; most of the data relating to chemokines and B16 F0 cells 
uses transfected cells that have been modified to express chemokines or receptors.  
The B16 F0 model of tumourigenesis relies on injection of cells into syngeneic mice. The 
number of cells injected has been shown to influence the amount of time from injection 
to first appearance, fewer cells results in a longer lag period, but once tumours appear, 
they grow at the same rate. In these experiment, all tumours grew uncontrollably until 
they killed the mouse, with no evidence of gross metastases (284). It would be interesting 
to see if reducing or increasing the dose of B16 F0D6 cells is able to alter tumour growth. 
The results presented here suggest that D6 is able to limit the development of tumours in 
D6KO mice, but this inhibition of tumour growth appears to be incomplete as tumours are 
still able to grow.  
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5 Metastasis 
5.1 B16 F10 Experimental Metastasis 
5.1.1 Metastasis 
The results presented above, together with evidence from the literature (142), suggest 
that D6 is involved in tumour growth. As mentioned in the introduction (section 1.11), 
when a tumour develops a vasculature and lymphatic supply, the tumour can become 
metastatic and tumour cells can spread throughout the body. The role of chemokines and 
their receptors in metastasis has been well described, for example expression of CCR9 by 
human melanoma is associated with metastasis to the small intestine, and CCR10 
expression by melanoma cells is associated with metastasis to the skin (274, 282). Since 
D6 is expressed on lymphatic endothelial cells, which line afferent lymphatics (143), and 
lymphatics can play a role in metastasis, it was decided to investigate the role of D6 in 
metastasis 
A model of metastasis was chosen which was directly related to the B16 F0 model of 
tumour growth. As mentioned above (section 1.13.2), B16 F10 cells have been selectively 
cultured in vitro and in vivo to generate variants on the original parental cell line. This 
process of selective culture has created a cell line which is able to colonise the lungs after 
intravenous injection (286, 311) an ability that is retained after repeated passages in vitro 
(303). This makes B16 F10 cells ideal to be used in a model of experimental metastasis. 
Experimental metastasis models differ from models of spontaneous metastasis in that the 
metastatic colonies do not come from a primary tumour within the mouse (283). As B16 
F10 cells were easy to culture in vitro, and are similar to the B16 F0 cells used in the 
tumour model, it was decided use these cells to investigate the role of D6 in melanoma 
metastasis.  
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5.1.2 B16 F10 Metastasis Model 
In the model of melanoma growth described in chapter 4, D6KO mice have an increased 
rate of tumour growth (although this is not significant), compared to WT mice, which is 
not caused by differences in cell populations (T cells and macrophages) or the 
development of blood vessels in the tumours. As D6 seems to play a role in tumour 
growth, it is possible that D6 may affect metastasis. In order to determine if D6KO mice 
have any differences in melanoma metastasis, the B16 F10 experimental metastasis 
model was performed on WT and D6KO mice. The model involved injecting B16 F10 cells 
into the tail vein of WT and D6KO C57Bl/6 mice, as described in materials and methods 
(section 2.3.2). Fourteen days after injection, mice were sacrificed and the lungs perfused 
with formalin before removal, followed by further fixation in formalin.  
 
Figure 5-1: Metastatic colonies on lungs from B16 F10 treated C57Bl/6 mice.  
14 days following B16 F10 cell intravenous injection, WT and D6KO C57Bl6 mice were sacrificed and their 
lungs were perfused with formalin to facilitate removal for histological analysis. Colonies were identified 
by the presence of melanin. A – WT mouse lungs, B – D6KO mouse lungs. String was tied around the 
trachea following formalin perfusion to prevent formalin from leaking out.  
Figure 5.1 shows lungs taken from WT and D6KO mice following intravenous injection of 
B16 F10 cells. Metastatic colonies are visible on the external surface of the lungs, as they 
produce melanin. When the lungs are perfused with formalin, the trachea is ligated with 
string, to prevent the formalin from leaving the lungs, which is shown in figure 5.1. 
Picture A shows lungs from a WT mouse, with visible metastatic colonies covering the 
entire surface of the lungs. Picture B shows lungs taken from a D6KO mouse, which shows 
very few surface metastatic colonies, compared to the WT lungs. The metastatic colonies 
Claire L. Burt, 2011   157 
were only present on the lung surface, not on the trachea. Lungs from WT mice had 
metastatic colonies all over the lungs surface, on all lobes of both the right and left lung. 
In D6KO mice, external colonies could be found on all surfaces of the lungs, but at a much 
lower number, with some mice having no evidence of metastatic colonies on the lungs 
surface.  
There was an obvious visual difference in the number of external metastatic colonies, 
comparing WT to D6KO mice, so the external colonies were counted per lung and the 
results are shown in figure 5.2. Metastatic colonies were counted using a dissecting 
microscope, which allowed the entire surface of the lungs to be viewed. The sizes of 
colonies was not measured, a colony was defined as an area of melanin containing cells, 
which could be easily identified on the dissecting microscope. The colony sizes appeared 
similar in D6KO and WT lungs, the only observable difference being the number of 
colonies. These data show that D6KO mice have a significant reduction in the number of 
metastatic colonies developing on the surface of their lungs, compared to WT mice. WT 
mice had an average of 35.9 (+/- 28.46) metastatic colonies on the surface of the lungs, 
whilst D6KO mice had an average of 5.7 (+/- 8.5) colonies on the lungs surface. This 
difference was statistically significant (p < 0.0001 Students unpaired t test).  
 
Figure 5-2: B16 F10 external lung colony counts 
Colonies that could be identified on the external surface of B16 F10 treated WT and D6KO C57Bl/6 mice 
were counted using a dissecting microscope. Metastatic colonies could be identified by the presence of 
melanin. Results are expressed as the number of colonies per lung. Results are from 3 separate 
experiments, n = 9 per group. P <0.0001, Students unpaired t test.  
Once the external colonies had been counted, the lungs from both D6KO and WT mice 
were processed for histological analysis in order to evaluate the internal structures of the 
lungs, and to identify any internal metastatic colonies. Lung sections were cut and stained 
Claire L. Burt, 2011   158 
with H&E, as described in section 2.3.7. Figure 5.3 shows representative lung sections 
from D6KO and WT mice. Picture A shows a section from a D6KO mouse lung with blood 
vessels, bronchioles and alveoli identified. These features could easily be identified in 
sections from both WT and D6KO lungs. Metastatic colonies within the lung tissue were 
also easy to identify, as they appeared more densely packed than the surrounding lung 
tissue. Identification was aided by the presence of melanin, which was often detected 
within these colonies. Internal metastatic colonies could be identified in both WT and 
D6KO lung sections. The location of these colonies was throughout the lung tissue, with 
some next to blood vessels and bronchioles, whilst some colonies were distant from 
these features. Picture B in figure 5.3, shows a section from a WT mouse lung, and shows 
a section through a metastatic colony that is present at the lungs surface. This would have 
been one of the external metastatic colonies that would have been counted using the 
dissecting microscope.  
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Figure 5-3: H&E stained lung sections from B16 F10 treated mice 
WT and D6KO C57Bl/6 mice that received B16 F10 cells were sacrificed 2 weeks after injection and lungs 
were processed for histological analysis. Serial lung sections were taken from processed lungs and 
stained for H&E. Metastatic colonies could be identified by the presence of melanin and the different 
morphology from the surrounding lung tissue, as shown above. Images shown were taken at 50x 
magnification, to create the ‘overlay pictures’, close up images taken at 400x magnification. A – D6KO 
lung section, B- WT lung section. 
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The numbers of internal colonies were counted per tissue section and an average number 
of colonies per lung section were calculated. WT mice had, on average, 2.08 (+/- 2.03) 
internal metastatic colonies, whilst D6KO mice had, on average, 0.6 (+/-0.633) internal 
metastatic colonies. These data are presented in figure 5.4 and show that D6KO mice 
have a trend towards a reduced number of internal colonies, although this difference is 
not quite statistically significant (p=0.0759 Students unpaired t test). Examination of the 
sizes of the metastatic colonies, revealed no apparent differences in the size of internal 
metastatic colonies, in WT or D6KO mice.  
 
Figure 5-4: Internal metastatic colony counts from B16 F10 treated mice 
Metastatic colonies inside the lungs were analysed by counting the number of colonies in serial sections 
from WT and D6KO C57Bl/6 mice that received B16 F10 cells. The number of internal colonies were 
counted on H&E stained sections and are expressed as the number of metastatic colonies per section. N = 
9, from 3 separate experiments. NS, Students unpaired t test.  
To summarise these results, using a model of experimental metastasis, D6KO mice 
develop significantly fewer metastatic colonies on the surface of the lungs than WT mice. 
As well as having a significant reduction in external metastatic colonies, D6KO mice also 
have a reduction in the number of internal metastatic colonies within the lungs, 
compared to WT mice, although this difference is not significant. 
5.1.3 Lung Cell Analysis 
The data above show that there is a significant reduction in the number of external 
metastatic colonies developing in D6KO mice, as well as a potential reduction in the 
number of internal colonies. D6 expression has been shown on various different 
leukocyte populations (143, 144). Analysis of the populations of leukocytes within the 
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lungs of D6KO mice has never been performed, so it was decided to look at the leukocyte 
populations within the lungs, to try to identify if a lack of D6 has altered cell populations, 
which might have relevance for the development of metastatic colonies. In order to do 
this, lungs from resting WT and D6KO mice, as well as WT and D6KO mice which had 
received B16 F10 cells, were digested (as described in materials and methods section 
2.3.6) and stained with a panel of lineage markers, to identify different leukocyte 
populations by flow cytometry. Cells were analysed using the MACSQuant, selecting for 
live cells based on their FSC and SSC, these results are shown in figure 5.5.  
 
Figure 5-5: FACS analysis of cell populations in the lung from WT and D6KO mice.  
Lungs from untreated mice (A) and B16 F10 treated mice (B) were digested with collagenase and a single 
cell suspension was stained with a panel of lineage markers to define the cell populations within the 
lungs by flow cytometry. A – Lungs from WT and untreated mice were stained with the markers described 
above, results are expressed as the number of live cells, which were gated on using FSC and SSC. N = 2 per 
group, NS, students unpaired t test. B- Lungs from WT and D6KO mice that received B16 F10 cells. Cell 
numbers are a proportion of the total cells, which were gated to exclude dead cells using FSC and SSC. N = 
3 per group, NS, Students unpaired t test.   
The results above show the number of cells identified for each population. The markers 
used were CD45 to identify leukocytes, CD3 to identify T cells, CD19 to identify B cells, 
CD11b and CD11c were used together to identify dendritic cells. Only CD45+ cells were 
analysed for their expression of the relevant lineage markers. Graph A shows the 
comparison between lung populations from resting lungs from WT and D6KO mice. There 
were no significant differences comparing the number of gated live cells in resting WT 
and D6KO lungs, untreated WT lungs had 86250 gated live cells (+/- 6554) gated live cells, 
compared to 67696 (+/- 3337) gated live cells in D6KO lungs. In the resting lungs, there 
were no significant differences in any cell population in D6KO mice compared to WT.  
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In B16 F10 treated lungs, again there was no difference in the average number of gated 
live cells, with WT B16 F10 treated mice having an average of 67429 (+/-9193) gated live 
cells, and D6KO B16 F10 treated mice had an average of 67251 (+/- 7378) gated live cells. 
Looking at the other leukocyte populations, there were no significant differences 
comparing any of the cell populations, between WT and D6KO lungs. Results shown in 
graph B, suggests that in D6KO mice there is an increase in CD45+ CD11b-CD11c+ cells, 
but this difference is not significant. This cell population could be a population of antigen 
presenting cells resident in the lungs (353), but this experiment would have to be 
repeated to confirm this difference and to fully characterise these cells. As these results 
showed no significant differences in the leukocyte populations in the lungs of D6KO mice, 
it is not possible to account for the differences seen in metastatic colony numbers. The 
results from resting lungs were from two mice per group, so it is possible that there may 
be an increase in certain populations of CD45+ leukocytes in the lungs of D6KO mice, but 
more mice would be required to detect this difference. Three mice were used for both 
genotypes in the B16 F10 treated graph, and these results suggest that there are no 
significant differences in the number of total leukocytes, or specific populations, in the 
lungs of D6KO mice compared to WT. Although they do suggest that there may be 
differences in a CD45+ CD11b+CD11c- cells, but this difference is not significant. 
5.1.4 Pleura 
The data above show a striking difference in the number of colonies developing in D6KO 
mice, which is more pronounced in the development of external colonies. This difference 
appears not to be caused by a difference in leukocyte populations within the lung. The 
major difference in colony development is seen at the surface of the lungs, so it seems 
there could be two options as to the fate of B16 F10 cells. The cells may enter the lungs 
and move out to the lung surface, where they can develop into colonies. On the other 
hand B16 F10 cells could be entering the lungs via the alternative vasculature of the 
pleura, and forming colonies at the lung surface. This led to the theory that the anatomy 
of the lungs may be somehow altered in D6KO mice, which causes the difference in 
colony formation.  
The external surface of the lung is covered by a thin serous membrane known as the 
pleura (see figure 5.6), which is present to help provide lubrication as the lungs expand 
and contract during inhalation and exhalation (354, 355). There is evidence to suggest 
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that the pleura may play a role in cancer. In human melanoma, metastasis can occur to 
the pleura, as well as to the lungs but the two do not always go hand in hand (356). 
Mesothelioma is a cancer of the pleura, which is often fatal (357). The pleura also has a 
different blood vasculature and lymphatic supply from the lungs (354). This evidence led 
to the decision to look at the pleura in WT and D6KO mice, since it is in contact with the 
external surface of the lungs, which is where the major differences in colony formation 
are evident. As D6 is known to play a role in the clearance of inflammatory chemokines 
(see section 1.8.1) it was thought to be possible that the levels of chemokines in the 
pleura may be altered in D6KO mice, which may be affecting the development of 
metastatic colonies.  
Therefore what could be happening in the lungs is that in WT mice B16 F10 cells enter the 
lungs via the blood stream, where they can form colonies inside the lungs. Some of these 
tumour cells can then migrate to the external surface of the lungs, possibly in response to 
chemokines produced by the pleura, and here they form metastatic colonies. 
Alternatively, the cells may be entering the lungs via the pleural vasculature, as the 
vasculature of the pleura is reported to be different to that of the lungs (354), and 
forming colonies at their point of entry, at the pleural surface. In D6KO mice, the 
chemokine microenvironment at the pleural surface may be altered, due to the lack of D6 
in the lungs. This altered environment may either be undesirable for the growth of B16 
F10 cells, and cause cell death, or the B16 F10 cells may migrate out of the lungs via the 
lymphatic or vasculature drainage of the pleura.  
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Figure 5-6: The thoracic cavity 
The lungs and the heart are surrounded by the pleura, a thin serous membrane which provides 
lubrication for the lungs during respiration. The pleura is one continuous membrane, but it is referred to 
as the parietal pleura when covering the ribcage, and the visceral pleura when covering the lungs. The 
pleural cavity forms between the visceral and the parietal pleura, and contains a small amount of fluid. 
(Diagram adapted from (354)) 
When the lungs were removed from mice that had received B16 F10 cells intravenously, 
the pleura was easy to identify within the thoracic cavity. Unfortunately it tended to 
shrivel up when the ribcage was opened, which made it very difficult to remove. 
Numerous attempts were made to isolate the pleura from WT and D6KO mice – both 
untreated mice and those that received B16 F10 cells - but these repeatedly failed. 
Metastatic colonies had been noted on the pleura in both WT and D6KO mice, but their 
number could not be analysed properly, due to problems with trying to remove the 
pleura, which was very fragile and easily torn. 
It was therefore assumed that when the lungs were removed, the visceral pleura (see 
figure 5.6 and 5.7) remained on the surface of the lungs. Lungs from WT and D6KO mice 
were removed as before, and snap frozen in liquid nitrogen. The surface of the lungs, 
where it was assumed the visceral pleura remained, was then scraped off, in the hope 
that enough tissue could be collected to analyse the expression of chemokines, by RT-
PCR. This approach failed due to the small amount of tissue isolated.  
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Figure 5-7: H&E stained lung sections showing the location of the pleura 
Lung sections from B16 F10 treated mice stained with H&E. The pleura is a thin serous membrane which 
covers the lungs, which is indicated in these sections. A metastatic colony has developed at the pleural 
edge of the lungs (B). Pictures were taken at 200x magnification. 
As mentioned above, the pleura could be causing differences in the lung 
microenvironment due to the production of chemokines, which may account for the 
differences in colony numbers at the external surface of the lungs. As the isolation of the 
pleura was repeatedly unsuccessful, an alternative approach was taken, to try to analyse 
the chemokine levels in the space between the lungs and the pleura. This technique 
involved injecting ~5mls sterile PBS into the pleural cavity (between the ribs, without 
piercing the lungs) and removing the fluid, which could be analysed for the presence of 
chemokines and other proteins. Pleural washes were collected successfully and protein 
concentrations were analysed. These ranged from 0.01mg/ml – 0.36 mg/ml. Since the 
protein concentrations were low, pleural washes were concentrated (as described in 
materials and methods, section 2.3.2.1) and the final concentrations ranged from 
0.06mg/ml – 1.57 mg/ml. Analysis of chemokine levels was performed using a custom 
made Luminex kit (11-plex) from Millipore, as described in materials and methods 
(section 2.3.2.2). Table 5.1 describes the chemokines and cytokines that were analysed 
using this kit.  
Claire L. Burt, 2011   166 
Chemokine/Cytokine Systematic Name Luminex results
Eotaxin CCL11 See figure 5.9
TNF-α See figure 5.9
MCP-1 CCL2 WT F10 sample alone
RANTES CCL5 WT F10 sample alone
MIG CXCL9 WT F10 sample alone
MIP-1α CCL3 Out of range (too low)
MIP-1β CCL4 Out of range (too low)
KC CXCL1 Out of range (too low)
MIP-2 CXCL2 Out of range (too low)
IP-10 CXCL10 Out of range (too low)
IL-17 Out of range (too low)                          
Table 5-1: Chemokines and cytokines analysed in pleural washes.  
A summary of the chemokines and cytokines which were analysed by Luminex, in pleural washes from 
untreated and B16 F10 treated WT and D6KO mice. Chemokines and cytokines could not be analysed in 
all samples, those that could be detected are indicated.  
For the majority of chemokines tested, the levels in pleural wash samples were too low to 
be detected. The only analytes that were detectable in all samples were CCL11 and TNF-α. 
The results for these two analytes are shown in figure 5.9. The results for CCL11 (graph A) 
show that there appears to be a trend towards a reduction in CCL11 in D6KO mice – 
untreated WT had a mean CCL11 concentration of 9.9 (+/- 17.15) pg/ml compared to 
untreated D6KO which had a mean CCL11 concentration of 21.67 pg/ml (+/- 5.5). This 
difference is not significant, p = 0.04358, Students unpaired t test. Examination of mice 
that received B16 F10 cells showed WT mice to have a mean CCL11 concentration of 
33.46 pg/ml (+/-23.4) compared to 17.8 pg/ml (+/- 16.1) in D6KO mice that received B16 
F10 cells. Again, these values were not statistically significant (p = 0.3939 students 
unpaired t test).  
Untreated WT mice had a mean TNFα concentration of 0.633 pg/ml (+/- 0.756) compared 
to D6KO mice, which had a mean TNFα concentration of 0.58 pg/ml (+/-0.39). The results 
(shown in graph B of figure 5.8) from mice that received B16 F10 cells are again at the low 
end of detection – WT plus B16 F10 cells had a mean TNFα concentration of 0.44 pg/ml 
(+/-0.43), whilst D6KO mice that received B16 F10 cells had a mean TNFα concentration 
of 0.07 pg/ml (+/- 0.075). These results for TNFα suggest that D6KO mice that received 
B16 F10 melanoma cells have a reduction in TNFα in the pleural cavity, however these 
values are not statistically significant (p=0.2102 students unpaired t test). As so few 
samples gave a positive result, a difference in pleural chemokine levels in D6KO mice, and 
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their effects on metastatic colony formation, is difficult to rule out. Increased sample 
numbers are required to provide statistical significance.  
 
Figure 5-8: Chemokines and cytokines detected in pleural washes from untreated and B16 F10 treated 
D6KO and WT mice 
The only two analytes which could be detected in pleural wash samples were CCL11 and TNFα, but not in 
all pleural wash samples. A – CCL11 levels detected in pleural washes from untreated WT and D6KO mice, 
and B16 F10 treated WT and D6KO mice. n = 3 per group, 2 per group in D6KO untreated. NS – Students 
unpaired t test. B – TNFα levels detected in pleural wash samples. NS Students unpaired t test. Both 
CCL11 and TNFα levels were at the lower limits of the detection system.  
Looking at other chemokines analysed by Luminex, the only samples that gave a positive 
result for the majority of analytes were from two WT mice that had received B16 F10 
cells. These samples were positive for CCL2, CCL5, CXCL9 (data not shown), CCL11 and 
TNFα. These results suggest that in WT mice that receive B16 F10 cells there may be an 
increased inflammatory microenvironment in the pleural cavity, which is missing in D6KO 
mice. This increased inflammatory microenvironment may be beneficial for B16 F10 cell 
growth, and may account for the increased colony number on the surface of the lungs. 
This result is unexpected, as a lack of D6 has been shown to increase the inflammatory 
microenvironment in a variety of in vivo models (152, 157). These results are from two 
separate mice, and may suggest that after injection of B16 F10 cells, WT mice have 
increased levels of inflammatory chemokines in the pleural cavity, which may contribute 
to the differences seen in metastatic colony numbers.   
To summarise, the role of the pleura in the development of metastatic colonies cannot be 
ruled out. Isolation of the pleura proved difficult for both WT and D6KO mice. Analysis of 
the chemokine levels in the pleural cavity could not be performed fully, as the levels of 
majority of chemokines were too low to detect. The only analytes that could be detected 
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were TNFα and CCL11, with no significant differences between genotypes and no 
differences with the addition of B16 F10 cells. Samples from WT mice that received B16 
F10 cells were found to have CCL2, CCL5, CXCL9, CCL11 and TNFα, which may suggest that 
WT mice receiving B16 F10 cells have higher levels of inflammatory chemokines than 
D6KO mice, but this was only on two samples. The experiment would need to be 
repeated in order to confirm this hypothesis. 
5.1.5 Immunohistochemistry 
The data shown previously demonstrated that D6KO mice have a significant reduction in 
external metastatic colony number on the lungs compared to WT mice. This difference is 
not caused by any alterations in leukocyte abundance, and the evidence shown in section 
5.1.4 suggests that differences in pleural chemokine concentration may not be 
responsible for this difference. When B16 F10 cells are administered, they are injected 
into the tail vein, and so they must use the vasculature to get to the lungs. Once in the 
lungs, what could be happening is B16 F10 cells move to the external surface of the lungs, 
where the majority of colonies form. Alternatively B16 F10 cells may be using the 
vasculature of the pleura to reach the lungs surface where they can form colonies. Within 
the lungs, B16 F10 cells may be interacting with leukocytes in the lung tissue, which may 
alter the lung microenvironment to encourage or discourage colony growth, or even 
promote B16 F10 cell survival or death. 
Analysis of the leukocyte populations of the lungs showed that there were no significant 
differences in total leukocyte populations within the lungs. As the metastatic colonies 
differ in their location within the lungs, the location of leukocyte populations within the 
lungs was analysed using immunohistochemistry. T cells and macrophages were analysed, 
as both cell populations are known to play roles in tumour development and metastasis 
(see section 1.10 and 1.11). To determine if differences in the vasculature or lymphatic 
vessels of the lungs may be responsible for the differences seen in colony number, 
immunohistochemistry and immunofluorescence was performed to stain blood vessels 
and lymphatic vessels. These results are presented below.  
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5.1.5.1 Macrophage Staining 
Macrophages can have a role in metastasis by secreting growth factors that can help to 
create the pre-metastatic niche, as described in section 1.11.1.3. It was decided to stain 
lung sections for macrophages to determine if a difference in macrophage number or 
location could be responsible for the differences in metastatic colony numbers. Mac-2 
immunohistochemistry was carried out as described in materials and methods (section 
2.4.5.3), on lung sections from WT and D6KO mice that had received B16 F10 melanoma 
cells.   
 
Figure 5-9: Identification of macrophages in lungs of B16 F10 treated mice  
Lung sections from B16 F10 treated WT and D6KO C57Bl/6 mice were processed for histological analysis 
and stained with an antibody against Mac-2 to identify macrophages. A – positive cells in a lung section 
from a WT mouse. B – Positive cells highlighted in a lung section from a D6KO mouse. Images are taken at 
400x magnification  
Figure 5.9 shows representative staining from both WT and D6KO mice. These sections 
show red stained macrophages present within the lung tissue in WT and D6KO mice and 
this positive staining was distributed throughout the lungs in both genotypes. Mac-2 
positive cells could be found surrounding and within metastatic colonies, as well as being 
present along the pleural edge of the lungs. Quantitative analysis of staining was 
performed by counting the total number of macrophages within the lung tissue, in a 
minimum of eight random fields, at 200x magnification. Counting the number of positive 
cells at the pleural edge, and measuring the distance around the lungs was separately 
carried out to measure the number of macrophages present at the pleura. Macrophages 
were counted at the pleural edge in order to try and determine if any differences in cell 
populations at the pleural surface could be accounting for the differences in metastatic 
colony development. These results were expressed as the average cell number per μm. 
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Figure 5-10: Analysis of macrophage staining of B16 F10 treated lungs 
A- Mac-2 positive cells were counted in lung sections from B16 F10 treated mice, in at least 8 random 
fields at 200x magnification. Results are expressed as the average number of cells per 200x field, n = 9 per 
group, p = 0.0190, students unpaired t test. B – Positive cells were counted at the pleural edge, and are 
expressed as the number of positive cells per μm of pleura (measured using Axiovision software). NS, 
Students unpaired t test, n = 9 per group. Results are from 3 separate experiments.  
The results in graph A of figure 5.10 show that there was an increase in macrophage 
numbers in the lungs of D6KO mice, that received B16 F10 cells, compared to WT mice. 
WT mice had an average of 12.9 (+/- 10.005) Mac-2 positive cells within the lungs, 
compared to 28.81 (+/- 15.31) Mac-2 positive cells in D6KO lungs. This difference is 
statistically significant (p=0190, Students unpaired t test). The number of macrophages at 
the pleural edge (shown in graph B of figure 5.10) in B16 F10 treated mice remained at 
similar numbers in WT and D6KO mice (WT mice had an average of 0.0039 (+/-0.0016) 
positive cells compared to 0.0044 (+/-0.0016) positive cells in D6KO lungs, p = 0.5070 
Students unpaired t test). From these results, it can be concluded that the difference in 
the number of metastatic colonies in WT and D6KO mice may be due to an increased 
number of macrophages in D6KO lungs.  
5.1.5.2 T cell Staining 
Many leukocyte populations are known to play a role in metastasis (see section 1.11). 
With respect to the B16 F10 metastasis model, T cells have been shown to influence the 
development of metastatic colonies. They may do this by interacting with B16 F10 cells in 
the blood or within the lungs during colonisation (286, 315). Lung sections from both WT 
and D6KO mice were stained for CD3 to identify T cells. This was carried out to determine 
if alterations in the numbers of T cells, or their location may correlate with the 
development of metastatic colonies. The staining was performed as described in 
materials and methods (section 2.4.5.5). Representative images are shown in figure 5.11, 
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picture A and B from WT lungs, picture C and D from D6KO lungs. CD3+ cells were 
distributed throughout the lung tissue, and at the pleural edge of the lungs. When 
metastatic colonies were visualised, CD3+ cells could be found bordering the edges of the 
colonies as well as being inside the metastatic colonies. Quantitative analysis of this 
staining was performed by counting the number of T cells within metastatic colonies, 
counting positive cells bordering metastatic colonies as well as positive cells per μm of 
pleura.  
 
Figure 5-11: Identification of T cells in the lungs from B16 F10 treated mice  
T cells were identified in lung sections from B16 F10 treated WT and D6KO mice using an antibody 
specific for CD3. Positive cells could be identified throughout the lungs, at the pleural edge (picture A – 
WT mouse, picture C – D6KO mouse) and within metastatic colonies (picture B – WT mouse, picture D – 
D6KO mouse). Images are representative of 3 experiments, taken at 400x magnification. 
 
The results of CD3+ cell analysis are shown in figure 5.12. The number of CD3+ cells 
bordering metastatic colonies was similar in WT and D6KO mice, this data is shown in 
graph A (mean CD3+ cell number – WT  = 8.6 (+/-3.57), D6KO = 7 (+/- 7)). Graph B in 
figure 5.12 shows the average number of CD3+ cells per μm of pleura, which was 0.006 
cells (+/- 0.0026) for WT mice, and 0.0056 cells (+/- 0.0033) for D6KO mice. This 
difference was not significant (p = 0.7444 Students unpaired t test). The number of CD3+ 
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cells within metastatic colonies was quantified; WT mice had an average of 10.89 (+/- 
10.11) positive cells, whilst D6KO mice had on average 7.17 (+/- 9.57) positive cells. These 
data are shown in graph C and show that there is no significant difference between the 
numbers of CD3+ cells within metastatic colonies when comparing WT to D6KO mice (p = 
0.4343 Students unpaired t test). These results show that the distribution and number of 
T cells is unlikely to be responsible for the difference seen in the number of metastatic 
colonies, comparing D6KO mice to WT mice.  
 
Figure 5-12: Analysis of T cell staining of B16 F10 lung sections 
T cells were identified using an antibody against CD3; these were present at the edges of metastatic 
colonies, at the pleural edge and bordering metastatic colonies. A – CD3+ cells were identified at the edge 
of metastatic colonies, in both WT and D6KO B16 F10 treated mice. These cells were counted at 400x 
magnification and are expressed as the number of positive cells per metastatic colony. B –CD3+ cells were 
counted at the pleural edge of lung sections and are expressed as the number of positive cells per μm 
pleura, 400x magnification. C – CD3+ cells were counted within metastatic colonies, in at least 8 random 
400x fields. These results are expressed as the average number of cells per 400x field.  Results are pooled 
from 3 separate experiments, n = 9 per genotype, NS – Students unpaired t test.   
To summarise, analysis of macrophage and T cell staining in the lungs of WT and D6KO 
mice that received B16 F10 cells shows that there are no significant differences in either 
absolute cell numbers or in their location with respect to metastatic colonies. These data 
suggest that it is unlikely that T cells are contributing to the differences seen in metastatic 
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colony number, but it is possible that the increased macrophage number within the lungs 
of D6KO mice may be responsible for the reduction in metastatic colonies.  
5.1.5.3 Blood Vessel Staining 
B16 F10 cells are injected intravenously, so the circulation plays a vital role in allowing 
these cells to reach the lungs. Since the blood vessel supply to the lungs is required in 
order for metastatic colonies to develop in the lungs, it may be possible that differences 
in blood vessel number and/or location may differ comparing WT to D6KO lungs, and 
these differences may account for the differences in metastatic colony formation. In 
order to try to examine this, vWF staining, which identifies blood vessels, was performed 
on lung sections (materials and methods section 2.4.5.1). Figure 5.13 shows 
representative vWF stained lung sections. Blood vessels were present throughout lung 
sections, as shown by vWF positive staining, as well as the presence of red blood cells and 
leukocytes within the vessels. Blood vessels could be found close to metastatic colonies 
and within metastatic colonies, in both WT and D6KO lungs. The size of blood vessels 
within the lungs did not appear to differ between WT and D6KO lungs (data not shown).  
 
Figure 5-13: Identification of blood vessels in lungs from WT and D6KO B16 F10 treated mice 
Blood vessels were stained using an antibody against vWF in lung sections from B16 F10 treated mice. 
Images shown are at 200x magnification and are representative of both WT (picture A) and D6KO (picture 
B) lungs. 
This staining was analysed by counting the total number of positive vessels per lung 
section for each experiment, these results are shown in graph A of figure 5.14. WT mice 
that had received B16 F10 cells had an average of 59.28 (+/-22.89) vWF positive vessels 
throughout lung sections, compared to 58 (+/- 28.06) vWF positive vessels present in 
D6KO lungs that had received B16 F10 cells. These data show that there is no significant 
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difference between the numbers of vWF positive vessels in B16 F10 treated WT and D6KO 
lungs (p = 0.9170 Students unpaired t test). 
The distance between positive vessels and metastatic colonies was measured, to 
determine if there was a correlation between blood vessel proximity and number of 
metastatic colonies. These results are shown in graph B, figure 5.14. WT mice had an 
average distance of 146.13 μm (+/-72.44) between vWF positive blood vessels and 
metastatic colonies. D6KO mice had an average distance of 94.78 μm (+/- 111.99) 
between vWF positive vessels and metastatic colonies. This difference is not statistically 
significant (p = 0.2651 Students unpaired t test). The proximity of blood vessels to the 
pleura was also analysed to determine if blood vessels were closer to the pleura in WT 
mice, which may contribute to the increased colony numbers on the surface of the lungs. 
These results are shown in graph C, figure 5.14. The average distance between vWF 
vessels and the pleura was 209.27 μm (+/-56.3) in WT lungs and 211.39 μm (+/-26.84) in 
D6KO lungs. These data show that there is no significant difference in the distance 
between blood vessels and the pleura in D6KO lungs, compared to WT (p = 0.92 Students 
unpaired t test).  
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Figure 5-14: Analysis of vWF staining of B16 F10 treated lungs 
Blood vessels were identified using an antibody against vWF. A – the total number of positive vessels 
were counted throughout lung sections from WT and D6KO B16 F10 treated mice, at 200x magnification, 
and are expressed as the total number of positive vessels per section. B – the distance between vWF 
positive vessels and metastatic colonies was measured at 200x magnification using Axiovision software, 
results are expressed in μm. C- the distance between positive vessels and the pleura was measured using 
Axiovision software. Results are pooled from 3 experiments, n = 9 per group, NS – Students unpaired t 
test.  
Taken together, these results show that in WT and D6KO mice, there is no difference in 
the location of blood vessels with respect to metastatic colonies or the pleura. Although it 
appears that in D6KO mice there is a slight reduction in the number of vWF vessels, this 
difference is not significant. These data suggest that differences in blood vessel number 
or location are unlikely to be responsible for the differences seen in colony numbers. 
5.1.5.4 Lymphatic Vessel Staining 
Lymphatics are also known to play a role in metastasis. D6 expression has been 
demonstrated in the lung in mice, and shown to be expressed by lymphatic endothelial 
cells in humans (143). Whilst D6 expression has not been demonstrated on murine cells, 
two recent studies looking at D6 in models of colitis, have attributed differences in colitis 
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susceptibility to non-haematopoeitic cells in the gut, and suggested these may be 
lymphatic cells (158, 159).   Whilst B16 F10 cells use blood vessels to get into the lungs, 
lymphatics may be responsible for the clearance of these cells. Once B16 F10 cells enter 
the lungs, they may migrate through the lung tissue and leave via lymphatic drainage of 
either the lungs or the pleura. It is at this point that differences between WT and D6KO 
mice may account for the differences in metastatic colony number.  In order to try and 
address this theory, lung sections from WT and D6KO mice that received B16 F10 cells 
were stained for LYVE-1 to identify lymphatic vessels.  
Lymphatic vessels within the lungs were stained using an antibody against LYVE-1, as 
described previously (materials and methods section 2.4.5.2). Staining was initially 
performed using streptavidin coupled HRP, followed by DAB as the HRP substrate on 
paraffin embedded lungs, (see figure 5.15, picture A and B) but this protocol could not be 
easily reproduced on sections from all experiments. The protocol was altered (see 
materials and methods section 2.4.5.2), to use a fluorescent secondary and counter stain 
(streptavidin coupled to Cy5, with DAPI). This fluorescent protocol could be used to 
analyse lymphatics on paraffin embedded lung sections that could not be stained with the 
DAB protocol. Pictures A and B show lung sections from WT and D6KO mice, which have 
been stained using LYVE-1 with DAB as the HRP substrate. Brown coloured vessels can 
clearly be seen throughout the lung tissue. Pictures C and D (figure 5.15) show lung 
sections from WT and D6KO mice that have been stained with LYVE-1 using streptavidin 
coupled Cy-5 as the HRP substrate. Positive vessels are shown with a pink outline, and 
again were present throughout the lung tissue. Lymphatics could be identified close to 
metastatic colonies, but no lymphatic vessels could be identified within metastatic 
colonies.  
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Figure 5-15: Identification of lymphatic vessels in lungs from B16 F10 treated mice 
Initially an immunohistochemical protocol was used to stain lung sections from WT and D6KO B16 F10 
treated mice, picture A – LYVE-1 positive vessel in WT lung section, picture B – LYVE-1 positive vessel in 
D6KO lung section (200x magnification). The protocol was altered as subsequent staining attempts were 
unsuccessful. Immunofluorescent staining of lymphatic vessels in lungs from D6KO B16 F10 treated lungs 
(picture C) and WT B16 F10 treated lungs (picture D). 200x magnification. Images are representative of 3 
separate experiments.  
The analysis of LYVE-1 staining was performed by counting the number of positive vessels 
in stained tissue sections. Lungs from WT mice had on average 75.17 (+/-13.32) LYVE-1 
positive vessels whilst D6KO lungs had on average 77 (+/-21.62) LYVE-1 positive vessels. 
The results shown in figure 5.16 (graph A) show there was no significant difference in the 
total number of LYVE-1+ vessels comparing D6KO mice to WT mice. The size of LYVE-1 
vessels was measured using the Axiovision software, as it appeared there was a visual 
difference in the cross-sectional area of lymphatic vessels, comparing WT to D6KO lungs. 
LYVE-1 positive vessels in WT lungs had an average diameter of 108.4 μm (+/- 28.98), and 
LYVE-1 positive vessels in D6KO lungs had an average diameter of 119.37 μm (+/- 38.12). 
These results are shown in figure 5.16 (graph B) and illustrate that there was no 
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significant difference in the size of the lymphatics comparing D6KO and WT lungs (p = 
0.5017 Students unpaired t test). 
 
Figure 5-16: Analysis of lymphatic vessel staining in B16 F10 treated lung sections 
The number of positive vessels were counted in entire lung sections from WT and D6KO B16 F10 treated 
mice, at 200x magnification. A – total numbers of positive vessels throughout lung sections. B – the size 
of LYVE-1 positive vessels were measured using Axiovision software and these results are expressed as 
the average diameter per lung section.  Results are pooled from 3 experiments, n = 9 per group, NS – 
students unpaired t test.  
As with vWF staining, the distance of LYVE-1+ vessels from metastatic colonies and the 
pleura was measured using the Axiovision software. Looking at the distance from LYVE-1 
positive vessels to metastatic colonies, WT mice had an average distance of 102.8 μm (+/- 
68.37) and D6KO mice had an average distance of 17.16 μm (+/- 35.74). These results are 
shown in graph A of figure 5.17, and show that there is a significant difference in the 
distance between LYVE-1 positive vessels and metastatic colonies, with WT mice having a 
greater distance between the two (p = 0.0042 Students unpaired t test). The distance 
between LYVE-1 positive vessels and the pleura was also measured; WT mice had a mean 
distance of 169.38 μm (+/- 24.09) and D6KO mice had a mean distance of 150.62 μm (+/- 
28.22). This difference was not significant (p = 0.1488 Students unpaired t test). These 
results are shown in graph B of figure 5.17. It may be possible that the difference in the 
location of the lymphatics, with respect to metastatic colonies, may contribute to the 
difference in the number of metastatic colonies.  
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Figure 5-17: Distances of LYVE-1 positive vessels to metastatic colonies and the pleura 
A- The distance between LYVE-1 positive vessels and metastatic colonies was measured using Axiovision 
software, throughout lung sections of WT and D6KO B16 F10 treated mice. Results are expressed as the 
average distance in μm. P= 0.0042, Students unpaired t test. B- the distance between LYVE-1 positive 
vessels and the pleura was measured using the Axiovision software throughout lung sections of WT and 
D6KO B16 F10 treated mice. NS (Students unpaired t test) Results are pooled from 3 separate 
experiments, n = 9 per group.  
5.1.5.5 Summary 
To summarise, there are no significant differences between the number and location of T 
cells within the lungs of WT and D6KO mice that received B16 F10 cells. Looking at 
macrophages, there is a significant increase in the number of macrophages within the 
lungs of D6KO mice, compared to WT mice, suggesting that the number of macrophages 
may be contributing to the development of metastatic colonies. These data suggest that 
differences in T cell number or location are unlikely to be responsible for the differences 
seen in metastatic colony numbers. Analysis of blood vessel number and location show 
that there are no significant differences between WT and D6KO lungs. Looking at 
lymphatic vessels, again there are no significant differences between the number and the 
size of lymphatic vessels comparing D6KO to WT lungs. However, when the distances 
between lymphatic vessels and metastatic colonies were measured, D6KO lungs were 
found to have lymphatic vessels significantly closer to metastatic colonies than WT lungs. 
There were no significant differences in the distance between lymphatic vessels and the 
pleura, comparing D6KO lungs to WT lungs. In conclusion, it is unlikely that the number or 
location of blood vessels is responsible for the difference in metastatic colonies. The 
number and size of lymphatics is also unlikely to be responsible for this effect. It is 
possible that the distance between lymphatics and metastatic colonies may play a role in 
the differences in colony number. In D6KO mice, lymphatics are significantly closer, which 
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may mean that when B16 F10 cells are in the lungs of D6KO mice, rather than forming 
colonies, they are leaving the lungs via lymphatics, which leads to the reduction seen in 
colony numbers in D6KO mice.  
5.1.6 B16 F10 Chemokine Receptors 
Results shown above demonstrate that there is a clear difference in the number of 
surface colonies on the lungs of WT and D6KO mice, which is unlikely to be attributed to 
differences in T cell, macrophage, and blood vessel number or location. As mentioned 
above, it is possible that the location of lymphatics plays a role in the differences in 
metastatic colony number. As there were no major differences in the structure of the 
lungs, it was decided to investigate this further by examining how B16 F10 cells get to the 
lungs. B16 F10 cells have been selected to specifically colonise the lungs, possibly due to 
the lungs being the first capillary bed they encounter (308), but this lung colonisation may 
be specific, and may be related to chemokine receptor expression. In order to try to 
address this, the chemokine receptor profile of B16 F10 cells was analysed. 
 
Figure 5-18: Chemokine receptor expression by B16 F10 cells 
Chemokine receptor expression of B16 F10 cells was analysed by isolating RNA from cultured cells and 
performing RT-PCR, as described in materials and methods.  
Chemokine receptor expression analysis was performed using RT-PCR as described 
previously (materials and methods section 2.5). The results in figure 5.18 show the RT-
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PCR analysis of chemokine receptors expressed by B16 F10 cells. These data show that 
B16 F10 cells do not express CCR 1-5, but they are CXCR4 positive. The positive control 
here was a mixture of murine lung, spleen, liver and skin cDNA. The only chemokine 
receptor that was detected on B16 F10 cells was CXCR4, so these cells may potentially use 
CXCR4 to get to the lungs.  
5.1.6.1 AMD3100 
As shown above, CXCR4 is the only chemokine receptor shown to be expressed by B16 
F10 cells. As CXCR4 is known to play a role in metastasis to the lungs when over-
expressed by B16 F10 cells and in human melanoma, (292, 332, 337) it is possible that 
CXCR4 expressed on these cells could be responsible for their specific colonisation of the 
lungs. If this is the case then CXCR4 may be involved in the initial colonisation of the 
lungs, and D6 may act at a later stage of metastatic colony development.  
AMD 3100 was originally discovered as an impurity in cyclam samples and was named as 
the bicyclam JM3100. It was found to block the entry of HIV into cells. AMD3100 
(AnorMed) specifically interacts with CXCR4, and inhibits the signal transduction 
downstream of CXCL12 binding CXCR4. Trials with HIV patients led to the discovery that 
AMD3100 can mobilise CD34+ stem cells, and has a potential role in cancer (335). 
AMD3100 is a specific reversible antagonist of CXCR4 and is licensed for use in stem cell 
mobilisation in humans (Plerixafor). 
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Figure 5-19: Metastatic colonies on lungs from WT C57Bl/6 mice that received B16 F10 cells followed by 
treatment with AMD3100  
Picture A shows lungs from control mice that received B16 F10 cells followed by daily PBS injections for 
14 days. Picture B shows lungs from mice that received B16 F10 cells followed by daily injections of 
AMD3100 for 14 days.  
An experiment was designed in which mice received B16 F10 cells intravenously, as 
previously described (materials and methods section 2.3.2.3), but were treated with twice 
daily doses of AMD3100, in order to try and block B16 F10 cell movement to the lungs. If 
CXCR4 was essential in this colonisation, then AMD3100 should prevent metastasis 
formation in the lungs. Figure 5.19 shows the lungs taken from control and AMD3100 
treated mice. There are visibly more colonies present on the surface of control lungs than 
lungs taken from AMD3100 treated mice. Lungs were processed for histology as 
described previously (materials and methods section 2.3.2) – internal metastatic colonies 
were counted on H&E stained serial lung sections. Representative sections are shown in 
figure 5.20. These images show whole lung sections taken from control and AMD3100 
treated mice. Picture A shows lungs from a control mouse, with metastatic colonies 
identified, these are present throughout the lung tissue and external colonies can be seen 
at the edges of the section. Picture B shows a lung section from an AMD3100 treated 
mouse, with fewer internal and external metastatic colonies visible.  
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Figure 5-20: H&E stained lung sections from WT mice treated with B16 F10 cells and AMD3100.  
Lungs from both control (picture A) and AMD3100 treated (picture B) WT mice that received B16 F10 cells 
were processed for histology and stained with H&E. Images were taken at 50x magnification and 
‘overlaid’ to show the entire lung section. Metastatic colonies are identified with arrows.  
External colonies were counted as described previously (section 5.1.2). Graph A in figure 
5.21 shows the average number of external metastatic colonies for control and AMD3100 
treated mice. In the control group, the average number of external metastatic colonies 
was 260.33 (+/- 102.34) compared to 52.33 (+/- 42.77) external colonies in the AMD3100 
treated group. This difference is statistically significant (p = 0.0314 Students unpaired t 
test). Graph B shows the number of internal metastatic colonies from control and 
AMD3100 treated mice. The control group had on average 8.53 (+/- 3.6) internal 
metastatic colonies, compared to 2.93 (+/- 1.09) internal metastatic colonies in the 
AMD3100 treated group. This difference was not statistically significant (p = 0.0614 
Students unpaired t test). These data show that AMD3100 treatment significantly reduces 
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the number of external colonies on the lungs of WT mice that received B16 F10 cells. As 
well as reducing external colonies, AMD3100 treatment reduced the number of internal 
colonies in B16 F10 treated lungs, but this difference was not significant. 
 
Figure 5-21: Enumeration of metastatic colonies of untreated and AMD3100 treated WT mice that 
received B16 F10 cells 
WT C57Bl/6 mice received B16 F10 cells followed by daily injections of PBS control or AMD3100 for 14 
days. External metastatic colonies were counted using the dissecting microscope (graph A), internal 
colonies were counted on H&E stained serial sections and are expressed as the average number of 
colonies per section (graph B). A – p=0.0314, students unpaired t test, B – NS, students unpaired t test. n= 
3 per group 
These results show, for the first time, that AMD3100 treatment significantly reduced the 
number of external metastatic colonies and caused a reduction in the number of internal 
metastatic colonies in the B16 F10 model of metastasis. These data show that CXCR4 is 
involved in B16 F10 colonisation of the lungs, and is required for the development of both 
internal and external colonies. As AMD3100 treatment did not fully prevent the 
development of metastatic colonies, it is likely that other mechanisms are involved in lung 
colonisation. What may be happening in the lungs is that CXCR4 is involved in getting B16 
F10 cells to the lungs, and once there, the cells may grow or they may leave via pleural 
lymphatics. It may be here that D6 plays an important role. D6 may alter the chemokine 
levels within the lungs, which may affect the lung tissue, making the environment suitable 
for metastatic colony growth. Similar experiments have been performed, using B16 F10 
cells transfected with CXCR4, these show that when CXCR4 is over-expressed in B16 F10 
cells, the number of metastatic colonies increases, and CXCR4 can also promote cell 
survival in vitro (292, 330).  The enhanced metastasis to the lungs caused by CXCR4 can 
be blocked using T22, an inhibitor of CXCR4 (330) 
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5.1.7 B16 F10 Overload 
The results above (figure 5.2) show that D6KO mice had a significant reduction in the 
number of metastatic colonies that developed in the lungs. B16 F10 cells are well known 
for their lung colonisation capabilities (see section 1.13.2), but it may be possible that in 
D6KO mice, due to altered chemokine levels, they are colonising other organs rather than 
the lungs. This may reduce the number of cells that reach the lungs, explaining the 
reduction in colony numbers. If this was the case, giving mice double the number of cells, 
so ‘overloading’ the system, may show where these metastases are present in other 
organs.  This ‘overload’ experiment (same protocol as described in section 2.3.2. with 
double the cell number) was performed on both WT and D6KO backgrounds. Table 5.2 
shows the organs in which metastatic colonies were present in WT and D6KO mice.   
Organ WT D6KO
Lung +++ +
Liver - +
Heart - +
LN + +
Spleen - +
Testicles - +
Seminal Vesicles - +
Kidney + +
Membranes 
(omentum/peritoneum)
- +
                                    
Table 5-2: Organs that contained metastatic colonies from WT and D6KO mice after receiving B16 F10 
cells 
WT and D6KO C57Bl/6 mice received double the dose of B16 F10 cells; 14 days later mice were sacrificed 
and organs which displayed metastatic colonies were noted.  Results are representative of 2 separate 
experiments. Plus signs indicate the presence of metastatic colonies on that organ; multiple symbols 
indicate increased colony numbers. A minus sign indicates no colonies were present on that organ.  
In both backgrounds lung colonies were present, consistent with previous experiments. 
Graph A of figure 5.22 shows that, as with previous results (figure 5.2), D6KO mice had a 
significant reduction (p < 0.0001 Students unpaired t test) in the number of external 
metastatic colonies. WT mice had on average 83.5 (+/- 10.85) metastatic colonies whilst 
D6KO mice had on average 30 (+/- 12.26) external metastatic colonies. Graph B shows 
that D6KO mice also have a significant (p < 0.0001 Students unpaired t test) reduction in 
the number of internal metastatic colonies (WT mice had an average of 20.37 (+/- 4.07) 
internal colonies whilst D6KO had on average 4.5 (+/- 1.97) internal colonies).  
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Figure 5-22: Metastatic colony counts on lungs from B16 F10 overload experiments 
WT and D6KO mice received double the dose of B16 F10 cells and metastatic colonies were counted on 
the external surface of the lungs, and within the lung tissue. A – external colony counts, analysed using a 
dissecting microscope, and expressed as the number of colonies per lung. P<0.001 (Students unpaired t 
test). B – Internal colonies were counted on H&E stained lung sections, at 50x magnification. Results are 
expressed as the average number of colonies per section, p<0.001 (Students unpaired t test), n= 3 per 
group.  
Other organs, which had obvious metastatic colonies on their surface, were removed, 
fixed and processed for histology, usually only one metastatic colony was evident upon 
dissection in each of the above organs. External colonies that could be identified by eye 
were confirmed by H&E staining of tissue sections. Representative sections from the 
mediastinal lymph node and testicle from a D6KO mouse are shown in figure 5.23; these 
organs contain metastatic colonies. Picture A shows a section from the testicle of a D6KO 
mouse that had been ‘overloaded’ with B16 F10 cells. Metastatic colonies could be 
identified on the external surface of the organ, and an internal metastatic colony can also 
be identified. The mediastinal lymph node from an ‘overloaded’ mouse is shown in 
picture B. This was isolated using a dissecting microscope and could be easily identified 
due to the large metastatic colony which is shown in the picture.  
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Figure 5-23: Organs containing metastatic colonies from mice that received double the dose of B16 F10 
cells 
WT and D6KO C57Bl/6 mice that received double the dose of B16 F10 cells had any organs with obvious 
metastatic colonies excised and processed for histological analysis. Picture A shows a testicle from a 
D6KO mouse with metastatic colonies identified. Picture B shows a lymph node from a D6KO mouse that 
contains a metastatic colony. Pictures were taken at 50x and ‘overlaid’ to show the entire tissue section.  
Looking at the results presented in table 5.2, D6KO mice appeared to have metastatic 
colonies in many more organs than WT mice, e.g. liver, heart, spleen, testicles and 
seminal vesicles. These results suggest that in D6KO mice, B16 F10 cells have the ability to 
colonise many more organs than in WT mice. This may be due to an altered chemokine 
environment within these mice, caused by a lack of D6. The colonisation of other organs 
may explain the reduction in lung colonies in D6KO mice. In D6KO mice B16 F10 cells may 
initially enter the lungs, but encountering an environment that is unsuitable for 
metastatic growth may results in the cells leaving the lungs, possibly via pleural 
lymphatics or vasculature. This may then allow B16 F10 cells to go on and colonise other 
organs. The cell number used in the original metastasis experiments may not have been 
enough to allow the development of visible metastatic colonies on other organs, which 
explains why these organs were not selected for analysis. Evidence in the literature has 
shown that B16 F10 cells preferentially grow in the lungs. Grafts of pulmonary and renal 
tissue show the same degree of B16 F10 cell arrest, but only metastatic colonies 
developed in the lungs (309). Taken together, these results that a lack of D6 in the lungs is 
causing alterations to the pulmonary microenvironment, which makes them unsuitable 
for B16 F10 metastatic colony growth.    
Claire L. Burt, 2011   188 
5.2 Summary  
The data presented above show that D6KO mice have a significant reduction in external 
metastatic colonies, compared to WT mice. D6KO mice also have a reduction in internal 
colony number, although this difference is not significant. There is a significant reduction 
in internal colony number in D6KO lungs compared to WT lungs in the overload 
experiment, so this suggests that this difference in internal colony number, although not 
significant in the initial experiments, is a true observation. Immunohistochemical analysis 
has shown that these differences are unlikely to be due to differences in T cell location or 
number. There is a significant increase in the number of macrophages in the lungs of 
D6KO mice, suggesting that differences in macrophage number may be contributing to 
differences in metastatic colonies. These results suggest D6 inhibits macrophages within 
the lungs, which are crucial to the development of metastases in this model. Analysis of 
blood vessel number and location shows that there are no significant differences when 
comparing D6KO to WT lungs, which suggests that differences in blood vessels are not 
responsible for differences in metastatic colonies. Analysis of lymphatic vessel number 
and size, again, shows no differences comparing D6KO to WT lungs. There is a significant 
difference between locations of lymphatics with respect to metastatic colonies; D6KO 
mice have lymphatic vessels significantly closer to metastatic colonies than WT mice, 
which suggest the location of lymphatics may affect metastatic colony number.  
The chemokine receptor profile of B16 F10 cells was analysed in order to try to determine 
how these cells were getting to the lungs. The only chemokine receptor that was found to 
be expressed was CXCR4. To try and determine if CXCR4 is responsible for B16 F10 
colonisation of the lungs, WT mice were treated with a specific CXCR4 antagonist, 
AMD3100, which significantly reduced the number of internal and external metastatic 
colonies compared to control mice. These data suggest that CXCR4 is involved in B16 F10 
cell colonisation of the lungs. The microenvironment of the lungs is essential to the 
growth of B16 F10 cells (309), as D6 has been shown to be expressed by the lungs, it 
seems possible that a lack of D6 may alter the chemokine microenvironment of the lungs. 
This different microenvironment may no longer allow growth of B16 F10 cells within the 
lungs in D6KO mice. In D6KO mice, the B16 F10 cells may simply not be able to survive 
within the lungs, or they may be able to leave and colonise other organs.  
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An ‘overload’ experiment was performed to try to determine if B16 F10 cells are able to 
colonise more organs in D6KO mice, possibly due to altered chemokine levels. These 
results show that in D6KO mice, whilst B16 F10 cells form fewer colonies in the lungs, 
they are able to form metastatic colonies in the liver, heart, spleen, testicles, seminal 
vesicles and the peritoneum, which are not seen in WT mice. This suggests that whilst the 
lungs may be suitable for B16 F10 growth, in D6KO mice these cells are able to colonise 
many more organs.  
Taken together, these results suggest that CXCR4 may be involved in colonisation of the 
lungs. A hypothesis for the situation in D6KO mice could be that CXCR4 directs B16 F10 
cells to the lungs. Once B16 F10 cells have entered the lungs, in WT mice they are able to 
grow and form metastatic colonies, but this does not happen in D6KO lungs. This could be 
due to an altered environment in the lungs which may not be suitable for B16 F10 cell 
growth, so these cells either die, or are able to re-enter the circulation and form 
metastatic colonies in other organs. 
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6 Discussion  
The chemokine decoy receptor D6 was initially reported in 1997 during a search for novel 
CCL3 receptors (130, 131). Since then, D6 has been shown to have the ability to bind to 12 
different CC chemokines, all of which fall into the category of inflammatory chemokines 
(128). D6 is referred to as a decoy receptor, as it is able to bind to inflammatory CC 
chemokines, internalise and target them for degradation, without appearing to induce 
any classical chemokine related signalling pathways. As a result, it is known as a member 
of the atypical chemokine receptor family, along with DARC, CCX-CKR and CXCR7. 
Expression of D6 has been shown in the skin, gut, lungs and placenta, as well as cellular 
expression on lymphatic endothelial cells and D6 is expressed by a wide variety of 
leukocytes (130, 143, 144). Leukocyte expression of D6 has been shown to be at the 
highest levels in B cells and DCs, and its expression can be modulated by pro and 
inflammatory stimuli (144, 145). On leukocytes and lymphatic endothelial cells, D6 may 
be present in order to scavenge and help to clear inflammatory CC chemokines from the 
environment. On leukocytes D6 may scavenge chemokines, but evidence suggests that D6 
expressing cells may have reduced chemotaxis towards ligands that can bind both D6 and 
signalling chemokine receptors. This work showed no effect on chemotaxis towards non-
D6 ligands when D6 was over-expressed with a CXCR; this work was carried out using 
transfected cells, so this observation may be a result of the artificial system (141).  
The function of D6 in vivo has been studied extensively using animal models. Using the 
TPA model of skin inflammation, D6 has been shown to be required for the resolution 
phase of the inflammatory response (152). In the EAE model, D6KO mice have a reduced 
disease severity, which is thought to be a result of DCs being unable to leave site of 
inoculation (153). Transgenic D6 expression in the epidermis has been shown to be 
protective in a model of inflammation driven tumour formation, and D6 may be involved 
in colon cancer (142, 158, 159). In the placenta, D6 has a role in protecting the foetus 
from inflammation induced foetal loss (149).  
As mentioned above, there is evidence to suggest that, despite its apparent inability to 
signal, D6 may be able to affect chemotaxis and may affect leukocyte chemotaxis in vivo. 
The work presented in this thesis set out to further elucidate the role that D6 may play in 
chemotaxis, using both in vitro and in vivo models.  
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Evidence in the literature has suggested that D6 may be involved in blunting chemotactic 
responses to the CC chemokines that D6 is able to bind. This has been shown in cell lines 
which co-express D6 and CCR4; the expression of D6 prevents migration towards CCL4. 
This phenomenon seems to be restricted to D6 ligands, as D6 co-expression with CXCR4 
has no effect on migration towards CXCL12 (141). This effect of D6 on this chemotactic 
response may be artificial, as these cells were transfected with both D6 and the 
appropriate signalling chemokine receptor, in other words, this phenomenon may only be 
observed in transfected cells. Initially we set out to try to investigate the effect that co-
expression of D6 would have in chemotaxis of cell lines. The approach taken involved 
using cells which expressed either inflammatory CC chemokine receptors (THP1 cells) or 
homeostatic chemokine receptors (Hut78). Attempts were made to stably transfect these 
cells with D6, with the aim of measuring their chemotactic capabilities in vitro, 
unfortunately the generation of stable transfectants proved unsuccessful. The baseline 
migration capabilities of these cells could be determined, but the chemotaxis assays gave 
highly variable results, which made analysis difficult.  
An alternative approach involved looking at primary murine cells from WT and D6KO 
mice. Splenocytes and neutrophils were isolated from the spleen and bone marrow 
respectively, dendritic cells were generated by culturing bone marrow cells in GM-CSF. 
Using both the Transwell assay system and the modified Boyden chamber (Neuroprobe), 
chemotaxis results for all these cell types were highly variable, despite repeated attempts 
to optimise these assays. As a result, these data have been omitted from this thesis. 
Although, in my hands, these assays were highly variable and did not yield reproducible 
results, these assays have been used successfully in other studies. In particular, a recent 
report shows that neutrophils isolated from D6KO mice have an increased chemotactic 
response to CCL3, compared to WT neutrophils, suggesting D6 may be limiting the 
responses of neutrophils to CCL3 (140). These data also show that migration towards 
CCL4 and CXCL8 is unaffected in primary neutrophils from D6KO mice (140). Previous 
evidence showing D6 has an effect on CCR4 mediated migration in response to CCL4 was 
performed in transfected cell lines, so D6 expression is likely to be higher than normal, 
and it may only be in this ‘artificial’ situation that D6 can affect other signalling 
chemokine receptors (108).  
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The next approach aimed to investigate a phenomenon observed in the skin of TPA 
treated D6KO mice. This model of TPA skin inflammation has been well described in D6KO 
mice, and results in an exaggerated inflammatory response, characterised by increased 
levels of inflammatory chemokines, T cell and mast cell infiltration, and a delayed 
resolution of inflammation (152). The skin of 129/Bl6 D6KO mice develops a psoriasis like 
pathology, which does not occur in WT mice of the same genetic background (152). Other 
features of this model include the altered positioning of neutrophils in the skin of D6KO 
mice. In WT mice, after TPA inflammation, neutrophils are found in the dermal 
compartment of the skin, shown by myeloperoxidase staining (see figure 3.2, (140)). 
However in D6KO skin, neutrophils are found closer to the dermal/epidermal junction. In 
order to explain this altered neutrophil positioning, two hypotheses were proposed – D6 
has been shown to be expressed by neutrophils, so a lack of D6 on neutrophils may affect 
their chemotaxis on a cell autonomous basis, meaning they are unable to halt their 
migration in the dermal compartment, and continue to the dermal/epidermal junction. 
This theory has been supported by the in vitro chemotaxis work mentioned in (140). 
Alternatively, after TPA inflammation, D6KO skin has been shown to have an increased 
accumulation of chemokines, and it could simply be the increased chemokine levels, 
which are attracting neutrophils to the dermal/epidermal junction, irrespective of D6 
expression on the neutrophils.  
In order to try to test these hypotheses, a model of neutrophil adoptive transfer was 
designed. This model involved inducing inflammation in the skin of 129/Bl6 D6KO mice 
with TPA, injecting fluorescently labelled WT and D6KO neutrophils into the tail vein, and 
looking at samples of the inflamed skin at certain timepoints following induction of 
inflammation. Extensive optimisation of this protocol had to be undertaken, but 
eventually a successful protocol was developed. This allowed the identification of labelled 
neutrophils in the skin of D6KO mice, and allowed enumeration and measurement of 
their distance from the epidermis. Control skin sections were consistently negative for 
fluorescent cells, so it was assumed that any fluorescent cells within the skin of treated 
mice were neutrophils. An additional control to confirm that these cells were in fact 
neutrophils, would be to co-stain skin sections with a neutrophil marker, 
myeloperoxidase for example. If D6 on neutrophils was influencing their positioning in the 
skin, it was expected that D6KO neutrophils would be situated closer to the 
dermal/epidermal junction. These results showed that WT neutrophils were significantly 
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closer to the epidermis 11 hours after TPA treatment, compared to D6KO neutrophils. 24 
hours after TPA treatment, WT neutrophils were significantly further away from the 
epidermis, compared to their position at 11 hours. These results suggest that D6 
expressed on neutrophils may affect their position relative to the dermal/epidermal 
junction, early on in the inflammatory response, but as the inflammatory response 
progresses, D6 on neutrophils does not affect their positioning within the skin.  
Results from the neutrophil adoptive transfer experiments are included in a study 
investigating the regulation of neutrophil migration by D6 (140). In this study, it is 
suggested that these results show that D6 does not affect the point of entry of 
neutrophils into the inflamed skin. However, this experiment cannot be used to 
determine the point of entry of neutrophils into the skin, as both neutrophil genotypes 
are injected into the tail vein together. As the neutrophils re-circulate, they will enter the 
skin at the same point, in vessels situated below the epidermis. In order to get to the 
dermal/epidermal junction, neutrophils will have to migrate through the dermis to the 
epidermis (358). These results show that D6 may influence the positioning of neutrophils 
in inflamed skin, but a lack of D6 does not explain their positioning at the 
dermal/epidermal junction, observed in D6KO skin (140). This report also states that 
D6KO neutrophils are not restricted in their migration in the inflamed skin, which allows 
them to accumulate at the dermal/epidermal junction (140). The results presented here 
suggest the opposite, WT neutrophils, that express D6, are found closer to the 
dermal/epidermal junction, compared to D6KO neutrophils, suggesting that a lack of D6 is 
restricting their location in the skin.  
Neutrophil migration into inflamed skin can be regulated by CXCL1 and CXCL2, under the 
influence of CXCR2 (359). These chemokines are not able to bind to D6, but when CXCL2 
blocking is carried out on D6KO mice, this reduces the development of the psoriasis-like 
pathology (140). Whilst D6 and CC chemokines are important in this model, CXCL2 is also 
important and may be influencing the positioning of neutrophils in inflamed skin. 
Neutrophils are known to express CXCR2, and they have been shown to express CCR1, 
which is able to bind to the D6 ligands CCL3 and CCL5. Administration of a CCR1 
antagonist to D6KO mice reverses the aberrant neutrophil accumulation at the 
dermal/epidermal junction, so CCR1 is crucial to these neutrophils getting to the 
dermal/epidermal junction in D6KO skin. Looking at CCL3 expression, the major site of 
CCL3 expression seems to be the epidermal compartment, CCL5 expression was not 
194 
analysed. These results suggest that CCR1 is required for neutrophil positioning in 
inflamed D6KO skin (140).  
It is possible that the results presented here are not a true reflection of the differential 
positioning seen in D6KO skin, as this is an artificial system, where neutrophils are 
removed from the bone marrow, stained and re-infused. This process may affect the 
neutrophils and could potentially alter chemokine receptor expression. An alternative 
method of testing these hypotheses would be to use bone marrow chimeras, putting WT 
bone marrow into D6KO mice, and vice versa, to determine conclusively if D6 is affecting 
the positioning of neutrophils in inflamed skin, or if the work in (140) suggests, other 
chemokine receptors or secondary effects of the increased inflammation is responsible. 
Further work to identify the location of chemokine expression in inflamed D6KO skin is 
required to clarify why neutrophils are found at the dermal/epidermal junction. These 
results contribute to the body of work investigating the TPA inflammation model in D6KO 
mice, but further work is required to fully elucidate the mechanisms of alternative 
neutrophil placement in the skin of these mice.  
Much of the knowledge regarding D6 has come from a variety of different in vivo models, 
including skin inflammation, tuberculosis infection, EAE, skin and colon cancer (142, 152, 
153, 157-159). In a model of inflammation driven skin tumour formation, transgenic over 
expression of D6 in the epidermis has been shown to be protective. In the same model, a 
lack of D6 is able to render resistant mice susceptible to tumour formation (B6/129) and 
increase the tumour burden in susceptible mice (Fvb/N) (142). In models of colitis driven 
colon cancer, D6KO mice are more susceptible to the development of cancer (158).  D6 
expression has also been demonstrated on lymphatic endothelial cells in squamous cell 
carcinomas, endometrial carcinoma, Kaposis sarcoma and cases of IBD that developed 
into colon cancer. Both of these models of tumourigenesis are similar in the fact that they 
rely on repeated rounds of inflammation to promote the tumour formation (142, 158). 
We decided to investigate the role of D6 in a different model of skin cancer, melanoma, 
which has a different mechanism of tumourigenesis, injecting melanoma cells into 
syngeneic mice. Using WT and D6KO mice, it would be possible to identify any potential 
role that D6 may play in affecting this model of tumour growth.  
The B16 F0 model of melanoma was chosen as it differed in action to the model of skin 
tumourigenesis used previously, and was easy to manipulate. Tumour cells were injected 
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into WT and D6KO mice and the resultant tumour growth was measured against time. 
Initial experiments showed that D6KO mice developed tumours before WT mice, and 
tumours in D6KO mice subsequently grew at a faster rate, although this difference was 
not significant. This enhanced growth rate resulted in a reduced survival for the D6KO 
mouse group, as tumours reached the point of sacrifice sooner, again this difference was 
not significant Tumours were excised for histological and immunohistochemical analysis. 
There were no visible differences in tumours that developed in D6KO mice, compared to 
WT; tumours from both WT and D6KO mice had the same general histological features 
(see section 4.1.2). Immunohistochemical analysis showed that there were no differences 
in T cell or macrophage numbers in WT and D6KO tumours, and there were no 
differences in the number of blood vessels that developed within the tumours. Together, 
these results show that there are no significant differences in the cell composition, blood 
vessel development and growth rate of B16 F0 tumours in D6KO mice compare to WT.  
Tumour growth appeared to be slightly enhanced in D6KO mice, although not significantly 
increased, so B16 F0 cells were stably transfected with D6 (as they were previously shown 
to be D6 negative), to investigate the effect of D6 expression in tumour growth. The 
growth of tumours derived from B16 F0 D6 cells was compared to that of B16 F0 cells in 
both WT and D6KO mice. These results showed that in D6KO mice, D6 expressing tumours 
developed at a significantly slower rate than D6 expressing tumours in WT mice. As with 
B16 F0 tumours before, all B16 F0D6 tumours were analysed by histology and 
immunohistochemistry. To summarise these results, there were no differences in blood 
vessels, T cells or macrophages that could explain this difference in observed growth rate.  
Initially, it was hypothesised that D6KO mice were developing an immune response 
against the previously unseen D6 expressed by the tumour cells, which was causing the 
reduced growth rate. However this is unlikely to be the case, as a higher number of T cells 
and macrophages would be expected in the tumours if these mice were mounting an 
immune response against the tumour cells. Another explanation for what could be 
happening in these D6 expressing tumour cells may lie in their chemokine receptor 
expression. B16 F0 cells were shown to be CCR5 and CCR7 positive by RT-PCR. D6 can 
bind to the same ligands as CCR5 (CCL3, 4, 5) but not to CCL19 and 21, which bind CCR7. 
This suggests that D6 expressed on these tumour cells may be able to somehow interfere 
with CCR5 function. Without D6 on B16 F0 cells, CCR5 may be influencing the cell survival 
and the subsequent tumour development. Evidence in the literature suggests that CCR5 
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can be anti-apoptotic in macrophages, and can promote the survival of lymphoma cells 
(349, 350). 
In D6KO mice, there may be a general increase in levels of inflammatory CC chemokines, 
such as CCL3, 4, and 5, all of which can bind to CCR5. In D6KO mice, these chemokines 
may induce signalling via CCR5 that promotes the survival of B16 F0 cells and results in a 
faster tumour growth rate, compared to WT mice. In B16 F0 cells that express D6, D6 may 
be acting to reduce the local levels of inflammatory chemokines, which may result in 
reduced CCR5 signalling therefore decreased tumour cell survival. Alternatively, D6 
degradation of inflammatory chemokines may somehow interfere with CCR5 induced 
signalling, with the same end results of reducing the tumour cell growth rate, or a 
reduction in the levels of inflammatory chemokines may simply create an unfavourable 
environment for melanoma growth.  
Chemokines are known to contribute to the survival of melanoma cells (274, 276, 277), it 
would be useful to look at the effects of D6 ligands on B16 F0 cells, to try to explain the 
possible differences in tumour growth. Although this study showed no differences in T 
cell or macrophage numbers, the subsets of these cells may be altered in D6 expressing 
tumours. The balance of macrophages, in particular, is known to be crucial to tumour 
growth; too many M1 macrophages can cause tumour suppression, too many M2 
macrophages can promote tumour growth (238, 241, 242). The cell subsets within B16 F0 
and B16 F0D6 tumours would need to be analysed in more detail, by flow cytometry for 
example, to determine the leukocyte subsets that may be contributing or inhibiting 
tumour growth. An altered chemokine microenvironment in D6KO mice, which normally 
promotes tumour growth, perhaps by recruiting M2 macrophages, may be altered by the 
expression of D6 within the tumour. Evidence in the literature suggests that chemokines 
are able to inhibit growth in this type of tumour model (289, 291), but these studies have 
the drawback of only looking at one chemokine at a time, using transfected tumour cells.  
In the case of D6, multiple CC chemokines (and possibly CXC chemokines (152)) may be 
affected, and are likely to have multiple and cumulative effects on different cell 
populations. In conclusion, these results show that B16 F0 tumours grow at a faster rate 
in D6KO mice, which can be reversed by expression of D6 in the tumour cells. These 
results suggest that D6 is having some effect on the local chemokine environment, or 
other chemokine receptors expressed by B16 F0 cells to influence tumour growth. These 
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results highlight a potential therapeutic role for D6 expression in solid tumours and 
contributes to the existing data showing a role for D6 in tumourigenesis (142, 158). 
 The role of chemokines and their receptors in metastasis has been well defined in many 
types of cancer. In melanoma, chemokine receptor expression has been shown to 
influence the site of metastasis (see introduction section 1.12.1.2). As D6 has been shown 
have an effect tumour growth using the B16 F0 model, it was decided to determine if D6 
has a role in melanoma metastasis. This was carried out using model related to the B16 F0 
melanoma model. The B16 F10 model uses cells which have been derived from the 
original B16 F0 cell line, that have been selected to be highly selective for the lungs (286, 
311). As a result, when these cells are injected intravenously into syngeneic mice, 
metastatic colonies form in the lungs. This model was administered to WT and D6KO mice 
to determine if D6 plays a role in melanoma metastasis.  
The B16 F10 model of melanoma metastasis results in the formation of metastatic 
colonies on the external surfaces of the lungs and inside the lungs. A striking difference 
was observed, with D6KO mice having a significant reduction in the number of external 
metastatic colonies, with a reduction in internal metastatic colonies, although this 
difference was not significant. To investigate what could be contributing to the 
differences in metastatic colony formation, lungs were digested to create a single cell 
suspension, which was then stained for a panel of lineage markers and analysed by flow 
cytometry. No significant differences were found in relation to leukocyte populations of 
untreated WT and D6KO lungs, and those that received B16 F10 cells.  There seemed to 
be an increase in a population of CD45+ CD11b+ CD11c- cells in the lungs of D6KO mice 
that received B16 F10 cells, but this increase was not significant. Previous studies looking 
at the role of D6 in colitis development, have showed that CD45- cells, or non-
haematopoeitic cells, express D6, and these cells may be responsible for the D6 
expression in the gut (158, 159). It would be useful to sort out the various cell populations 
and characterise the expression of D6 within the lungs, as this has not been characterised 
fully, it is possible that CD45- cells may be influencing metastatic colony formation, 
perhaps by influencing the development of the premetastatic niche (261, 263). 
The major difference in metastatic colony formation was shown at the external surface of 
the lungs, which, in vivo, is covered by the pleura, a thin serous membrane. Metastatic 
colonies were observed on the pleura, but technically it was challenging to enumerate 
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these, or to analyse the pleura to compare differences between WT and D6KO. Pleural 
washes yielded low protein concentrations that made analysis of chemokine and cytokine 
levels difficult. The only samples which could be detected were those from B16 F10 
treated WT mice, which although these were at the limits of detection, may suggest that 
in WT mice that receive B16 F10 cells, there may be a low level of inflammation within 
the lungs. It may be that lungs of mice that received B16 F10 cells may have an increased 
baseline inflammatory microenvironment, compared to D6KO and untreated WT mice. In 
order to confirm this, the experiment would have to be repeated with many more mice.  
Lungs from B16 F10 treated mice were processed for immunohistochemical analysis, to 
analyse the cell populations within the lungs, and to define their location with respect to 
metastatic colonies. T cells have been shown to influence the development of metastatic 
colony formation by forming clusters with B16 cells, the more clusters form with T cells, 
the more metastatic colonies (286, 306). Lung sections were stained for CD3, and show 
that there are no differences in the number or location of T cells in B16 F10 treated WT 
and D6KO lungs. Macrophages are well known for their role in tumour formation and can 
also influence the development of metastatic colonies (255). Macrophage staining within 
the lungs was carried out and showed that there was a significant increase in the number 
of macrophages within the lungs of D6KO mice. This increased number did not alter their 
location with respect to the pleura or metastatic colonies. It is possible that this increase 
in macrophages correlates with the increased number of CD45+CD11b+CD11c- found in 
the lungs of B16 F10 treated D6KO mice, by flow cytometry. These cells may be 
responsible for causing the reduction in colony formation in the lungs. Evidence in the 
literature suggests that after OVA induced inflammation, a population of CD11b+ CD11cint 
cells increase in the lungs, and these cells stain positive for macrophage markers (360). 
Within the lungs, populations of CD11b+CD11c- cells have been identified as antigen 
presenting cells (353). The lungs are full of alveolar macrophages, which typically express 
CD11c+CD11b-, whilst macrophages that are CD11c-CD11b+ are typically found in the 
tissues (361). The results presented here, although preliminary, suggest that there may be 
differences in macrophage populations in the lungs of D6KO mice. If an altered 
macrophage population is present in the lungs of D6KO mice, these cells may be 
destroying the injected B16 F10 cells before they are able to develop into metastatic 
colonies. Alternatively, different populations of macrophages may influence the 
microenvironment of the lungs, and may alter the development of the pre-metastatic 
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niche, which has been shown to be contribute to the growth of B16 F0 metastatic 
colonies (328, 329).  
Blood vessels and lymphatic vessels were analysed by immunohistochemistry; no 
differences were observed with respect to blood vessels within the lungs. However 
lymphatic vessels in D6KO lungs were significantly close to metastatic colonies than in T 
mice. This may have implications for B16 F10 cell exit from the lungs. It may be possible 
that when the colonies are developing, if a lymphatic vessel is close, some of the cells 
may be able to leave, which may reduce the number of metastatic colonies which can 
form in that area. Whilst D6 expression has not been shown on murine lymphatic 
endothelial cells, two recent studies looking at D6 in colitis have suggested that D6 on 
non-haematopoietic cells or CD45- cells may be affecting colitis development (158, 159).  
It is possible that these same cells may express D6 in the lungs, and may influence the 
development of metastatic colonies, through the development of the pre-metastatic 
niche (329).  
Other variables which could influence the development of metastatic colonies, include 
the initial stages of lung colonisation. Chemokines, receptors in particular, are known to 
influence metastasis (274, 282), so the chemokine receptor expression of B16 F10 cells 
was analysed to determine if they express specific receptors that may direct them to the 
lungs. RT-PCR analysis of chemokine receptor expression showed expression of CXCR4 
alone, this receptor has been linked to metastasis in murine and human cancer (213, 267, 
274). The use of the specific reversible antagonist of CXCR4, AMD3100, showed that B16 
F10 cells rely on CXCR4 to colonise the lungs, this was the first time that AMD3100 has 
been used in this model. A similar technique was used with CXCR4 transfected B16 cells; 
using T22, an inhibitor of CXCR4, showed that the colonisation of the lungs could be 
prevented in these transfected cells (330). It is possible that CXCR4 may be involved in the 
initial colonisation stages of the lungs, but once B16 F10 cells reach the lungs, the lung 
microenvironment may be crucial for metastatic colony growth. 
It seems plausible that D6KO mice may have a general increase in inflammatory 
chemokines in the numerous organs where D6 is expressed, and this increase in 
chemokines may alter the normal colonisation patterns of B16 F10 cells. Once injected, 
B16 F10 cells may alter their chemokine receptor expression, meaning that CXCR4 may 
not be the only receptor directing their colonisation. In order to try to address this, an 
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experiment was designed which used double the number of B16 F10 cells, in order to try 
to ‘overload’ the system. This would provide enough cells in the system to identify any 
other organs where metastatic colonisation was taking place. These results showed that 
in WT mice, the only organs which had metastatic colonies were the lungs, kidney and 
mediastinal lymph node, whilst in D6KO mice, multiple organs, including the heart, liver, 
spleen, peritoneum and testes, developed metastatic colonies. These results suggest that 
despite being unable to detect inflammatory CC chemokine receptor expression by RT-
PCR, B16 F10 cells may express receptors that are able to bind to D6 ligands. Knowing the 
function of D6, it is likely that increased levels of pro-inflammatory CC chemokines in 
these organs may be causing this difference. Isolating organs and performing Luminex or 
ELISA analysis to determine the chemokines and their relative levels in each organ could 
test this relatively easily. There is no evidence in the literature looking at the effects of 
inflammatory chemokines on chemokine receptor expression of B16 F10 cells.  
Based on the functions of D6, it seems plausible to assume that a reduction in D6 would 
increase the levels of pro-inflammatory chemokines in the lungs, which may explain the 
reduction in metastatic colonies. However, evidence suggests that a pro-inflammatory 
environment may actually promote lung colonisation. S100A8 and S100A9 are proteins 
which are chemotactic for neutrophils and are useful markers in diseases associated with 
inflammation (362) and are known to be pro-inflammatory. In the B16 model, S100A8 and 
S100A9 are upregulated in the lungs prior to melanoma cell colonisation, neutralisation of 
these reduces the number of lung colonies (261, 262). Mice that have been treated with a 
model of OVA induced lung inflammation show increased lung colonies, and this can be 
reduced by treatment with corticosteroids, showing that the inflammatory milieu is 
permitting enhanced colony growth (363). A wound healing environment, whilst not 
thought of as pro-inflammatory, also increases the development of lung colonies (310). It 
appears that simply thinking of the environment as pro or anti inflammatory is too 
simplistic, as IFNγ administration decreases the number of lung colonies, due to 
increasing MHC I expression on B16 F10 cells surface (313, 314). The chemokine 
microenvironment of the lungs in D6KO mice needs to be fully characterised, which may 
determine a potential mechanism for the reduction in metastatic colony growth.  
The pre-metastatic niche has been mentioned above, this describes the phenomenon by 
which tumour cells can increase fibronectin expression in the lungs, and cause 
recruitment of VLA4+VEGFR1+ haematopoietic cells, which interact with stromal cells to 
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produce chemokines, growth factors and MMPs (261, 262, 364). B16 F10 cells can recruit 
CCR5+ pulmonary fibrocytes to the lungs, which produce MMP9, which creates the ideal 
environment for metastatic colony growth. If CCR5 is knocked out, these mice display a 
phenotype similar to that of D6KO mice, with significant reductions in metastatic colony 
formation. These studies used bone marrow chimeras to demonstrate that CCR5 
expression on non-haematopoietic cells was essential for the development of metastatic 
colonies (328, 329). In D6KO mice, it is possible that there may be a cell population similar 
to pulmonary fibrocytes that are missing, which would explain the reduction in metastatic 
colony formation. Bone marrow chimera experiments would help to determine if D6 
expressed on haematopoietic cells, or non-haematopoietic cells are involved in B16 F10 
lung colonisation.  
The B16 F10 model has been shown to be influenced by cell interactions, in particular B1 
cells, T cells and platelets (306, 318, 326). B1 cells are an interesting subset of B cells, 
known as innate B cells. B1 cells are found in the peritoneal and pleural cavity, express 
IgM and CD5. They have a limited antibody diversity and are capable of self-renewal (316, 
317). When B1 cells are co-cultured with low metastatic B16 cells, they increase their 
metastatic potential in a cell contact dependent mechanism, associated with an 
upregulation of CXCR4 and MMP9 (318). When B1 cells are depleted, the number of 
metastatic colonies in the lungs is reduced (318). Recent unpublished work has shown 
that B1 cells in the peritoneal cavity express D6 (personal communication, Chris Hansell). 
At this moment, it is unknown if B1 cells in the pleural cavity express D6, but since these 
cells derive from a common precursor (317), it seems feasible that they may express D6. 
As B1 cells are linked to metastatic colony formation in this model, the numbers of B1 
cells in the pleura may be reduced in D6KO mice, which may be causing the reduction in 
metastatic colonies. B16 F10 cells preferentially grow at blood vessels and the pleura, 
their pleural growth may be linked to the B1 cells found in the pleura (308). It would be 
interesting to look at models of mesothelioma, a malignancy of the pleura, and 
metastasis to the peritoneal cavity to examine the roles that D6 may play in the pleural 
and peritoneal cavities. Platelets have been shown to aggregate with B16 F10 cells, and 
this aggregation can increase the size of metastatic colonies, conversely 
thrombocytopenia is associated with a reduction in colony development (252, 253, 324). 
D6 expression has been shown on T cells and platelets ((144) and Catherine Wilson, 
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personal communication), so it is possible that these cells may be altered in D6KO mice 
and this could be causing the phenotype exhibited.  
In conclusion, the work presented in this thesis contributes to the body of work 
describing a role for D6 in neutrophil migration in the well-characterised TPA skin 
inflammation model. These data show that D6 on neutrophils does not affect their 
positioning in inflamed skin, further work is needed to investigate the hypothesis that 
altered chemokine clearance within the skin is responsible for the altered neutrophisl 
positioning. With respect to melanoma growth this work shows that D6 over-expression 
may be a potential therapeutic target for melanoma growth, although further work is 
required to elucidate the precise role D6 plays in melanoma growth. Finally, this data 
shows for the first time, the significant role that D6 plays in melanoma metastasis to the 
lungs. Further work is required to define the involvement of D6 in metastasis, but this 
work suggests that D6 may be involved in the development of metastasis to the lungs and 
the pleura, by affecting both macrophages and lymphangiogenesis, and may represent a 
novel therapeutic target for the treatment of metastasis and possibly mesothelioma.  
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